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Summary
Comparative studies on the biological and pathogenic characteristics of wild-type 
strains of Japanese encephalitis (JE) virus and their attenuated derivatives were 
undertaken in the present project.
Two envelope (E) protein reactive monoclonal antibodies (MAbs) (V23 and T60) 
were found to recognize the attenuated JE vaccine strains (SA-14-2-8, SA-14-5-3 and 
SA-14-14-2/PHK and PDK9) derived by passage in primary hamster kidney (PHK) 
cells, but not any wild-type strains examined. While five MAbs (KIO, K13, K39, K43 
and J44jshowed the reverse recognition. Thus, vaccine and wild-type specific epitopes 
were identified on the E protein of JE virus.
Wild-type strains Nakayama-original and 826309, but not SA-14 and Beijing-1, 
were attenuated for adult mice after six or fewer passages in HeLa cells. The 
attenuated HeLa passaged JE viruses gained the vaccine specific epitope recognized 
by MAb V23 and lost the wild-type epitope(s) recognized by MAbs K13 and K39. 
The non-attenuated HeLa cell passaged JE viruses showed no changes in the above 
epitopes. Thus, studies with two different attenuation processes (PHK and HeLa cells) 
would suggest that the E protein epitopes of JE virus are associated with the 
attenuation and virulence of JE virus.
Both attenuated and virulent strains of JE virus were found to bind to mouse brain 
membrane receptor preparations (MRPs). Binding of wild-type, but none of the 
attenuated, strains to the MRPs was blocked by preincubation of the MRPs with 
spiperone, an antagonist for the receptors of the neurotransmitters dopamine and 5- 
hydroxytryptamine, suggesting that wild-type and attenuated strains have different cell 
receptors in mouse brain neurones.
Taken together, it would appear that mutations in the E protein gene play an 
important role in the attenuation and/or virulence of JE virus. In addition, studies on 
the attenuated HeLa cell passaged Nakayama-original virus indicate that this virus 
may have promise as a potential live JE vaccine virus.
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Chapter 1 
Literature Review
1.1. Flaviviiidae
1.1.1. Classification
Flaviviruses, together with alphaviruses, were orginally classified as members of the 
family Togaviridae using morphological and serological criteria, although some 
differences between the alphaviruses and flaviviruses have been known for a long 
time (Porterfield et ah, 1978). The change in the classification was the result of 
recent molecular research that clearly demonstrated that flaviviruses, although 
generally similar to alphaviruses in their morphology, differed markedly from the 
alphaviruses in their virion structure, strategy of replication, and morphogenesis. 
Thus, only a single envelope protein could be found in flaviviruses, whereas 
alphaviruses have at least two, sometimes three, envelope proteins. The alphaviruses 
specify a subgenomic 26S mRNA corresponding to the 3’ end of the genom^r __ 
codes for the structural proteins (Kaariainen and Soderlund, 1978). In contrast, no 
such subgenomic mRNA was found in flavivirus-infected cells (Westaway, 1973; 
Westaway, 1997). Therefore, in 1984, the International Committee on Taxonomy of 
Viruses (ICTV) approved a proposal by the ICTV Togaviridae Study Group to 
remove the genus flavivirus from the family Togaviridae and to recognize them as the 
basis for a new family Flaviviridae (Westaway et al., 1985).
The family Flaviviridae, for which the type species is yellow fever (YF) virus, 
contains a single genus Flavivirus (Westaway et al., 1985). Currently, 68 viruses 
have been described in this family (Calisher et ah, 1989). All flaviviruses share a 
group-specific antigen (Brinton, 1986). Antigens presented on the virion surface are 
reactive in binding assays (immunofluorescence and enzyme or radionuclide-based 
immunoassays), complement-fixation (CF) assays, haemagglutination-inhibition (HI)
and neutralization (N) assays. The flaviviruses were originally grouped on the basis 
of cross-reactivities in the HI test performed with polyclonal antisera by Casals and 
Brown in 1954. The HI test and binding assays detect the group-reactive determi­
nants, whereas the CF test is intermediate in specificity, and the N test is relatively 
type-specific. The N test is used to distinguish individual viruses in the family and to 
define subgroups of closely related viruses (Monath, 1989).
On the basis of cross-neutralization using polyclonal hyperimmune sera, de Madrid 
and Porterfield (1974) classified 36 flaviviruses into seven complexes or subgroups, 
whereas six remaining viruses were antigenically distinct. A more recent analysis of 
66 flaviviruses defined eight antigenic subgroups encompassing 49 viruses: tick-borne 
encephalitis (12 viruses), Rio Bravo (6), Japanese encephalitis (JE) (10), Tyuleniy (3), 
Ntaya (5), Uganda S (4), dengue (DEN) (4) and Modoc (5), leaving 17 other viruses 
unassigned (Table 1.1) (Calisher et ah, 1989). This antigenic classification conforms 
to major biological and epidemiological characteristics of the flaviviruses.
1.1.2. Medical and veterinary importance
Of the 68 currently registered flaviviruses, approximately 50% have been associated 
with diseases in human (Table 1.2) (Karabatsos, 1985). Three viruses: DEN, YF and 
JE, are prevalent enough to engender global or panregional public health concern.
DEN is caused by four serologically related viruses (DEN 1 to 4) and are self­
limited infectious diseases, which occur in epidemic form in the Caribean basin. 
Southeast Asia, East Africa and Oceania, affecting hundreds of thousands to millions 
of persons annually. Sequential infection by different DEN viruses can lead to dengue 
haemorrhagic fever (DHF) and in its extreme form, termed dengue shock syndrome
Table, 1.1 Antigenic Classification of Flaviviruses
Mosquito-borne
viruses
Antigenic
Group
Tick-borne Antigenic 
viruses Group
Vector-unknown Antigenic 
viruses Group
Alfuy 3 Karshi 1 Carey 1
Japanese enc. 3 Kayasanur Forest 1 Phnom Penh bat 1
Kedougou 3 Langat 1
Kokobera 3(5?) LoupmgiU 1
Koutango 3 Negishi 1 Apoi 2A
Kunjin 3 Omsk 1 Bukalasabat 2A
Murray Valley 3 Powassan 1 Dakar bat 2A
St. Louis enc. 3 Royal Farm 1 Entebbe bat 2A
Stratford 3 Tick-borne enc. 1 Rio Rravo 2A
Usutu 3 Saboya 2A
West Nile 3
Yaounde (3)*
Sponweni 4 Meaban lA Cowbone Ridge 2B
25ka 4 SaumarezReef lA Jutiapa 2B
Tyuleniy lA Modoc 2B
Bagaza 5 SalVieja 2B
Isreal Turkey 5 SanPerlita 2B
Ntaya 5
Tembusu 5
Yokose 5
Benzi 6
Bouboui 6
Edge Hill 6
Potiskum (6)*
Uganda S 6-
Dengue 1 7
Dengue 2 7
Dengue 3 7
Dengue 4 7
Busuquara U Gadgets Gulley U Aroa U
Uheus U Kadam U Batu Cave (U)*
Jugra u Cacipacore u
Naranjal u Montana M.L. u
Rocio u ^kuluk u
Sepik u Tamanabat u
Wesselsbron u
Yellow fever u
Total 36 14 19 = 69
This table was summarized from Calisher etaJ.
U: unrelated to any other flaviviruses.
*: Batu Cave, Potiskum and Yaounde viruses were not examined in 
their studies but are included for completeness.
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(DSS), can often lead to a fatal outcome (Shope, 1980; Halstead, 1981). Despite the 
introduction of the 17D YF vaccines, YF still remains as an important health problem 
in tropical America and Africa. In past two decades, recurring outbreaks in West 
Africa have affected more than 250,000 persons (Monath, 1986; Nasidi et al. , 1989). 
The disease is characterized by fever, hepatic, renal and myocardial dysfunction, and 
haemorrhage, and has a case fatality rate of approximately 20%-50%. JE occurs in 
endemic form over a wide area of Asia. Morbidity and mortality estimates are 
inaccurate and incomplete, but it is certain that tens of thousands of cases occur 
annually. The case fatality rate is usually 20%, and a high proportion of survivors are 
left with permanent neuro-psychiatric impairment. More details of this disease will 
be reviewed in Section 1.5. The tick-home flaviviruses, such as Powassan (Canada), 
louping ill (British Isles), Kyasanur Forest Disease (India), tick-borne encephalitis 
(TBE) (East Europe, USSR and Scandinavia), Russian spring-summer encephalitis 
(USSR), and Omsk haemorrhagic fever (Siberia) viruses, induce human meningitis 
or encephalitis with a case fatality ranging from 1 to 30% (Shope, 1980). Other 
viruses listed in Table 1.2, West Nile (WN) fever (Africa, the Middle East, Europe 
and Asia), Murrey Valley encephalitis (MVE) (Australia), St. Louis encephalitis 
(SEE) (USA) and Rocio encephalitis occur as intermittently epidemic diseases.
Eight flaviviruses have been reported to cause diseases in domesticated or wild 
animals of economic importance (Table 1.3.). The most important of these is JE 
virus, which causes epizootic encephalitis in horses and stillbirth/abortion and 
decreased fecundity in swine in many areas of Asia (Umenai et al. , 1985)."pie various 
surveys in the endemic areas showing the high incidence of horses, cattle and swine 
with high antibody titre indicate that the infection must occur frequently in a mild
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form in these animals. It was reported that this virus could produce fatal disease in 
all of these species by intracerebral (i.e.) inoculation of the virus (Hagen et al., 1982; 
Huang, 1982). Wesselsbron virus is associated with congenital malformation, and 
severe neonatal disease in lamb and ewes in Southern Africa (Henderson et al., 
1970). Louping ill (LI) virus causes an encephalitic illness in sheep in parts of British 
Isles (Monath, 1989). Israel Turkey meningencephalitis (ITME) virus caused central 
nervous system (CNS) disease in turkey populations in Israel between 1958 and 1959 
with morbidity approximately 50% and a case fatality rate of 10-12% (Komarov and 
Kalmar, 1960). Other flaviviruses of some veterinary importance include WN and 
Kunjin virus infections of horses. The latter is related to MVE virus and was isolated 
from the spinal cord of a horse with severe encephalomyelitis in Australia (Guillon 
et al., 1968; Badman et û/., 1984).
1.2. Virion morphology and physicochemical properties
1.2.1. Morphology
Flaviviruses contain a central nucleocapsid (25-30 nm in diameter) surrounded by a 
lipid bilayer. Virions are icosahedral and have a diameter of about 40-50 nm. On the 
outer surface of the virion envelope is the envelope protein, which is seen as 
projections that are 5-10 nm long with terminal knobs 2 nm in diameter (Murphy,
1980).
1.2.2. Physicochemical properties and chemical compositions
The buoyant density of flavivirions is 1.22-1.24 g/cm^ in caesium chloride and 1.18- 
1.20 g/cm^ in sucrose (Smith et al., 1970). The sedimentation coefficient for virions
8
in sucrose has been reported to be 175-218S (Boulton and Westaway, 1972). The 
infectivity of the virions is most stable in the range of pH 7-9. Virions are rapidly 
inactivated at 50°C, with a decrease in infectivity of 50% in 10 minutes at this 
temperature (Porterfield et al., 1978). Virion infectivity is also sensitive to 
inactivation by ultraviolet light, ionic and nonionic detergents, and trypsin digestion 
(Biinton, 1986).
The chemical composition of a flavivirus virion is 6% RNA, 66% protein, 17% 
lipid and 11% carbohydrate (Trent and Naeve, 1980). However, various types of 
tissue culture cells that differ in their phospholipid composition have been found to 
produce progeny flavivirus virions with a phospholipid composition similar to that of 
the host cell (Trent and Naeve, 1980). This result indicates that the virion 
phospholipids are derived from the pre-existing host cell lipids.
1.3. Molecular biology of flaviviruses
1.3.1. Structure of the flavivirus genome
I. Physical structure of the genome 
The genome of flaviviruses is one single-stranded RNA molecule approximately 11 
kilobases (KB) in length (Westaway, 1980; Deubel et ah, 1983). The genomic RNA 
is plus-stranded and infectious, and thus the incoming RNA must be translated to 
produce any enzymes required for the RNA replication. No subgenomic messenger 
RNAs (mRNAs) have been identified in flavivirus infected cells and it is generally 
believed that the virion RNA (or RNA molecules virtully identical to this RNA) is the 
only flavivirus-specific mRNA (Boulton and Westaway, 1977; Naeve and Trent, 
1978; Wengler et ah, 1978; Westaway, 1980). The genomic RNA has a type-I cap
at its 5’ end of the form m^GPPP-AMP (Wengler et al., 1978) and lacks cap- 
associated and internal base methylated adenine residuals (Cleaves and Dubin, 1979). 
The 5’ cap is followed by the conserved dinucleotide sequence AG. Genomic RNAs 
of mosquito-bome flaviviruses appear to lack a 3'-terminal poly (A) track (Wengler 
et ah, 1978; Wengler and Wengler, 1981; Vezza et al., 1980; Deubel et al., 1983) 
and terminates with the conserved dinucleotide CU. However, TBE virus RNA 
probably terminates with the dinucleotide AC (Mandl et al., 1989; Pletnev et al., 
1990).
The most notable feature of the flavivirus genome is the presence of one open 
reading frame (ORE) of over 10,000 bases. The ORE for different flaviviruses 
(starting at the first Met residue) range from 10,158 bases (DEN 4) to 10,302 (MVE) 
and encode polyproteins of 3,386 to 3,434 amino acids (see review by Chambers et 
al., 1990). No other conserved ORFs have been identified in either the genomic sense 
RNA or its complement. Flanking the long ORE are 5’ (from 95 to 132 bases in 
length) and 3’ noncoding regions. The 3’ noncoding region of TBE virus (114 bases) 
appears to be much shorter than that any of the mosquito-bome flaviviruses (from 385 
to 585 bases in length) and lacks a nunmber of RNA sequences and structures 
common for the mosquito-bome vimses (Chambers et al., 1990).
n. Gene order
In recent years, nucleotide and protein sequence data for many flavivimses have 
accumulated to shape the current view of the flavivims gene order and viral protein 
synthesis (see reviews by Rice et al., 1986; Westaway, 1987; Chambers et al., 1990). 
The order of proteins encoded in the long ORE is:
10
5’-C-PrM(M)-E-NSl-NS2a-NS2b-NS3-NS4a-NS4b-NS5-3’ (see Figure 1.1) 
The structural proteins C (capsid, the C precursor is called anchored C), M 
(membrane, the M precursor is called PrM), and E (envelope) are encoded in the 5’ 
quarter of the genome and the genes for the nonstructural (NS) proteins are located 
in the remainder. The NS proteins include the large, highly conserved proteins NS 1, 
NS3 and NS5, and the four small hydrophobic proteins NS2a, NS2b, NS4a and 
NS4b.
1.3.2. Viral proteins
I. Structural protein
All flavivirus virions contain three structural proteins, i.e. the capsid (C) protein, the
'V fp lA C
membrane (M) protein and the envelope (E) protein (Brinton, 1986). . peptide
maps of the three structural proteins of several flaviviruses indicated that each was 
a unique protein (Wright and Wastaway, 1977).
The C protein present in virions is a small (predicted molecular weight (MW) 12- 
14 kilodaltons (Kd)), highly positively charged protein (27% Lys +  Arg for YF 
virus), which forms the structural component of the nucleocapsid (Rice gr al., 1986). 
Flavivirus C protein sequence homology is low, except for the regions, where 
hydrophobic and hydrophilic amino acids are conserved, including a coterminal 
hydrophobic domain that is immediately proceded by a hydrophilic region, and a 
central hydrophobic region. These conserved domains may be involved in protein- 
protein or specific protein-RNA interactions, or both, during nucleocapsid assembly 
and acquisition of the lipoprotein envelope (Mandl et al., 1988). The purified C 
protein elicited no neutralizing antobodies in mice but was found to have group
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reactive antigenic determinants (Brinton, 1986).
The PrM protein is a glycoprotein precursor (predicted MW 18-19 Kd) modified 
by addition of carbohydrate to the structural protein M. This precursor undergoes a
delayed cleavage to form M protein, and the N-terminal Pr segment, the fate of which 
is unclear (Chambers et al., 1990). The M protein is associated with the virion 
envelope, but is not glycosylated with a MW of 7-9 Kd. The role of the M protein 
in flavivirus replication is currently unknown. However, it was postulated that a part 
of the M protein may be exposed on the surface of flavivirus virions and that the M 
protein may interact with the cell surface based on the interference effect observed 
with Banzi virus infection of cells, which were pre-treated with purified Banzi virus 
M protein (Lee and Schlormer, 1981). Neutralizing activity can be elicited following 
incubation of purified M protein into mice (Brinton, 1986).
The E protein (predicted MW 53-54 Kd) is the major structural protein of the
flavivirus virion. The glycosylated forms are found in some, but not in all,
liésA
flaviviruses ( - V WN and Kunjin viruses). This protein presumably plays a major 
role in a number of biological activities including virion assembly, receptor binding 
and membrane fusion, and is the major target for neutralization (N) and 
haemagglutination inhibition (HAI) antibodies (Brinton, 1986; Heinz, 1986; and 
references therein). Comparison of deduced E protein amino acid sequences reveals 
areas of striking homology as well as divergence (Mandl et al., 1988).
A major recent advance is the derivation of two dimensional models for the 
structure of the E protein. These models assume a general conserved structure for 
the flavivirus E protein. The most extensive studies have utilized the TBE E protein 
(Figure 1.2). Heinz and coworkers (see review by Heinz, 1986) characterized three
13
Figure 1.2 Structure of the TBE virus E protein 
(taken from Heinz et a l 1990)
CNBr
COOH
B
1) A. B. C: correspond to different antigenic protein domain recognized by MAbs.
2) Disulphide bridges are marked by connecting solid lines.
3) Thin lines indicate variable sequences.
4) Thick lines indicate hypervariable sequences.
5) Diamonds indicate potential N-glycoprotein sites for TBE and other flaviviruses.
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major epitope clusters (A, B and C domains) in the E protein ectodomain by using 
a panel of MAbs in competitive-binding assays. All three domains contain epitopes 
involved in N and HAI, but only domain A contains flavivirus cross-reactive epitopes.
This domain undergoes a pH-dependent conformational change consistent with its 
possible role in endocytotic fusion events (Guirakhoo et al., 1989). Domain B 
consists of a trypsin-resistant fragment. Using E protein subregions from JE virus 
expressed in bacteria, the region between residues 303-396 has been shown to contain 
both JE specific and serogroup cross-reactive neutralizing epitopes dependent upon 
a disulfide cross-linkage between residues 304-335 (Mason et al. , 1987; Mason et al. , 
1989). Two studies have provided evidence for the biological importance of this 
domain in modulating pathogenicity in vivo. A  monoclonal antibody (MAb) 
neutralizing escape mutant of TBE virus that maps to Tyr^g )^ is attenuated in mice and 
confers protection against lethal challenge (Heinz et al., 1990). Similarly, a change 
at Asp(390) selected during passaging of MVE virus in Human adenocarcinoma SW13 
cells also appears to lead to attenuation in mice (Lobigs et al. , 1990). It is of interest 
that Asp(390) is within an Arg-Gly-Asp (RGD) sequence. An RGD sequence is 
responsible for the cell attachment activity of a range of extracellular proteins 
including fibronectin, vitronectin and von Willebrand factor (see review by Hynes, 
1987). The cell attachment site on foot-and-mouth disease virus includes an RGD 
sequence (Fox et al., 1989). An RGD sequence in this region is also found for JE and 
YF-17D viruses (Lobigs et al., 1990). These observations suggest that this region 
may be involved in tissue tropism and perhaps E protein-host cell receptor 
interactions. Clearly, molecular biological studies of flavivirus mutants varying in 
their cell receptor binding ability will aid in understanding the role of this region in
15
relation to the virus-cell receptor interactions. The domain C is composed of a 
disulfide free loop. The serological and/or biological functions of this domain are 
unclear.
n . Nonstructural proteins
Processing of the flavivirus polyprotein generates at least seven nonstructural (NS) 
proteins, whose cleavage sites are conserved amongst the flaviviruses examined to 
date (Rice and Strauss, 1991). The NSl protein is a glycosylated protein (MW 39-41 
Kd) and exists as cell-associated, cell-surface and extracellular nonvirion forms 
(Westaway, 1987; Wingler et al., 1988). The protein includes 12 strictly conserved 
cysteine residues (except DEN-4) in variant glycosylation sites, and additional regions 
of high sequence homology (Rice et al., 1986). Flavivirus infections elicit antibodies 
to NSl with complement fixing (CF) activity and the secreted form of this protein has 
been called the soluble complement fixing (SCF) antigen (Smith and Wright, 1985). 
Type-specific, complex-specific and group-reactive epitopes have been identified for 
NSl protein and appear to play a role in protective immunity (Henchal et al., 1987). 
Active immunization with NSl or passive immunization with anti-NSl protein MAbs 
protects animals against challenge with homologous flaviviruses (Bray et al., 1989; 
Cane et al., 1988; Gould et al., 1986; Schlesinger et al., 1985, 1986, 1987; Zhang 
et al., 19SS).
The NS3 and NS5 proteins are the two largest flavivirus proteins with MW of 68- 
70 and 103-104 Kd respectively. Both proteins are highly conserved among 
flaviviruses and contain no long hydrophobic stretches (Mandl et al., 1989; Rice et 
al., 1986). A role for NS3 in viral RNA replication has been postulated, and recent
16
sequence comparisons suggest that it is probably at least bifunctional, containing both 
a protease activity and possibly a nucleotide triphophatase/helicase activity (Bazan et 
al., 1989; Gorbalenya et al., 1989). Regions of sequence conservation are distributed
throughout NS5. A highly conserved domain in NS5 contains the sequence motif Gly- 
Asp-Asp, which is present in NS proteins from a number of positive stranded RNA 
viruses and is believed to play a role in RNA-dependent RNA synthesis (Rice et al., 
1986).
NS2a, NS2b, NS4a and NS4b are four relatively small non-glycosylated proteins 
with deduced MW of 18 Kd, 13 Kd, 31 Kd and 12 Kd respectively (Rice et al., 
1986). These small proteins are poorly conserved among flaviviruses, but contain 
similar structural features consisting predominantly of multiple hydrophilic domains 
(conserved among flaviviruses in position but not sequence) (Rice et al., 1986). The 
biological functions of these proteins are currently unknown.
1.3.3. Replication
Flaviviruses can replicate in a wide variety of cultured cells of vertebrate and 
arthropod origin. The specific steps in flavivirus replication are not known in detail. 
Based on electron microscopic data it has been postulated that free flavivirus virions 
and virus-antibody complexes enter the cells by receptor-mediated endocytosis 
followed by fusion of the viral membrane with the endosomal membrane (Gollins and 
Porterfield, 1984, 1985; Kimura et al., 1986; Ng and Lau, 1988). It is clear that 
flavivirus protein and RNA synthesis as well as virion assembly occur in the 
perinuclear region of the infected cells (Hase et al., 1989). RNA replication involves 
synthesis of complementary minus strands that are then used as templates for
17
production of additional genome-length plus stranded molecules. These plus stranded 
RNA molecules can be used subsequently for either translation of structural and NS 
polypeptides, minus stranded RNA synthesis, or to be encapcidated into virions 
(Westaway, 1987). Evidence suggests that plus-stranded RNA molecules are 
synthesized from the genome-length minus-stranded templates by a semiconservative 
mechanism involving replicative intermediates (RIs) and replicative forms (RFs). RFs 
are defined as duplex RNA molecules; RIs, in addition, nascent single stranded RNA 
molecules (Chu and Westaway, 1985). It has been suggested that the virion assembly 
may occur within lucent vesicles and the virion is released by budding the membranes 
of the endoplasmic reticulum and Golgi apparatus (Leary and Blair, 1983).
1.4. Biological characteristics of flaviviruses
1.4.1. Virus-cell interactions
A major change in flavivirus infected cells is proliferation and hypertrophy of rough 
endoplasmic reticular membranes with which virus particles accumulate. Host cell 
macromolecular synthesis is not markedly decreased until the late stage in flavivirus 
infection, when cytopathic effects (CPEs) appear (Murphy, 1980). At the ultra- 
microscopic level, cellular pathologic changes include mitochondrial damage, 
fragmentation of reticular membranes, formation of distended vacuoles and inclusion 
bodies, increase in lysosomal bodies, and rarefaction of cytoplasm. Activities of 
lysosomal enzymes increase in the infected tissue. At the microscopic level, 
susceptible vertebrate cells, such as HeLa, BHK-21, porcine kidney, and primary 
chicken or duck embryo display cell rounding, shrinkage, pyknosis of nuclei, and 
dislodgement from the growth surface. Cell fusion and syncytial formation
18
(polykaryo|cytosis) have been observed in BHK-21 cells (Murphy, 1980).
Unlike vertebrate cells, arthropod cells infected with some flaviviruses are capable 
of massive proliferation and hypertrophy of cytoplasmic membranes, as well as great 
production of virus, without sustaining cytopathologic changes. Infection of mosquito 
cells with certain flaviviruses may result in CPEs characterized by syncytium 
formation (Paul et ah, 1969). In contrast to mosquito cell cultures, those derived 
from ticks do not demonstrate CPEs after infection with tick-bome flaviviruses 
(Monath, 1990; and the references therein).
In gerneral, mosquito-borne viruses replicate in mosquito cell culture, and a few 
(such as SEE and WN viruses which have been isolated from ticks in nature) will also 
grow in tick cell cultures. Tick-bome flaviviruses replicate in tick cell cultures, but 
not in mosquito cells (Monath, 1990).
The antigenic reactivity of some flaviviruses is altered by replication in mosquito 
cells. For example, DEN and Kunjin viruses lose HA activity on passage in Aedes 
albopictus cells (Ng and Westaway, 1983). Barrett et al. (1989) found that many 
monoclonal antibodies that they used showed host dependent neutralizing activity 
against the YF vaccine viruses. The viruses grown in human cells SW13 were 
neutralized, whereas, the same virus grown in mosquito cells C6-36 was not.
1.4.2. Propagation and assay in cell culture
Flaviviruses produce CPEs and plaque formation in a variety of primary and 
continuous cell cultures derived from human, monkey, rodent, swine and avian tissues 
(Karabatsos, 1980). In general, the BHK-21 (baby hamster kidney), SW13 (human 
adenocarcinoma), PS (porcine kidney), C6-36 {Aedes mosquito larvae cells), and
19
primary chicken and duck embryo cells produce the highest virus yields. In 
comparison with alphaviruses, the latent period of flavivirus growth is relatively long, 
and growth is slow. At high multiplicity of infection in BHK-21 cells, SLE virus has 
a latent period of 11 hours and reaches peak infectivity titre at 28 hours post 
infection. Plaques appear after 4-6 days; double overlay procedures are often required 
for optimal plaque assays in mammalian cell cultures. Addition of neutral red to agar 
may enhance the plaque size.
1.4.3. Infection in experimental animals
The susceptibility of experimental animals and host range vary dependent on 
individual flaviviruses. Generally, newborn mice and hamsters inoculated 
intracerebrally are more sensitive for infectivity assay and primary isolation of many 
flaviviruses than cell cultures; the slight advantage in sensitivity is, however, offset 
by the expense and inefficiency of in vivo assays. For other flaviviruses, including 
YF, DEN and IE, cell cultures provide more sensitive assay systems (Monath, 1990; 
Huang, 1982). In gerneral, intrathoracic or intracerebral inoculation of live mosquito 
adults or larvae provides the most sensitive system for assay of mosquito-bome 
flavivimses (Monath, 1990).
1.5. Japanese encephalitis
1.5.1. History of Japanese encephalitis
Japanese encephalitis (JE) is mosquito-bome infectious disease caused by a member 
of the family Flaviviridae. A disease resembling JE was recognized in horses and 
humans as early as 1871 (Rosen, 1986). A severe epidemic occured in Japan in 1924
ft ^
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and a filterable agent was extracted from the brain of a human fatal case and was 
passed to rabbits. In 1934, Hayashi reproduced the disease in intracerebrally 
inoculated monkeys. In 1935, the agent was recovered from the brain of a human 
fatal case in Tokyo and was virologically and serologically established as the 
prototype, termed strain Nakayama. The virus was first recovered from the brain 
tissue of a sick horse in 1937. Mosquito transmission was suspected during the early 
1930s; in 1938, Mitamura et al. reported isolation of the virus from the mosquito 
Culex tritaenorhynchus rivlonath, 1990; Rosen, 1986; and references therein).
1.5.2. Epidemiology of JE
JE virus is widely distributed in Asia, including China (mainland and Taiwan), Japan, 
Korea, Far Eastern USSR, all of Southeast Asia and the Indian subcontinent (Table 
1.4). In China, the disease is very widespread. Practically, all provinces except the 
two most western ones, i.e. Xinjiang (Sinkuang) and Xizang (Tibet), are epidemic 
areas (Huang, 1982).
Since the late 1960s, the incidences of the disease have declined in China, Japan, 
and Korea (Umenai et al., 1985). Fewer than 20 cases now occur annually in Japan; 
and the morbidity rates in Beijing, China, have decreased from 15 to 30 per 100,000 
to around 2.5 per 100,000 (Huang, 1982; Umenai et al., 1985). In contrast, large 
epidemics have appeared in South and Southeast Asia, including India, Nepal, 
Bangladesh, Burma, Thailand, Vietnam, etc. The causes for the change are not clear 
but the following factors may be involved: 1) changes in agriculture, such as adoption 
of paddy (rice) cultivation, use of pesticides, and establishment of large modern pig 
farms; 2) changes in socioeconomic status involving a shift to rice cultivation from
21
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dry land crops and the promotion of pig breading as a food source; 3) climate, 
including effects of temperature and rainfall; 4) effects of vaccination of the human 
population and pigs ( the amplifying host); 5) possible role of additional potential 
amplifying hosts other than pigs; and 6) the wide variety of mosquito species in 
Southeast Asia, and their different vectorial capacities (Umenai et al., 1985).
Epidemiologically, there are two characteristic patterns of infection, which appear 
to be related to climate and seasonal conditions (see Table 1.5). In tropical areas, 
there is an epidemic pattern with occurrence of sporadic cases throughout the whole 
year. However, in temperate zones and in the northern part of the tropical zone, the 
outbreak has a marked seasonal incidence (July to September when the mosquito 
population are maximum). Precipitation and temperature are important determinants 
of vector density and the rate of virus transmission (Umenai et al., 1985).
The transmission cycle of JE was established by Scherer et al. in 1959. Birds and 
pigs are effective viraemic amplifying hosts. In temperate regions, the virus first 
appears in July in the mosquitos, following within one to three weeks in pigs and 
birds, principally ardeid species (egrets, black-crowned night herons) and ducks. 
Human infections occur several weeks later. The main epidemic vectors are Culex 
(Cx) species. Cx. tritaenorhynchus being the most important. Other species implicated 
in the transmission include Cx. vishnui, Cx. gelidus, Cx. fusocephalus, and Cx. 
annulirostris.
The overwinter maintenance of JE virus in the temperate areas has been the 
subject of much speculation and study in China, Japan and Korea (Huang, 1982). 
Although, it has not been fully elucidated, transovarial transmission of JE virus in 
mosquitos, especially Aedes spp., has been demonstrated in the laboratory and
23
Table 1.5
Two epidemiological patterns of JE (Umenai etal. 1985)
climatic
zones
occurence 
of disease
countries,
regions season
tropical epidemicwith 
sporadic cases
South India, Indonesia, 
Malaysia, Singapore, 
South Thailand
No seasonal 
pattern
North part of 
tropical zone
outbreaks China, Japan, republic of 
Korea, Nepal, Northern 
part of Burma, India, 
Tailand and Vietnam
late summer and
autumn 
(end of rainy season)
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isolations have been made from field-collected Xetfej larvae (Huang, 1982; Rosen et 
al., 1978). In tropical regions, year-round transmission of the virus between 
mosquitos, birds and pigs is thought to occur.
JE virus, like many other infectious disease agents, causes both clinical and 
inapparent infections. The ratio of inapparent to apparent (clinical) infections has been 
reported to be between 25:1 and 2000:1 varying in different localities and in different 
years (Huang, 1982; Monath, 1985). Among the factors which influence this ratio are 
age, differences in the virulence of the virus strains, and cross-protective immunity 
to other flavivirus infections, especially DEN virus infection (Grossman et al., 1974). 
Although, only a small fraction of persons infected with JE virus develop clinical 
manifestations of encephalitis, those manifestations are so severe that the disease is 
greatly feared, especially when it occurs in an epidemic form. Bredeck (1935) has 
reported that the case-fatality ratio could be as high as 90%. Not only is the 
encephalitis associated with a high death rate, but also severe permanent neurological 
sequelae occur in a high proportion of patents (see next section).
In addition to human disease, JE virus also causes abortion and neonatal death in 
swine and encephalitis in equine. Both types of animals are of economic importance 
in the areas where JE occurs; pigs as food and horses as draft animals and racehorses.
1.5.3. Clinical manifestations of JE
The incubation period of JE is between 6 to 16 days. The illness may be manifested 
by a febrile headache syndrome, aseptic meningitis, or encephalitis (Gatus and Rose, 
1983). In the full-blown encephalitic form, the onset is rapid, beginning with a 2 to 
4-day prodromal phase of headache, fever, chills, anorexia, nausea, vomiting,
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dizziness and drowsiness. These symptoms are followed by the appearance of nuchal 
rigidity, photophobia, altered status of consciousness, hyper excitability, and varying 
objective neurological signs, including dull, musk-like facies, muscular rigidity, 
cranial nerve palsies, tremulous eye movement, coarse tremors of the extremities, 
involuntary movements, generalized and localized paresis, incoordination, and 
pathologic reflexes. Convulsions are frequent in children but rare in adult patents. 
Death occurs on the fifth to ninth day or during a more protracted course with 
cardiopulmonary complications. A poor prognosis is associated with respiratory 
dysfunction.
Neuropsychiatrie sequelae occur in ; . 70% of survivors and are particularly 
severe in children. Sequelae include Parkinsonism, convulsive disorders, motor 
abnormalities, impaired and emotional disorders. The social prognosis of
survivors is generally poor.
1.5.4. Pathogenesis and pathology of JE
During the acute stage of JE, congestion, edema and small haemorrhages are found 
in the brain. Microscopic lesions include neuronal degeneration and necrosis, 
neuronophagia, glial nodules, and perivascular.‘ftammation. These changes occur in 
gray matter and predominantly affect diencephalic, mesencephalic and brain stem 
structures. A variety of pathological changes in extraneural tissues have also been 
noted, including hyperplasia of germinal centre of lymph nodes, enlargement of 
malpighian bodies in spleen, interstitial myocarditis, swelling and hyaline changes in 
hepatic Kupffer’s cells, pulmonary interalveolitis, and focal haemorrhages in the 
kidneys (Monath, 1990 and references therein).
26
In one study of fatal human cases, JE viral antigens were localized to neurones, 
with no evidence of glial cell infection (Johnson et al., 1985). The highest 
concentration of infected neurones was found in the thalamus and brain stems. Dual 
human infections with JE and herpes simplex viruses have been described (Hayashi 
and Arita, 1977). In analogous experiments in mice, JE viral antigens were localized 
in herpesvirus infected areas of the brain, suggesting that JE virus gained access to 
the CNS at sites of blood-brain barrier disruption caused by the herpes virus.
Transplacental infection in swine results in abortion and stillbirth; abortuses show 
encephalitic lesions. The virus also produces hypospermia in boars (Habu et al., 
1977). Histopathological changes include epididymitis, spermatogenic arrest and 
inflammation of the tunicatestis. Transplacental infection in humans has been 
documented, resulting in abortion and isolation of the virus from the fetuses 
(Chaturvedi et al., 1980). Pregnant mice inoculated intraperitoneanlly also transmit 
JE virus to the fetus, with subsequent abortion (Mathur et al., 1982).
1.6. Control of JE
The applications of vaccination and vector control are considered as important 
preventive strategies of JE, and have been carried out in many Asian countries. 
Although the eradication of the disease from any particular geographical areas is 
unlikely to be achieved due to the lack of control of the vector, the vaccination 
policies using effective vaccines are of utmost concern in the prevention of JE 
(Huang, 1982; Umenai et al., 1985).
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1.6.1. Inactivated vaccines
The earliest controlled field trials with an inactivated vaccine against JE were carried 
out in Japanese schools in the latter half of the 1940s. The vaccine was derived from 
the prototype Nakayama strain of JE virus (see review by Stephenson, 1989). At 
present formalin-inactivated vaccines for use in humans are prepared from infected 
adult mouse brains or infected primary hamster kidney cell cultures with Nakayama 
or P-3 strains in Japan and in China respectively. Mass vaccination compaigns have 
been carried out in China, Japan and Korea, with children as the target population. 
Primary immunization requires two doses at a 7 to 14 day interval. Booster 
vaccinations are given during the first year after the primary immunization and then 
at 3 to 4 year intervals (Barrett, 1990a and references therein). The published data 
showed that the vaccines were highly effective with the protection rates of greater 
than 90%. Side reactions to the purified inactivated JE vaccines are relatively rare 
and insignificant, and there have been no cases of postvaccinal encephalitis (Monath, 
1990 and references therein).
In consideration of the antigenic diversity of JE virus strains, a bivalent vaccine 
has been prepared by incorporating the Nakayama and Beijing-1 virus strains. It was 
shown to induce satisfactory level of neutralizing antibodies to all known JE virus 
strains (Fukai et ah, 1983). However, Okuno et al. (1987) has reported that the 
monovalent inactivated vaccine derived from Nakayama-NIH strain could induce 
antibodies that neutralized both homologous and heterologous virus strains. Therefore, 
it may be that the antigenic variation is an academic problem rather than a practical 
one.
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1.6.2. Live vaccines
The development of a live attenuated JE vaccine has been investigated in China and 
Japan for a number of years. Several Japanese groups have derived attenuated 
variants for use as vaccines, but so far these have only been given clinical trials in 
domestic animals. The most widely used is the M strain, a mutant derived from a 
wild-type strain Mukai by repeated serial passages in embryonic mouse skin culture 
(Inoue, 1964; more details will be given in the next section). Open field trials with 
pigs have demonstrated that pigs immunized with this mutant developed a long-lasting 
immune response and this vaccine was capable of protecting pigs against the disease 
and reducing viraemia sufficiently to prevent the transmission of the virus by feeding 
mosquitos (Kodama et al., 1968). Other attenuated strains have also been used in 
experimental trials. However, the results were not satisfactory (Takenhara et al., 
1969; Hammon et al., 1963; Hammon et al., 1966).
The first successful attenuation of JE virus for vaccine purposes was achieved in 
China. The attenuated strains, SA-14-2-8, SA-14-5-3 and SA-14-14-2, were all 
derived from the wild-type strain SA-14 by repeated passages in primary baby 
hamster kidney (PHK) cell cultures. The detailed attenuation history and designation 
of these vaccine strains will be reviewed in next section. In a field trial involving 
500,000 horses, the vaccine SA-14-2-8 has demonstrated a protection efficiency rate 
of 87%, whereas only 50% of 8,000 children immunized with this vaccine developed 
neutralizing antibodies (Huang, 1982). This vaccine was withdrawn from clinical 
trials in humans. Extensive trials with the SA-14-5-3 and SA-14-14-2 vaccines have 
been carried out in humans and swine. Both these vaccines were equally effective in 
significantly reducing the incidence of stillbirths from pregnant sows (Ao et al.,
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1981). In human trials, however, the SA-14-14-2 vaccine, which was derived from 
the SA-14-5-3 variant by several passages in moue subcutaneous tissue, has been 
shown to be more immunogenic than the latter vaccine strain. Compared with the SA- 
14-5-3 vaccine, 100-fold less infectious SA-14-14-2 virus was required to infect and 
stimulate immunity in humans. Moreover, the seroconversion rate and the geometric 
mean antibody titres were higher following the SA-14-14-2 vaccine immunization than 
the SA-14-5-3 vaccination (seroconversion rate 95% vs 80%) (Liu, 1983). All these 
three vaccines were proven to be safe in humans, no side effects were reported to 
date. Currently, the vaccine strain SA-14-14-2 produced in PHK cells has been 
licensed for human use in China (Yu, personal communication).
1.7. Attenuation of JE viruses
Many workers have been trying to attenuate the pathogenicity of JE virus for mice 
in attempts to develop live JE vaccines since 1950s.
In 1957, Bhatt and Work, in their tissue culture studies on the JE virus 
serocomplex, reported that the prototype strain Nakayama of JE virus was attenuated 
to a degree for mice after passaging it repeatedly in primary monkey kidney (PMK) 
cell cultures. However, they found that the virus maintained the pathogenicity for 
mice following passages in primary chicken embryo (CE) cells. Li and Yu (1959) also 
found no reduction in the neurovirulence of the P3 strain of JE virus (which is used 
as the basis for the inactivated JE vaccine in China) even after 110 passages in CE 
cell cultures. Interestingly, Okuno (1959) demonstrated that a wild-type strain called 
Tanaka of JE virus was significantly attenuated in its pathogenicity for mice by 
repeated passages in 1-day old chicken embryos, although he confirmed that the
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Nakayama strain could not be attenuated after passages in above chicken embryo 
tissue.
In 1962, Rohitayodhin and Hammon developed an attenuated variant following 
temperature step-wise adaption of a wild-type isolate OCT-541 of JE virus in primary 
hamster kidney (PHK) cells. Further studies showed that this variant was so 
attenuated that it could not infect humans nor induce an immune response. Therefore, 
the potential of this attenuated variant for use as a vaccine was excluded (Hammon 
and Rhim, 1963; Hammon et ah, 1966). Using the same technique, however, they 
failed to attenuate the Nakayama strain (Rohitayodhin and Hammon, 1962). A similar 
observation was made by Takehara et al. (1969). They found that two Nakayama 
substrains, Nakayama-Yokken and Nakayama-NIH (both originated from the 
Nakayama-original strain by passage in mouse brain 102 and 47 times respectively), 
could not be attenuated by passage in PHK cell cultures. In comparison, the 
pathogenicity of another wild-type strain, AT31, for mice and piglets was significantly 
reduced following the same passage history in PHK cell cultures. Taken together, it 
seems that the Nakayama strain of JE virus is more difficult to attenuate by passage 
in primary cell cultures in comparison to other wild-type strains. This may be due to 
the strain differences. However, the cell substrates used for the passage should also 
influence the outcome, since the pathogenicity of the Nakayama strain was reduced 
by the passage in PMK cell cultures (but not other primary cell cultures used so far) 
(Bhatt and Work, 1957).
An attenuated mutant, termed the M mutant, was developed by Inoue in 1964 
following passages of the wild-type strain Mukai in embryonic mouse skin cell 
cultures. This attenuated mutant showed remarkably low pathogenicity for mice,
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monkeys (Ilyenko et al., 1972) and piglets (Kodama et at., 1968). Primary bovine 
kidney (PBK) cell cultures have also been used to attenuate a wild-type strain of JE 
virus. By repeated long passage of a wild-type strain Sagara in PBK cells at 
suboptimal temperature (30°C), the pathogenicity of the virus for mice and piglets was 
markedly reduced (Sazawa et ah, 1968; Fujisaki et ah, 1974). More recently, an 
attenuated strain, called ML-17, was developed by temperature step-wise adaption 
(37°G, 33°C, 30°C and 25°C) of a virulent wild-type strain JaOH-0566 in PMK cell 
cultures (Yoshida et ah, 1981). This attenuated variant was shown to be avirulent for 
adult mice, pigs, monkeys and, more importantly, for the mosquito Cx. 
tritaenorhynchm, the major vector for transmission of JE.
All the attenuated strains of JE virus except the ML-17 strain (as reviewed above) 
had the problem of genetic instability as they would readily revert back to virulence 
after only one or very few passages in mouse or monkey brains, or other primary cell 
cultures. Therefore, the studies on the use of these attenuated variants as practical 
JE vaccines were discontinued.
To date, the most extensive and complete study on the attenuation of a wild-type 
strain of JE virus for vaccine purposes was performed in China between the 1960s 
and 1970s (see review by Huang, 1982). After initially failing to attenuate the P3 
strain of JE virus by repeated passage in CE cell cultures (Li and Yu, 1959), a low 
peripheral pathogenic but highly neurovirulent strain SA-14 was chosen for passage 
in PHK cell cultures (Li et ah, 1962, 1966; Yu et ah, 1962, 1973, 1981). A 
significant drop in neurovirulence was observed after 20 passages, and after 100 
passages the virus was plaque purified. From the original low neurovirulence plaque 
variant, 12-1-7, three attenuated strains were derived for vaccine production. The SA-
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14-5-3 variant was obtained by further plaque purification of the 12-1-7 variant, while 
the SA-14-2-8 variant was obtained by further attenuation using ultraviolet irradiation 
and plaque purification. The third variant SA-14-14-2 was derived from the SA-14-5- 
3 variant by 7 mouse subcutaneous passages and further plaque purification. Both 
laboratory tests and field trials showed that these three variants are highly attenuated 
and the attenuated phenotype (for adult mice, monkeys, pigs and horses) is stable 
following several passages in suckling mouse brain (but these vaccine viruses are still 
virulent for suckling mice) and various tissue cultures. More importantly, it has been 
shown that the SA-14-2-8 and SA-14-14-2/PHK vaccine viruses lost mosquito- 
competence (Yu, personal communication). However, the mosquito-competence of 
the vaccine strain SA-14-5-3 has not been examined. Currently, the PHK cell grown 
SA-14-14-2 vaccine is being used in China for human vaccination (Yu, personal 
communication).
Although no apparent adverse reactions have been observed in humans receiving 
the SA-14-14-2 vaccine produced in PHK cell culture, alternative cell substrates might 
offer advantage in standardization of the vaccine, including testing for adventitious 
agents, and production. Therefore, the Chinese workers collaborated with an 
American group and adapted this vaccine virus to grow in primary dog kidney (PDK) 
cell culture. They demonstrated that this PDK cell adapted virus (after nine PDK cell 
passages) had the same biological characteristics as the PHK grown vaccine virus 
used in China (Eckels et ah, 1988). However, the results of clinical trials with this 
PDK derived SA-14-14-2 vaccine remain to be seen. The detailed attenuation history 
and designation of the SA-14 series vaccines are shown in Figure 1.3.
It is noteworthy that, to date, attenuation of JE viruses has only been obtained by
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Figure 1.3
History of derivation of SA-14 series vaccines
SA-14; parent seed : isolate from a pool of larvae of Cpipiens mosquitos: 
11 serial passages in weanling mice oy i.e. route
100 serial passages in primary hamster kidney (PHK) cell cultures:
3 X plaque purification in chick embryo (CE) cell cultures
clone*12-l-7 ultraviolet irradiation and plaque purification in PHK cells
1 mouse intraperitoneal passage with harvest of spleen; 
virus from spleen used for plaque purification in CE cells
clone 2
3 X plaque purification in CE cells SA^14-2-8
clone 9
1 mouse subcutaneous passage and 1 plaque purification in CE cells; 
subcutaneous tissue were used for the source of virus for plaque purification
clone 9-7
6 hamster oral passages; spleen harvested for virus passage 
and for 2 x plaque purification in PHK cells
clone 5-3
5 suckling mouse subcutaneous passages followed by 2 x plaque purification 
in PHK cells; tissue from injection site used for subpassage and 
plaque purification
clone 14-2/PHK
9 passages and plaque purification in PDK cells
clone 14-2/PDK9
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repeated prolonged passages in primary cell cultures, e.g. primary baby hamster 
kidney cell culture (PHK), primary bovine kidney cell culture (PBK), primary 
monkey kidney cell culture (PMK), primary chicken embryo (CE) fibroblasts (or 
tissue) and embryonic murine skin culture. The first attenuated flavivirus vaccine, the 
17D strain of YF virus was also developed by repeated (176) passage in primary 
tissue (whole chicken embryos) (see review by Barrett, 1987). Recently, DEN virus 
types 2 and 4 were attenuated for vaccine purposes by 53 and 48 passages in PDK 
cell cultures respectively (Bhamarapravati et al., 1987; Angsubphakom et al., 1988).
During 1960s, three different research groups demonstrated that attenuation of YF 
virus strain Asibi for monkeys could occur during only six consecutive passages in 
HeLa cells, a continuous cell line derived from a human cervical carcinoma (Hardy, 
1963; Hearn et ah, 1965; Converse et al., 1971). This work was recently confirmed 
and extended by Barrett et al. (1990), who reported that six sequential HeLa cell 
passages of the YF virus Asibi strain could result in the attenuation of the virus for 
both monkeys and newborn mice. The similar observation has also been reported for 
strains of WN virus, a member of the JE serocomplex, (Dunster et al., 1990). 
Another member of the JE serocomplex, MVE virus was found to be attenuated for 
adult mice following 10 passages in SW13 cells, a continuous cell line derived from 
a human adenocarcinoma, (Lobigs et al., 1990). To date, however, no studies have 
documented attenuation of JE virus using any continuous cell lines.
1.8. Antigenic studies of JE viruses
1.8.1. Antigenic classification
Since Hale and Lee reported that antigenic variation existed among different strains
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of JE viruses isolated in Malaya in 1954, comparative antigenic studies of different 
JE virus strains have been undertaken by many investigators.
In 1968, the antigenic characteristics of 26 JE virus strains isolated in Japan and 
Malaya between 1936 and 1966 were examined and compared using antibody- 
adsorption, haemagglutination inhibition (HAI) and complement-fixation tests (Okuno 
et al., 1968). From their studies, two immunotypes of JE virus were identified. One 
comprised two strains, Nakayama-NIH and 1-58, and was designated as the 1-58 
immunotype. Another immunotype, termed JaGArOl, comprised 17 strains, which 
shared the antigenic properties of the JaGArOl strain. They found that the 1-58 
immunotype differed more markedly from the related fiaviviruses, e.g. Murray Valley 
encephalitis (MVE) and West Nile (WN) viruses, than the JaGArOl immunotype.
Recently, the antigenic properties of different JE virus strains have been 
investigated and compared using monoclonal antibodies (MAbs) (Kobayashi et al., 
1984; 1985). The antigenic relationships among 27 strains of JE virus were analyzed 
by plaque reduction neutralization and HAI tests using 14 JE type specific MAbs. The 
results showed that the 27 strains of JE virus could be classified into at least 4 
antigenic groups (Table 1.6). From the table, it can be seen that at least three distinct 
antigenic groups exist among the JE virus strains isolated in Japan over a period of 
more than 40 years (Of the 27 JE virus strains, 24 were isolated from Japan and 3 
in Southeast Asia). However, JE virus strains from China, Korea, USSR, India and 
other countries were not included in their studies and these works only used JE virus 
type specific MAbs, which would not provide accurate reflection of the spectrum of 
the E protein epitopes. The mechanism of antigenic variation of different JE virus 
strains is obscure. Clearly, it is important to do further investigation into the antigenic
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Table 1.6
Antigenic classification of JE virus strains using MAbs
year
of isolation Group I Group II
Group III Group IV
1935 Nakayama-RFVL
Nakayama-Yoken
Nakayama-Yakken
1949
1952
1953
Kalinina
G-lIate
Sekiya
Mochizuki
Muar
1959
1964
1965
JaGArOl
JaGAr02
Nishizono
ChiangMai
JaGAr401465
JaGSOl
Hatano65
1966 Kamiyama
Sasazaki
1969 Mie44-1
691004
1971
1972
Fukuoka7101
Fukuoka7202
1973 Fukuoka7309
Fukuoka7311
1974 Fukuoka7452Fukuoka7463
1975 Fukuoka7506
1979 Kumamota80679
N.B. The results are summarized from Kobayashi etal. 1984.
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variation of different JE virus strains from the points of view of vaccines, diagnosis, 
ecology and epidemiology of JE virus. ^
1.8.2. Antigenic analysis of JE virus E protein using MAbs
The E protein is responsible for many biological activities of JE virus, e.g. HA, N 
and passive protection,. The purified E protein from JE virions ha$ been found to 
agglutinate red blood cells, to bind to HAI antibodies, and to elicit N antibodies and 
protection against JE virus infection when injected into mice (Takeyami et al. , 1982). 
To date, MAbs have been prepared against a number of wild-type strains of JE virus 
to analyze the E protein in detail.
The first isolation of anti-E virus MAbs was reported by Lin (1982) using an 
unnamed wild-type strain of JE virus. All the MAbs produced were JE antigenic 
subgroup reactive with HAI but no N activities, In 1983, Chen et al. prepared three 
hybridoma cell lines secreting MAbs against the wild-type strain SA-14 (the wild-type 
parent strain of the live attenuated vaccine strains SA-14-2-8, SA-14-5-3, and SA-14- 
14-2/PHK and PDK9) of JE virus, and three distinct activities were characterized. 
One MAb was shown to be JE and WN virus specific and elicit HAI activity only. 
While the other two were JE virus type specific and showed N activity only. It is 
interesting that one of these two MAbs was JE strain specific only neutralizing the 
SA-14 and its attenuated vaccine derivative SA-14-2-8, but not other JE virus strains 
examined.
The most complete analysis of the JE virus E proteins was performed by Kimura- 
Kuroda and Yasui (1983, 1986). Using the wild-type strain JaGArOl virus as 
immunogen, a panel of MAbs were prepared. They reported that the E protien of JE
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virus could be divided into at least eight epitopes based on the results obtained from 
ELISA, HAI, N and competitive binding assays (CBA) with the MAbs. The results 
are summarized in Table 1.7. It can be seen that one of the type specific epitopes 
(group 8) elicits MAbs that have high N titre both in vitro and in vivo, but no HAI 
activity. This epitope was postulated to be located in the domain on the E protein 
which must be critical for the infection of IE virus. The similar functionally important 
JE-type specific epitopes have also been identified by Zhang et al. (1989) and Xiu et 
al. (1985). In other fiaviviruses, namely TBE and SLE viruses, at least one similar 
critical neutralization site has been shown to be the virus type specific (Heinz et al., 
1983; Roehrig et al., 1983).
On the other hand, it can also be seen from Table 1.7 that at least one epitope 
recognized by MAbs eliciting HAI activity is conserved among fiaviviruses, because 
the MAbs in group one cross-reacted in HAI assays with fiaviviruses from other 
subgroups, e.g. DEN, YF and TBE subgroups. Moreover, enhancement of JE and 
DEN virus infectivities by these MAbs was observed in a mouse macrophage cell line 
P388D1 (Kimura-Kuroda and Yasui, 1986). With the aim of grouping different strains 
of JE virus, a panel of MAbs was prepared against the wild-type JE virus strain 
Nakayama-RFVL (Kabayashi et al., 1984, 1985; Section 1.8.1). All the MAbs were 
shown to possess HAI activity, and were characterized into JE virus type specific, JE 
virus antigenic subgroup specific and flavivirus group common based on ELISA tests.
Kedamath et al. (1986) prepared against a panel of 16 MAbs against an Indian 
wild-type strain (733913) of JE virus, and found the similar patterns of reactivity as 
reported by the previous workers, i.e. ranging in cross-rectivity from JE virus type 
specific to flavivirus group common. These MAbs were later used to map the
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Table 1.7
Biological activities of the epitopes on the E protein of JE virus
epitopes 
recognized by
biological
functions
cross-
reactivities
MAb group 1 HAI + + N- group-reactive
2 HAI + + N- subgroup-reactive
3 HAI- N+ JE virus-specific
8 HAI- N-)-+-f- JE virus-specific
7 HAI-l-H N ++ subgroup-specific
6 HAI- N- subgroup-specific
5 HAI- N-f subgroup-specific
4 HAI- N4- subgroup-specific
N.B. The results are summarized from Kimura-Kuroda and Yasui, 1986.
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epitopes on the E protein of JE virus (Cecilia et al., 1988). Their epitope mapping 
results generally confirmed the original work by Kimura-Kuroda and Yasui (1983, 
1986). However, it is noteworthy that at least one of the JE virus type specific 
epitopes, which is critical in respect to the virus replication based on the N tests in 
vitro and in vivo, was also identified in their studies. Other MAbs studies on the wild- 
type strains of JE virus including JaGArS982 and Nakayama strains provided similar 
information on the antigenic structure of the E protein of JE virus (Srivatava et al., 
1988; Mason cr al., 1987).
Based on the MAb analyses of JE virus E protein, it appears that the E protein I 
contains at least four antigenic determinants, i.e. JE virus strain specific, JE virus 
type specific, JE virus subgroup specific, and flavivirus group common. In addition, 
at least one of the JE virus type specific (strain) specific epitopes is critical in terms 
of the virus replication. The MAb studies on other fiaviviruses, e.g. TBE and SLE 
viruses, identified similar basic patterns of antigenic determinants (see reviews by 
Heinz, 1986; Roehrig, 1986).
It should be pointed out that all the MAb studies mentioned above were based on 
wild-type strains of JE virus. Therefore, no wild-type and/or attenuated vaccine strain 
specific epitopes were identified in these studies. To date, only one brief report has 
appeared describing MAbs specific for attenuated vaccine strains SA-14-2-8 and SA- 
14-5-3 (Fang and Chen, 1988). Thus, from both standpoints of view of characteriza­
tion of the live attenuated JE vaccines and understanding the mechanism of virulence 
and attenuation of JE virus, comparative MAb studies on wild-type and attenuated 
vaccine strains of JE virus are required to be undertaken.
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1.9. Nucleotide sequences of JE viruses
1.9.1. Comparison of the nucleotide and deduced amino acid sequences 
of JE virus E protein with other fiaviviruses
From the flavivirus genomic RNA sequence and the deduced protein sequence data,
it was observed that there was a high degree of conservation of amino acids in the E
protein of fiaviviruses, especially among the viruses belonging to the same antigenic
subgroup. Table 1.8 shows the homologies of the E protein of eight viruses in the JE
*
virus subgroup.
It can be seen from Table 1.8 that JE virus has the highest percentage of amino 
acid homology with MVE virus, and the lowest with SLE virus. This analysis 
corroborates the antigenic studies reported by Kimura-Kuroda and Yasui (1986). They 
found that JE virus was antigenically closest to MVE virus, but distant from SLE 
virus among the fiaviviruses in this subgroup.
According to the flavivirus RNA and the protein sequence data to date, especially 
the data of the E protein, it is likely that the broad cross-reactions among fiaviviruses, 
commonly observed in HAI assays and occasionally in N tests, are due to immune 
recognition of conserved E protein domains that mediate important biological 
functions in the virus life cycle, e.g. specific binding to host cells or virus fusion with 
intracellular membranes during penetration. The high amino acid homology among
the E protein of the fiaviviruses in the JE virus subgroup indicates the existence of
pi'^ ure
functional and presumably selective - to conserve the protein structure through 
evolution. The amino acid sequences of the E protein of the few wild-type strains 
JE virus so far published show a very high homology (Table 1.8) and are only 
different by, at most, eight of the 500 amino acids.
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Table 1.8
Comparison of amino acid homologies among the E protein* ' of various 
members of the JE subgroup in
Virus vs Virus
JE
MVE SLE WN KUNSA-14 Beijing-1 Nakayama JaOArS982
SA-14 (GDC) 98.6^ 99.0 98.6 81.8 70.5 77.2 77.8
Beijing-1 ---- 99.2 98.4 81.6 70.5 77.6 78.0
Nakayama ---- 9&8 822 70.7 77.6 77.8
JaOArS982 ---- 822 70.9 77.4 77.6
MVE 73.7 77.0 78.8
SLE 71.7 71.3
WN 926
KUN
N.B. 1) JE virus strain SA-14 was sequenced by Nitayaphan etal. 1990; strain Nakayama by McAda 
1987;strainBeijing-1 byHashimoto 1988; strain JaOArS982 by 
Sumiyoshi 1986.
2) MVE virus was sequenced by Dalgarno <?/.?/1986; SLE virus by Trent 1987;
WN virus by Wengler 1985; KUN virus by Coia 1988.
3) The Beckman MicroGenie programme was used for the sequence data analysis.
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1.9.2. Comparison of the nucleotide and deduced amino acid sequences of the 
wild-type strain SA-14 with its attenuated vaccine derivatives:
SA-14-5-3 and SA-14-14-2/PHK and PDK9
Recently, the genomes of the wild-type parent strain and its attenuated vaccine
derivatives SA-14-5-3 (Trent, personal communication), SA-14-14-2/PHK (Aiharaef
ah, 1991) and SA-14-14-2/PDK9 (Nitayaphan et ah, 1990) have been cloned,
sequenced and compared. The deduced amino acid substitutions in the viral protein
genes and the nucleotide changes in the 5’- and 3’-noncoding regions are compared
in Table 1.9.
Firstly, it should be noted that there are several nucleotide and/or amino acid 
differences between the genome sequences of the parent strain SA-14 reported by the 
two individual groups (Nitayaphan et a/.(GDC), 1990; Aihara et a/.(Japan), 1991) (E- 
315, E-439, NS1-292, NSl-339, NS1-351, NS1-354, NS1-392, NS2a-46 and NS5- 
328, and one nucleotide difference at position 10784 in the 3’-noncoding region). This 
variation in the results of the nucleotide sequence of the same JE virus strain SA-14 
may be due to the plaque purification prior to the molecular cloning or technical 
mistakes. Nonetheless, these differences make interpretation of the sequence data 
difficult. Thus, the vaccine derivatives were compared to the sequence results of the 
wild-type parent virus SA-14 reported by the appropriate groups (i.e. SA-14-5-3 and 
SA-14-14-2/PDK9 vs SA-14 sequence (Nitayaphan et a/., 1990); and SA-14-14- 
2/PHK vs SA-14 (Aihara et ah, 1991)).
There are a total of 45 nucleotide differences between the SA-14 and SA-14-14- 
2/PDK9 viruses coding for 15 amino acid substitutions (Nitayaphan et ah, 1990). 
Seven nucleotide changes, resulting in 5 amino acid substitutions, were found in the 
E protein genes. These are E-107 (Leu-»Phe), 138 (Glu->Lys), 176 (Ile->Val), 243
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Table 1.9
Comparison of nucleotide and amino acid differences between SA14 and its 
attenuated vaccinederivative SA-14-5-3, SA-14-14-2/PHK and PDK9
Position SA14 SA14- 14-2 SA-14-5-3 SA14 SA14
Nuc AA (CDC/JAPf (PHK) (PDK) (CDC) (CDC) (JAP)
15 5nc C C C G
39 5nc T A A A
292 C-65 leu* ser ser ser
1296 E-107 leu* phe phe phe
1389 E-138 gju* lys lys lys
1503 E-176 fle* val val val
1506 E-177 thr* ala thr thr
1704 E-243 ^u glu lys glu
1769 E-264 gin* his gin gin
1813 E-279 lys met met met
1921 E-315 val val val val ala*
2293 E-439 arg arg arg arg lys*
2402 E-474 ala ala ala val
3351 NSl-292 ser ser ser ser giy*
3493 NSl-339 met met met met arg*
3528 NSl-351 his asp asp asp asp*
3539 NSl-354 lys lys lys lys asn*
3652 NSl-392 val val val val ala*
3849 NS2a-46 val val val He val
4403 NS2b-63 glu* asp asp asp
4408 NS2b-65 asp* giy giy giy
4782 NS3-59 met* val val val
4825 NS3-73 arg lys lys lys
4921 NS3-105 ala* giy giy giy
5634 NS3-343 arg* trp arg arg
6634 NS4a-27 He* thr ile ilc
7227 NS4A-225 He* val val val
8658 NS5-328 lys lys lys
8832 NS5-386 his* tyr tyr tyr
9688 NS5-671 val* ala val val
10428 3nc U* C C C
10784 3nc c u c C -
SA14 (CDC/JAP) refers to where both the CDC and Japanese groups agree on the sequence o f SA14 
Nucleotidesand amino acids that are common to wild-type strains JaOArS982, Beijing-1 and the virus with the*
SA14-14-2 nucleotides/amino acids that are in bold refer to differences between the two vaccine clones
Data based on published sequences o f Nitayaphan etal. (1990) who reported the sequences ofSA14 (CDC) and SA14-14-2 (PDK) 
viruses, and Aihara etal. (1991)who reported the sequencesofSA14 (JAP) and SA14-14-2 (PHK) viruses
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(Glu->Lys) and 279 (Lys->Met). The other differences are one nucleotide change each 
in the 5’ and 3’ noncoding regions and the following amino acid substitutions: 1 in 
the capsid, 1 in the NS2a, 2 in the NS2b, 3 in the NS3, 1 in the NS4a and 2 in the 
NS5.
No amino acid substitutions in PrM, C and the nonstructural protein genes were 
found between the SA-14-5-3 and SA-14-14-2/PDK9 strains (Trent, personal 
communication). Compared with the wild-type parent strain SA-14, 5 amino acid 
substitutions were indentified on the E protein of the SA-14-5-3 vaccine virus, of 
which 4 (amino acid positions 107, 138, 176 and 279) are identical to that of the SA- 
14-14-2/PDK9 virus, plus one substitution unique each to the SA-14- 14-2/PDK9 
(position 243 Lys) and the SA-14-5-3 (position 474 Val). In addition to the same 
U-»A transversion at the position 39 of the 5’-noncoding region as the SA-14-14- 
2/PDK9 virus, a unique nucleotide substitution (C-^G) was identified for the SA-14-5- 
3 vaccine virus at the position 15 of this region. Thus, one unique amino acid 
substitution in the E protein gene and one unique nucleotide change in the 5’- 
noncoding region were identified as differentiating the SA-14-5-3 and SA-14-14- 
2/PDK9 vaccine strains. These unique nucleotide substitutions must contribute to any 
unique biological properties of the SA-14-5-3 strain in comparison with the wild-type 
parent and the other vaccine strain SA-14-14-2/PDK9.
The genome of the SA-14-14-2/PHK vaccine strain was sequenced and compared 
to that of the wild-type parent strain SA-14 (Aihara et oL, 1991). 57 nucleotide 
substitutions were found to distribute all over the genome and resulted in 24 amino 
acid changes. As can be seen in Table 1.9, 8 amino acid substitutions are located in 
the E protein at positions 107 (Leu-»Phe), 138 (Glu->Lys), 176 (Ile^Val), 177
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(Thr-^Ala), 264 (Gln-^His), 279 (Lys^Met), 315 (Ala->Val) and 439 (Lys^Arg). The 
remaining amino acid (or nucleotide) substitutions include: 1 nucleotide change in the 
5’-noncoding region (same as the SA-14-14-2/PDK9 at the position 39), 1 amino acid 
change in the C, 5 in the NSl, 2 in the NS2b, 4 in the NS3, 2 in the NS4a, 2 in the 
NS5, and 2 nucleotide changes in the 3’-noncoding region. Compared with the parent 
strain SA-14 and the other two vaccine strains (SA-14-5-3 and SA-14- 14-2/PDK9), 
the following amino acid substitutions are unique to the SA-14-14-2/PHK virus: E- 
177 (Ala), E-264 (His), NSl-351 (His), NS3-343 (Trp), NS4a-27 (Trp) and NS5- 
671/2 (Ala). The 3’-noncoding region change at position 10,784 was not identified 
by Nitayaphan et al. (1990).
The amino acid sequences of the viral proteins of the wild-type strains JaOArS982 
and Beijing-1 were also included in the comparison in Table 1.9. Conserved amino 
acids among the three wild-type strains JaOArS982, Beijing-1 and SA-14 are 
indicated by asterisks. It is of interest that all the amino acids, where the SA-14-14- 
2/PHK and PDK9 and SA-14-5-3 vaccine strains show substitutions except the one 
in NS3 (73), are conserved in these three wild-type strains. In addition, out of the 
three point mutations in the noncoding regions, two nucleotides (5’-noncoding region 
39 and 3’-noncoding region 10428) identified in the genome of the SA-14 are found 
to be conserved in the genomes of/other two wild-type strains. Thus, many of the 
mutations identified may be determinants of the attenuated phenotype. Among the 
amino acid substitutions in the E protein, 4 (position 107, 138, 176 and 279) are 
unique and identical to the attenuated vaccine strains (Table 1.10). While these four 
amino acids in the E protein of the wild-type parent strain SA-14 are conserved in the 
other four wild-type strains. Thus, it suggests that these amino acids in the E protein
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Table 1.10
Comparison of amino acid differences in the E protein between 
wild-type and vaccine strains of JE virus
Virus strains
amino acid number
1
9
1 1
I
1
9
2
\
2 2
I
3
I
4 4
\
SA-14-5-3 F K V T E Q M V R V
SA-14-14-2/PHK F K V A E H M V R A
SA-14-14-2/PDK9 F K V T K Q M V R A
SA-14 (CDC) L E I T E Q K V R A
SA-14 (Japan) L E T T E Q K A K A
JaOArS982 L E I T E Q K A K A
Nakayama L E I T E Q K A K A
Beijing-1 L E I T E Q K A K A
Sarawak L E I T E Q K A K A
N.B. Sequence data is taken from Cecilia and Gould (1991) [Sarawak]; 
Nitayaphan ^ /^/(1990) [SA-14, (CDC) and SA-14-14-2/PDK9]; 
Aihara etal. (1991) [SA-14 (Japan) and SA-14-14-2/PHK); 
Hashimoto (1988) [Beijing-1]; Sumiyoshi <?/^/(1987)
[JaOArS982]; McAda (1987) [Nakayama] and Trent 
(personal communication) [SA-14-5-3].
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may be conformationally or functionally important in relation to attenuation and/or 
virulence of JE virus. However, comparative studies on the biological characteristics 
of wi’ Id-type and attenuated strains of JE virus are required to elucidate the what role 
such mutations play in pathogenicity of JE virus.
1.10. Aims of the project
To date, although a large number of studies on fiaviviruses, involving molecular 
analyses of the structure and sequences of the viral proteins and genomic RNAs, have 
been reported (Rice et al., 1986; Chambers et al., 1990), the molecular basis for 
virulence and attenuation of fiaviviruses are poorly understood. Comparative studies 
on wild-type virulent strains and their attenuated derivatives are a key approach to 
reveal the molecular mechanism of virulence and attenuation of fiaviviruses, including 
JE viruses.
The availability of the wild-type virulent strain SA-14 and its attenuated vaccine 
derivatives (SA-14-2-8, SA-14-5-3 and SA-14-14-2) of JE virus provides an excellent 
system, with which to perform comparative studies to investigate the molecular basis 
of the virulence and/or attenuation of JE virus. As reviewed in Section 1.9.2, the 
complete genomes of the wild-type parent strain SA-14 and the two attenuated vaccine 
derivatives (SA-14-5-3 and SA-14-14-2/PHK and PDK9 derivatives) have been 
sequenced and compared. However, due to the lack of basic biological knowledge on 
these virus strains, such molecular biological studies give an ambiguous insight with 
respect to the molecular mechanism(s) of virulence and attenuation of JE virus. 
Therefore, the present project was initiated to investigate the following areas.
Firstly, the growth, pathogenic and antigenic characteristics of the wild-type parent
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strain SA-14 and the three vaccine derivatives, SA-14-2-8, SA-14-5-3 and SA-14-14-2 
(PHK and PDK9 derivatives), would be examined and compared with the aim to find 
the correlation between the attenuated phenotype and such biological markers. To 
date, attenuation of JE virus could only be obtained by repeated prolonged passages 
in primary cell cultures. Thus, the second aim of this project was to investigate 
whether or not wild-type strains of JE virus could be attenuated by only a few 
passages in HeLa cells, which have been used to attenuate YF and WN viruses after 
only six passages. The HeLa cell passaged JE virus would be examined for biological 
changes, which may be related to the virulence and/or attenuation of the virus. 
Thirdly, both attenuated (including the SA-14 series vaccine strains and the HeLa cell 
passaged wild-type JE viruses, which might be attenuated) and wild-type virulent 
strains of JE virus would be examined and compared for the early event in the virus 
replication cycle, i.e. the viral attachment, with the aim of discovering any correlation 
between this property and the attenuation and/or virulence of the virus.
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Chapter 2 
Materials and methods
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2.1. Cell cultures
2.1.1. Growth and maintanence of cell cultures
All the cell cultures used in this project were obtained from the I-  ^^  k
in the Author’s laboratory and were grown and maintained for propagation and 
various assays of virus. The designation and use of the cell cultures were included in 
Table 2.1.
All the cells were grown and maintained in Eagle’s minimal essential medium 
(EMEM, Flow laboratories, UK) supplemented with L-glutamine (2mM, Flow 
laboratories) and non-essential amino acids (ImM, Flow laboratories). In addition, 
the medium was supplemented with sodium bicarbonate (20mM, Flow laboratories), 
100 units/ml penicillin G (Sigma), 0.1 mg/ml streptomycin sulphate (Sigma), and 1% 
(v/v) or 5% (v/v) foetal calf serum (FCS, Flow laboratories) for either maintanence 
or growth medium respectively. Cells were incubated at 37°C (except the mosquito 
cells C6-36, which were grown at 28°C) under the condition of 5% carbon dioxide 
(COz).
Cells were sub-cultured by trypsinization of the confluent cell monolayers (trypsin, 
2.5% [w/v] in Hanks salts. Flow laboratories, EDTA 0.05% [w/v] in phosphate 
buffer saline [PBS]), prior to seeding of a fresh tissue culture flask (Nunc). Cells 
were normally amplified at split ratio of 1:5. The mosquito cells C6-36 and the 
mouse myeloma cells NS-1 were sub-cultured and amplified by trituration to remove 
the cells from the surface of a tissue culture flask prior to seeding of , new tissue 
culture flas^.
52
Table 2.1
Designation of cell cultures used in the present project
Cell cultures Abbreviations Source
African green monkey 
undifferentiated kidney 
cell line
Vero Row Laboratories
Rhesus monkey 
undifferentiated kidney 
cell line
LLC-MK2 Row Laboratories
Human adenocarcinama 
cell line
SW13 Row Laboratories
Human cer/ical carcinama 
cell line
HeLa Row Laboratories
AedesaJbopictus 
larvae cell line
C6-36 RowLaboratories
Baby hamster 
undifferentiated kidney 
cell line
BHK21 Row Laboratories
Mouse fibroblast 
cell line
L-929 Department of Biological sciences 
University of Warwick
Cicken embryo fibroblast 
primary cell culture
CEF Departmental stock
Mousemyeloma 
cell line
NS-1 RowLaboratories
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2.1.2. Storage and preservation of cell cultures
Subconfluent (80-90%) cell monolayers were detached from tissue culture flasks by 
the same procedure used in the cell sub-culture. Cells were pelleted at 2,000 rpm for 
5 minutes (mins) and then resuspended in the cell growth medium supplemented with 
7.5% dimethyl sulphoxide (DMSO, BDH AnalaR grade). The cells were aliquoted 
into liquid nitrogen ampoules (Nunc) and stored at -70°C overnight. Following this 
period, the ampoules were stored in liquid nitrogen (-196°C).
2.1.3. Resuscitation of preserved cell cultures
When required, ampoules of the desired cell cultures were removed from liquid 
nitrogen and defrosted in a 37°C water bath. The cells were pelleted. The supernatant, 
containing DMSO, was removed and the cells were resuspended in 1 ml cell growth 
medium. Then, the cell suspension was transferred into tissue culture flasks and 
incubated at 37°C in a 5 % CO2 atmosphere and grown to confluency before further 
sub-culture.
2.2. Viruses
The designation, abbreviations and origins of viruses used in this project are included 
in Table 2.2. All viruses were obtained as freeze-dried preparations. These were 
reconstituted in sterile deionized distilled water and used to prepare seed stocks by 
infection of cell cultures.
Cell monolayers (used to grow viruses) were washed once with PBS (Oxoid) and 
virus stocks were prepared by infection of subconfluent (80-90%) cell monolayers at 
a multiplicity of infection (m.o.i.) of 0.1-1.0 pfu. Viruses were allowed to absorb to
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Table2.2
Designation of viruses used in the present project
Viruses abbreviations origins
Japanese encephalitis 
wild-type strains:
JE
SA-14
Beijing-1
Nakayama-original
Nakayama-Yoken
malaysia
Sarawak
G8924
782219
826309
Saigon
Thailand
Nepal
Taiwan
Indonesia
Nakayama-O
GDC, Fort Collins* 
LSTMH
CDC, Fort Collins 
LSTMH
CDC, Fort Collins 
CDC, Fort Collins 
CDC, Fort Collins 
CDC, Fort Collins 
CDC, Fort Collins 
InstitutePasteur 
LSTMH 
LSTMH
CDC, Fort Collins 
CDC, Fort Collins
Japanese encephalitis 
vaccine strains:
SA-14-2-8
SA-14-5-3
SA-14-14-2/PHK
SA-14-14-2/PDK9
2-8
5-3
14-2/PHK
14-2/PDK9
CDC, Fort Collins 
CDC, Fort Collins 
NICPBP, Beijing 
CDC, Fort Collins
Otherflaviviruses:
WestNilevirus:
EgyptlOl
Sarawak
WN
ElOl
Sara
J. S. Porterfield, Oxford 
J. S. Porterfield, Oxford
Murray Valley encephalitis 
strain original
MVE
CDC, Fort Collins
Continued on next page.
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Table 2.2 continued from the previous page
Viruses abbreviations origins
Dengue virus: DEN
Dengue-2 New Guinea 2-NG CDC, Fort Collins
Dengue-2Jamaika 2-Jama CDC, Fort Collins
Tick-borne encephalitis: TBE
LangatTP21 LGT-21 H. Webb, St. Thomas
LangatTP64 LGT-64 Hospital, UK.
Yellow fever virus: YF
Asibi LSTMH
17D-204Holland Roll LSTMH
17DD Brazil Braz LSTMH
17D-204 Dakar Dakar LSTMH
Non-flaviviruses
Semliki Forest virus SFV
strain TS+ School of Biological Sciences
reovirus type-3 
strain Dearing
University of Warick
*: Arbovirus Reference Branch, Division of Vector-borne Viral Diseases, 
Centers for Disease Control, Fort Collins, USA.
LSTMH: London School of Tropical Medicine and r  ^^  ; London, UK.
NICPBP: National Institute for the Control of Pharmaceutical and 
Biological Products, Beijing, China.
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the cell sheet by incubation at room temperature for 30 mins prior to the addition of 
cell maintanence medium (as described in Section 2.1.1). Viruses were harvested as 
cell culture supernatants when 80-90% cytopathic effect (CPE) occurred. The cell 
debris were removed from the supernatant by centrifugation at 2,000 rpm for 5 mins. 
Then, the supernatant was aliquoted in cryotubes (Nunc) and stored at -7(PC.
2.3. Passage of viruses in HeLa cells
Four wild-type strains of JE virus (SA-14, Beijing-1, Nakayama-ori/iginal 
[Nakayama-O] and 826309), JE vaccine strains (SA-14-2-8, SA-14-5-3 and SA-14-14- 
2/PDK9), and an alphavirus (Semliki Forest virus [SFV] strain TS+) were used to 
passage in HeLa cells. HeLa cells were grown to subconfluent (80-90%) monolayers. 
Prior to infection with the virus, the monolayer was washed with PBS and then 
infected with the virus at a m.o.i. of 5 pfu per cell. The SA-14 virus was also 
passaged into HeLa cells at a m.o.i. of 0.1. After 30 mins incubation at room 
temperature, the cell maintanence medium was added to the infected cell monolayer. 
The infected HeLa cells were incubated at 37°C in a 5% CO2 atmosphere. The virus 
was harvested when 80-90% CPE occurred or 3 days post infection, whichever was 
the shorter time. The same procedure was used to passage the virus 5 more times
2.4. Virus infectivity titrations
Virus infectivities were titrated by plaque assays on either LLC-MK2 or HeLa cell 
monolayers seeded in six well tissue culture dishes (Nunc). Ten-fold dilutions of virus 
were prepared in PBS and lOOul samples of appropriate dilutions were inoculated 
onto the cell monolayers that had been washed with PBS. Following incubation for
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30 mins at room temperature, the monolayers were overlayed with 5 ml of a mixture 
of 2% agar (w/v) (Sigma) and double strength cell maintanence medium supplemented 
with 0.05% DEAE (w/v). After 3-10 days incubation (depending upon the virus 
strains and cells used) at 37°C in 5% CO2 atmosphere, 2 ml of a second overlay 
medium (as above) containing 0.008% (w/v) neutral red (Gibco) was added to each 
well. Following overnight incubation in the dark at 37°C, virus plaques were recorded 
via the use of a light box (Genetic Research Instruments) and the virus titre was 
determined as Logio of the amount of plaque forming units (pfus) per ml, i.e. Logio 
pfu/ml.
2.5. Temperature sensitivity (ts) assays
Virus infectivity was titrated by the plaque assay in LLC-MK2 cells as described in
the previous section at 37®C and 39.5°C. A virus was determined as ts if a > 2  Log^o
reduction in the virus infectivity titre was observed at 39.5°C compared to that at
37°C. In addition, the efficiency of plating (e.o.p.) was also calculated to determine
the relative ability of viruses to replicate at a supraoptimal temperature.
e.o.p. = pfu/ml at 39.5°C 
pfu/ml at 37°C
2.6. Preparation of hybridoma cell lines secreting monoclonal antibodies
These procedures have been described previously (Cao, 1988). Briefly, inbred 6-week 
old female Balb/c mice (Olac. UK) were immunized intraperitoneally with 
approximately 10^  pfu of the virus. Five days after the initial immunization, the mice 
were boosted with the same dose by the same route. This procedure was repeated 
twice, three and five weeks after the initial inoculation. Three or five days after the
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final boost, the spleen was removed from the mouse and teased through a wire mesh 
to prepare a single spleen cell suspension.
Approximately 10^  spleen cells were mixed with 10^  NS-1 mouse myeloma cells 
and the cell mixture was centrifuged at 1,800 rpm for 5 mins. 1 ml of 50% 
polyethylene glycol 1500 (PEG 1500, Sigma) in L-15 medium (Gibco) was then 
slowly added to the cell pellet over 1 min. After the mixture had been swirled in a 
37°C water bath for 1 min, the cells were resuspended in 10 ml of L-15 medium over 
a period of 10 mins. The suspension was then centrifuged for 5 mins at 1,000 rpm. 
The pellet was gently resuspended in 25 ml of L-15 medium supplemented with 20% 
ECS and HAT (lOum hypoxanthine, 0.04um aminopterine and 1.6um thymidine). 
Cell suspension (75ul) was seeded in each well of U-bottomed 96-well microtitre plate 
and a further 200ul of the above L-15 medium was added to each well.
The cell fusions were incubated at 37°C in a 5 % CO2 atmosphere and fed every 
3-4 days with the fresh medium. Colonies of hybrydomas appeared 10-14 days after 
the fusion and the culture supernatants were screened by indirect immunofluorescence 
(IIP) tests for the presence of the antibodies to the immunogen virus. Positive wells 
were selected for cloning and negative wells re-incubated and retested for antibodies 
at 20 days post fusion. Any remaining negative wells were rejected. Hybrydoma cells 
from positive wells were cloned by serial two-fold dilution of the cells in the 
microtitre plates, and single clones obtained at the end-point were retested for 
secretion of antibodies against the immunogen virus using IIP tests. Those clones still 
positive were amplified in L-15 medium containing HAT or HT (i.e. no 
aminopterine) depending on the hybrydomas.
Those hybridoma cell lines secreting the antiviral MAbs were grown as ascitic
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tumors in mice to produce the ascites, which contain high titre MAbs. Six week old 
female Balb/c mice (Olac. UK) were used to produce the ascites. One week before 
the inoculation of the MAb secreting hybridoma cells, the mice were primed 
intraperitoneally (i.p.) with 0.5 ml of pristane (2,6,10,4-tetramethylpentadecane). One 
mouse was inoculated i.p. with approximately 10^  cells, which were suspended in 0.3 
ml PBS. As soon as the accumulation of the ascites became evident, it was harvested 
using%terile needle from the peritoneal cavity (usually 3 weeks after the inoculation). 
The harvested ascites was centrifuged at 2,000 rpm for 5 mins and was stored at - 
20°C for further studies.
2.7. Determination of r-globulin concentration in the ascitic fluids
The MAb containing ascitic fluid was diluted 1:1000 and then mixed with the protein 
sensitive reagents (diluted 1:5, purchased as protein assay mixture from BioRad). 
Following 15 mins incubation at room temperature, optical density of the mixture was 
determined using a Pye Unicam Model PU 2280 spectrophotometer at the wavelength 
of 595 nm. The r-globulin concentration in the ascitic fluid was calculated by 
comparison to that of the standard protein sample provided.
2.8. Isotyping of MAbs
The MAbs were isotyped using a mouse MAb isotyping kit (Amersham International). 
MAb . samples were used as the supernatant collected directly from the hybridoma 
cell culture.
5 ml of the MAb sample was added to the isotyping stick ( The stick carries goat 
antibodies specific for different types of the peptide chain of immunoglobulins. A
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positive control is also incorporated onto the stick. The stick has been treated to 
prevent non-specific binding of proteins). Following 15 mins incubation at room 
temperature, the MAb sample solution was removed and the typing stick was washed 
twice in TBS-T buffer (pH 7.6, 20mM Tris base -f 137mM sodium chloride [NaCl]
-f 4mM HCl -f- 0.1% Tween). Then, the isotyping stick was incubated with 5 ml of 
peroxidase labelled anti-mouse antibody solution (in TBS-T) for 15 mins at room 
temperature. After the washing of the isotyping stick, 5 ml of the substrate solution 
(4-chloro-1 -naphthol and hydrogen peroxide) was added to the stick. Following a  
further 15 mins incubation, the stick was washed with distilled water and the results 
were interpreted immediately.
2.9. Determination of the protein specificity of MAbs
Radioimmunoprecipitation (RIP) was used to determine the viral protein specificity 
of MAbs prepared in this study.
Vero cells were infected with the IE vaccine strain SA-14-14-2/PDK9 at a m.o.i. 
of 1 pfu as described in Section 2.2. At 30 hours (hK) post infection, 2 ng/ml 
actinomycin D was added and incubated for 18 h^at 37°C. The medium was then 
replaced with methonine-deficient medium (Sigma) and incubated for 2 hf; followed 
by the addition of p^S]-methionine (50u Ci/ml, sp. act. 800 Ci/mmol; Amersham 
International) for 4 h^ Tat 37°C. Monolayers were washed with cold PBS, then Vero 
cells were lysed using RIP buffer (2% Triton X-100, 1% NP40, 1% sodium 
deoxycholate, 0.1 % SDS in PBS at pH 7.4). Lysates were clarified by centrifugation 
at 13,000 rpm for 10 mins and stored at -20°C.
For immunoprécipitation, 30 ul of the cell lysate was thawed and mixed with 2 ul
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of the MAb sample and 70 ul of the RIP buffer, and incubated overnight. Following 
2 hs incubation with 40 ul of 50% (v/v) suspension of protein A-Sepharose CL-4B 
(Pharmacia), the beads were recovered by centrifugation at 13,000 rpm for 2 mins, 
then washed three times with RIP buffer. The precipitated protein were solubilized 
in lOmM-Tris base containing 5% glycerol, 5% 2-mercaptoethanol and 2% SDS. 
Proteins were analyzed by polyacrylamide gel (PAGE) (Cook et al. , 1979), then dried 
and autoradiographed.
2.10. Properties of MAbs used in this project
MAbs, already prepared against wild-type strains SA-14 (J series), G8924 (K series) 
and vaccine strain SA-14-5-3 (T and V series) of IE virus (Sil et al., personal 
communication), were used in this project. These MAbs have been pièliminarily 
characterized using the immunogen virus and other flaviviruses (Sil, personal 
communication). The properties of these MAbs are included in Table 2.3.
2.11. Preparation of polyclonal sera
Female inbred (strain Balb/c) white mice (Olac. UK) of 6 weeks of age and weighing 
25-30 g were used to examine the immunogenicity of the virus. Mice were 
immunized i.p. with approximately 10^  pfu of the virus. Blood samples were collected 
from the heart on days 14 and 28 post infection respectively. Red blood cells were 
removed by centrifugation at 3,000 rpm for 3 mins and the remaining serum was 
incubated at 56°C for 30 mins to inactivate any complement elements and stored at 
4°C for use.
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Table 2.3
Properties of monoclonal antibodies (MAbs) used in the present project
MAbs reactivity pattern
biological activities 
N HAI
Series K
(immunogen 
virus JE G8924)
Kl group common +
K2 JEsubgroup common + +
K3 Oavivirus intermediate - +
K4 flavivirus intermediate - -
K5 flavivirus intermediate - +
K7 flavivirus intermediate - +
K8 JEsubgroup +
K9 group common - -
KIO JE type - +
K ll flavivirus intermediate + +
K12 JEsubgroup + +
K13 JE type - +
K14 JEsubgroup - -
K15 JE type + +
K16 group common - +
K17 JEsubgroup - +
K18 group common - -
K19 flavivirus intermediate - -
K20 JE type + +
K21 flavivirus intermediate - -
K23 JEsubgroup - +
K24 flavivirus intermediate - +
K25 group common - - +
K26 JE type +
K27 group common • +
K28 flavivirus intermediate - -
K29 group common - +
K30 JEsubgroup - +
K32 JEsubgroup - -
K33 JE type + -
K36 group common - -
K37 flavivirus intermediate - -
K38 flavivirus intermediate - -
K39 JE type -
K40 JEsubgroup - +
K41 flavivirus intermediate - +
K42 flavivirus intermediate - +
K43 JE type - +
K44 JEsubgroup - +
K45 flavivirus intermediate +
Continued on next page.
63
Table 2.3 continued from the previous page.
MAbs reactivity pattern
biological activities 
N. HAI
J Series 
(immunogen 
virus JE SA-14)
J20 group common +
J41 JEsubgroup - +
J42 group common + -
J44 JE type - +
J45 group common ND +
J48
T and V Series
JEsubgroup +
(immunogen 
virus JE SA-14-5-3)
T2 JEsubgroup +
T20 JEsubgroup - -
T53 flavivirus intermediate - +
T60 JE type - -
T65 JEsubgroup - -
T69 JEsubgroup - -
T81 group common - +■
T86 flavivirus intermediate - +
V4 group common - +
V23 JE type - -
N.B. 1) All the MAbs are specifically reactive with the virus E protein.
2) The gamma-globulin concentration in the ascities were used 
between 2 mg and 5 mg per ml.
^ 3 : H /IIa a^.4 fj (Jioo D-o
" HAI <Vvd A)'hlr£^ L'lor, J
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2.12. Indirect immunofluorescence (HF) assays
Vero cells were used to prepare the spotslide for IIP assays. Confluent Vero cell 
monolayers in 25 cm  ^ tissue culture flasks (Nunc) were infected with viruses at a 
m.o.i. of 5 as described in Section 2.2, and incubated at 37°C for 5-12 hs depending 
on the virus. The cells were then trypsinized, pelleted, washed in PBS and 
resuspended at approximately 10"^  cells in 25 ul of cell growth medium (per spot). 25 
ul of the above cell suspension was added onto each spot on PTFE-coated spotslides 
(Hendley, Essex) and incubated for 4 hs at 37°C in a moist atmosphere. After this, 
the spotslides were washed twice in PBS, then in ice-cold acetone and finally fixed 
by place in ice-cold acetone for 15 mins. Slides were then stored at -20°C for use.
For IIF assays, the above spotslides were thawed at room temperature and then 
incubated for 45 mins at 37°C with 25 ul per spot of a MAb sample, test or positive 
or negative control samples diluted appropriately, depending the particular MAb. The 
spotslides were washed twice in PBS for 15 mins each time and dried. Following this, 
25 ul of 1:50 dilution of goat anti-mouse polyvalent immunoglobulins conjugated to 
fluorescein isothiocyanate (FITC, Sigma) was added to each spot and the slides were 
incubated for further 30 mins at 37°C. The spotslides were washed twice in PBS as 
above, then distilled water and finally air-dried. Following the addition of mountant 
(10% saline in glycerol), the cells were examined under ultraviolet light using a Leitz 
dialux 20 epifluorescent microscope for fluorescence. Results of this assay were read 
by the Author with the help of another person reading slides independently.
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2.13. Haemagglutination and haemagglutination inhibition assays 
2.13.1 .Haemagglutination (HA) assay
Gander red blood cells (RBCs) and viruses harvested from tissue cultures (as 
described in Section 2.2) were used in HA assays. HA assays were performed 
according to that of Clarke and Casals (1958), modified for use with plastic 
disposable plates by Sever et ah (1964). The V-bottomed 96-well plates were used.
Prior to use in HA assaya, gander RBCs (Tissue Culture Services, Slough) were 
washed three times in dextrose gelatin veronal (DGV) buffer (0.058% [w/v] veronal 
[barbitone], 0.038% [w/v] sodium barbitone, 0.06% gelatin, 0.14% mM calcium 
chloride [CaCy, 0.49mM magnesium chloride [MgCy, 1.45M NaCl, 55.6mM D- 
glucose, pH 7.4) and centrifuged at 2,000 rpm for 5 mins. After the final wash, the 
gander RBCs were stored as a 8% stock suspension, this represented a concentration 
approximately 24 times higher than the dilution, at which they would be used for HA 
assays. Dilution of the stock gander RBC suspension in DGV buffer to yield an 
optical density (OD) of 0.75 as determined using a Pye Unicam Model PU 2280 
spectrophotometer at the wavelength of 490 nm.
50ul of viral antigens was diluted in two-fold in borate buffer saline (50 mM boric 
acid, 120 mM NaCl, 0.4% [w/v] bovine albumin, pH 9.0). The standardized gander 
RBCs (as described above) were diluted 1:220 in the appropriate pH buffer 
(monobasid [150 mM NaCl, 200 mM monobasic sodium phosphate] and dibasic [150 
mM NaCl, 200 mM dibasic sodium phosphate] sodium phosphate solutions, mixed 
in pre-determined proportions to produce the desired final pH value). 50ul of the 
above gander RBCs was added to each virus dilutions, shaken briefly and incubated 
at ro'ûm temperature for ; ; 90 mins. The HA titre of virus was determined as the
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highest virus dilution, at which HA occurred. The amount of virus (in 50ul) at this 
dilution was determined as 1 HA unit (HAU).
2.13.2.Haemagglutination inhibition (HAI) assays
HAI assays were based on HA assays. 25ul of antibody solutions was two-fold 
serially diluted in borate buffer saline (as used in HA assays) in V-bottomed 96-well 
plates. Four HAUs of virus in 25ul of borate buffer saline was added to each dilutions 
of antibodies. Then, the plate was shaken briefly and incubated for two hs at room 
temperature. Following this, 50ul of the gander RBCs (in appropriate pH buffer) was 
added to each well and further incubated for further 90 mins. HAI titres of antibodies 
were determined as the reciprocal of the highest antibody dilution, which completely 
inhibited the HA activity of 4 HAU virus.
2.14. Neutralization (N) tests
2.14.1."100 pfu" N tests
The infectivity titre of the virus used in this test had been determined by plaque 
assays as described in Section 2.4. The procedure of this test was essentially same as 
the plaque assay except: the virus under study was diluted to give 100 pfu per lOOul 
PBS and mixed with a equal volume of a serial diluted (1:2 or 1:10) of sera or ascitic 
fluids containing MAbs, and incubated at room temperature for 45 mins before added 
onto the cell monolayers (LLC-MK2). The N titre of the antibody preparation was 
determined as the reciprocal of the dilution of the serum or ascitic fluid containing 
a MAb, which neutralized 50% of the virus.
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2.14.2.Plaque reduction neutralization tests (PRNT)
This test was also performed using the plaque assay technique as described in Section
2.4, except that the virus dilutions were incubated for 45 mins at room temperature 
with a 1:20 dilution of MAbs containing ascitic fluids prior to infecting the cell 
monolayers (LLC-MK2). N titres were expressed as the Logio reduction in the virus 
titre compared to that of the control test, in which the virus was incubated with PBS 
or non-reactive MAbs only prior to infecting the cell monolayers. The N titres 
determined by PRNTs were termed serum neutralization indices (SNI).
2.15. Generation of MAb neutralization resistant (MAb^) mutants 
2.15.1.Selection of a MAb^ mutant from PRNTs
If a MAb neutralized one of the virus strains to a high SNI (> 3  preferred) in 
PRNTs, individual plaque isolates that had escaped the neutralization were cloned by 
plaque purification as described by Wiktor and Kowprowski (1980). Briefly, an 
individual plaque was picked in a plug of agar using a small glass pasteur pipette. The 
agar plug was broken up by dispelling through a fine bored pippete in 1 ml of the cell 
maintanence medium (see Section 2.2). The plaque selected virus was then amplified 
in the appropriate cells to obtain a working stock of the virus for further studies.
2.15.2.Confirmation of MAb^ mutants
Tha amplified putative MAb^ mutants were first examined by PRNT with the same 
MAb used to select them to investigate whether or not the individual plaque isolates 
still escaped the neutralization. Secondly, the amplified putative MAb^ mutants were 
examined in IIF assays (see Section 2.12) with the appropriate MAb to investigate
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whether or not the epitope recognized by the MAb was present or absent on the 
plaque selected virus.
2.16. Pathogenicity studies
2.16.1.Adult TO mice model
Female outbred (strain TO) white mice (Olac. UK) of 3-4 weeks of age and weighing 
between 25-30g were used to determine virus pathogenicity. Mice were inoculated 
with virus diluted in PBS by one of the following two routes: intranasally (i.n.) by 
placing 20 ul of virus dilution into the nostrils of a partially anaesthetized (diethyl 
ether) mouse or intracerebrally (i.e.) by inoculation of 20ul of the virus preparation 
into a partially anaesthetized mouse.
The inoculated mice were observed for period of upto 21 days, and then the 
average survival time (AST) and pfu/LDgg were calculated using the methods included 
in the appendix.
2.16.2.Sodium aurothiomalate (SATM) treated mice model
SATM has been shown to increase the susceptibility of mice to certain virus 
infections (Allner et al., 1974) when inoculated into the peritoneal cavity of the 
mouse prior to challenging with viruses. In this project, adult TO mice were treated 
with SATM for pathogenic studies of IE viruses.
SATM was supplied as a lyophilized preparation (Aldrich, UK) and resuspended 
in sterile distlled water pH 7.2 to a final concentration of lOOmg/ml. SATM was 
introduced into the mouse by i.p. inoculation of lOOul of such SATM solution. Three 
hs later, both the SATM and mock-treated (with PBS) control mice were inoculated
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with the virus by the i.e. or i.n. routes, and then monitored for 21 days. The AST 
and/or pfu/LD^g were calculated, where appropriate.
2.17. Virus binding assays using the mouse brain tissue homogenate (MBTH) 
The MBTH preparation was made based on the method by Fang and Chen (1989). 
Briefly, outbred (strain TO), 3-4 week old female mice (Olac. UK) were killed by 
cervical dislocation. The whole brains were raplidly dissected and homogenized by 
teasing through a 5ml hypodermic syringe. The cell growth medium (as included in 
Section 2.1) was used for the 5% (w/v) final suspension of the MBTH.
The virus binding assay was performed as follows. The freshly made MBTH 
(0.9ml) and the virus stock (0.1ml as described in Section 2.2) were mixed in an 
Eppendorf tube and incubated in a desired temperature (4°C, 26°C, or 37°C) water 
bath for 1 h. The tube was gently shaken every 5 mins. After incubation, the binding 
process was terminated by centrifugation at 13,000g for 10 mins using an Eppendorf 
centrifuge. The residual virus infectivity in the supernatant was determined by the 
plaque assay as described in Section 2.4. The degree of the virus binding to the 
MBTH was expressed as the Logio reduction of the virus titre in the supernatant 
compared to that of the control test, in which the virus was incubated with the cell 
growth medium only. The degree of the virus binding as determined above was 
termed as a binding index (BI).
2.18. Virus binding assays using continuous cell lines
Single cell suspensions of Vero and C6-36 cells were used in this assay. To prepare 
a single cell suspension, Vero and C6-36 cells were treated as described for their
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subculturing in Section 2.1. Cells were washed once in the cell growth medium by 
centrifugation at 2,000 rpm for 5 mins. Finally, cells were resuspended in the cell 
growth medium to a concentration of 10* cells/ml. In addition to the preparation of 
a single Vero cell suspension by trypsinization (as above), a single Vero cell 
suspension was also prepared by scrapping the cell sheet off the surface of tissue 
culture flasks using a plastic cell scrapper (Falcon). The rest of the procedure was the 
same as above.
The procedure for virus binding assay using the single cell suspension as prepared 
above was essentially same as the binding assay using the MBTH except: the cell and 
virus complex was pelleted at l,000g for 5 mins. The degrees of virus binding to the 
cells were by the BI as described in the previous section (2.17).
2.19. Virus binding assays using mouse brain membrane receptor preparations
The mouse brain membrane receptor preparation was made from the adult (3-4 weeks 
of age) female TO mice (Olac. UK) based on the method described for neurotrans­
mitter receptor binding assay (Middlemiss and Fozard, 1983). The whole brains were 
rapidly dissected, weighed and homogenized in 100 ml of Tris buffer (50mM, pH 
7.6) using a Kinematica Polytron (setting 3 for 30 seconds), the homogenate was 
centrifuged (35,600g for 10 mins), the pellet resuspended in the same volume of the 
Tris buffer and the process repeated two more times. Between the second and third 
centrifugations, the homogenate was incubated in 37°C water bath for 10 mins. The 
final pellet was resuspended in a volume of the Tris buffer (50mM, pH 7.6) to give 
a final protein concentration of approximately 20-40A  7ml.
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The virus binding assay using above membrane receptor preparation was 
performed by the method as described in Section 2.17 for the MBTH binding assay. 
The degree of binding was expressed using the same index, i.e. the binding index (BI, 
see Section 2.17).
2.20. Virus binding assay using the mouse or monkey liver 
membrane receptor preparation
The mouse (TO strain) and monkey {Cynomologus) liver membrane receptor
preparations were made based the the method by Witkin and Harden (1981). The
fresh livers were weighed, minced (using scissors) and homogenized in 100 ml of the
homogenate buffer (145mM NaCl, 2mM MgClz, 20 mM Tris, pH 7.5) using a
Kinematica Polytron (setting 3 for 30 seconds). The homogenate was centrifuged at
2,000g for 10 mins. The supernatant was collected and centrifuged at 40,000g for 15
mins. The pellet was resuspended in the homogenate buffer, and this process was
repeated two more times. Between the second and the third centrifugations, the
membrane receptor preparation was incubated at 3TC for 10 mins. The final pellet
was resuspended in a volume of Tris storage buffer (250 mM sucrose, 5 mM MgCl2,
50 mM Tris, pH 7.5) to give the same protein concentration as the brain membrane
receptor preparation (Section 2.19).
2.21. Virus binding inhibition assays using neurotransmitter ligands
The neurotransmitter ligands used in this assay were included in Table 2.4. 1 mM 
ligand stock solutions were prepared using the appropriate dissolvants included in 
Table 2.4.
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Table 2.4
Description of neurotransmitter ligands used in the present project
neurotransmitter selectivity of
ligand neurotransmitter system ( )
molecular 
weight (MW)
dissolvant
atropine muscarinic " I 
cholinergic
676.81 water
spiperone dopamine (D 2 ) " 
serotonin (5HT2>5HTi)
431.94 0.2% citric acid
(-)-propranolol serotonin (5HTi) 
B-adrenergic
295.8 water
(+)-SKF83566 dopamine (Dj) ^ 368.69 ethanol
5-aminovaleric
acid
GABA-B K 153.61 water
(-)-bicuculine GABA-A 509.28 water
N. B, All the ligands used in this project were purchased from 
Research Biochemicals Incorporated, U.K.
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The virus binding inhibition assay was performed as follows in the same Tris 
buffer as used for the final suspension of the mouse brain membrane receptor 
preparation (Section 2.19). 9 ul of the ligand stock solution (ImM) was added to 900 
ul of the membrane receptor preparation at the protein concentration required to give 
a final ligand concentration lOuM, and the mixture was incubated in a 37°C water 
bath for 15 mins. After this, 100 ul of the virus stock was added to the above ligand- 
bound membrane receptor preparation to a final volume of 1 ml, then incubated in 
a 26°C water bath for another 1 h. The binding reaction was terminated by 
centrifugation at 13,000g for 10 mins in an Eppendorf centrifuge. The supernatant 
was used to determine the residual virus infectivity and the BI was calculated and 
compared to that of the control tests, in which the virus incubated with the membrane 
receptor preparation treated with the appropriate ligand dissolvant only, and the virus 
incubated with Tris buffer and the appropriate ligand dissolvant.
2.22. Virus binding inhibition assays using MAbs against the virus
This assay was performed using the method described for the virus binding assay 
using the mouse brain membrane receptor preparation in Section 2.19 except that 
viruses were incubated with a 1:20 dilution of a MAb solution at 26°C for 45 mins 
prior to the incubation with the membrane receptor preparation. Only non-neutralizing 
MAbs can be used in this assay to investigate whether or not they can block the virus 
binding.
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Chapter 3
Preparation and characterization of monoclonal antibodies 
against Japanese encephalitis virus vaccine strain: SA-14-14-2/PDK9
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3.1. Introduction
Currently, the vaccination programme for the prevention of Japanese encephalitis (JE) 
uses inactivated vaccines, especially the ones derived from the Nakayama-NIH and 
P3 strains grown in mouse brain or primary hamster kidney cells respectively 
(Umenai et ah, 1985; Huang, 1982). Due to the cost of the inactivated vaccine, an 
experimental live attenuated JE vaccine strain SA-14-14-2, derived from the wild-type 
strain SA-14 by repeated passages in primary hamster kidney (PHK) cell cultures, has 
been developed in China (see the review in Chapter 1). Extensive field trials in 
children between ages of 5 and 12 showed that this vaccine was safe and highly 
immunogenic, compared with the conventional inactivated vaccines (Yu et ah, 1988). 
It is believed that this vaccine will take place of the inactivated vaccine in the near 
future, at least in China.
Although, no apparent adverse reactions were observed in humans receiving this 
SA-14-14-2 vaccine produced in PHK cells, alternative cell substrates that are 
approved by the World Health Organization (WHO) and offer advantages to testing 
and production of the future JE vaccines were investigated. Eckels et al. (1988) 
reported that the vaccine virus SA-14-14-2 derived from PHK cells was adapted to 
grow in primary dog kidney (PDK) cell cultures by nine sequential passages. 
Characterization of the PDK cell-grown SA-14-14-2 virus by various laboratory and 
animal tests indicated that the PDK cell adapted SA-14-14-2 virus (PDK9) maintained 
the same characteristics as the PHK grown virus used in China. However, before 
being licensed for use in a large scale vaccination, further studies are required to 
characterize this candidate JE vaccine.
The genomes of the SA-14-14-2/PHK and its PDK-adapted derivative (SA-14-14-
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2/PDK9) have been sequenced and compared to that of the wild-type parent strain 
SA-14 (Nitayaphan et ah, 1990; Aihara et al., 1991). It was identified that four 
amino acid substitutions in the E protein were unique and identical to the vaccine 
viruses, while these four respective amino acids in the E protein of the wild-type 
parent strain SA-14 are conserved in all the wild-type IE virus strains so far 
sequenced (see Chapter 1, Section 1.9.2). In contrastahese molecular studies, 
monoclonal antibody (MAb) studies on this vaccine have not been done. In this 
chapter, two panels of MAbs were prepared against the vaccine virus SA-14-14- 
2/PDK9 and characterized using a range of flaviviruses from different antigenic 
complexes in the Flaviviridae with the aim further analyzing the envelope protein 
epitopes of the vaccine and wild-type IE viruses.
3.2. Experimental procedures
3.2.1. Preparation of hybridoma cell lines secreting MAbs
Six-week-old female Balb/c mice were immunized with either 10^  pfus of the SA-14- 
14-2/PDK9 virus grown in SW13 cells or in mosquito cells C6-36 by intraperitoneal 
inoculation. Five days after the initial immunization the mice were boosted with the 
same dose by the same route. This procedure was repeated twice, three and five 
weeks after the initial inoculation. Three or four days after the final boost the spleen 
was removed from the mouse to prepare a single cell suspension. The detailed 
procedure for the fusion of the spleen cells with the NSl myeloma cells and the 
isolation of the single clones secreting anti-JE virus MAbs were described in Chapter 
2. Those positive clones were expanded and grown as ascitic tumors in pristane 
primed Balb/c mice. The ascitic fluid containing anti-JE virus MAbs were harvested
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for characterization. These procedures were undertaken as part of the Author’s M.Sc 
project.
3.2.2. Isotyping of the MAbs
This was performed using a mouse MAb isotyping ki^ (Amersham International) as 
included in Chapter 2.
3.2.3. Determination of the viral protein specificity of MAbs
The radioimmunoprecipitation (RIP) was used to determine the viral protein 
specificity of MAbs. The vaccine virus strain SA-14-14-2/PDK9 was used to prepare 
the radio-labelled viral protein. The detailed procedure was included in Chapter 2.
3.2.4. Characterization of the MAbs
The reactions of the MAbs with a variety of flaviviruses from different antigenic 
complexes (grown in Vero cells) were characterized in indirect immunofluorescence 
(IIF) tests as described in Chapter 2. The biological activities of the MAbs were 
examined using haemagglutination inhibition (HAI) and plaque reduction 
neutralization test (PRNT) against the immunogen SA-14-14-2/PDK9 and the wild- 
type parent SA-14 viruses.
3.3. Results
3.3.1. Production of MAb secreting hybridoma cell lines
Two panels of hybridoma cell lines were prepared against the JE vaccine virus SA- 
14-14-2/PDK9 grown in two different cell lines. One was the SA-14-14-2/PDK9 virus
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grown in human adenocarcinoma SW13 cells (series C hybridomas) and another was 
the virus grown in mosquito C6-36 cells (series E hybridomas). Eight series C (C7, 
C9, CIO, C ll, C13, C17, C23 and C26) and fourteen series E (E4, E12, E15, E16, 
E32, E33, E43, E46, E48, E49, E50, E51, E53 and E64) hybridoma cell lines 
secreting anti-JE virus MAbs were isolated and identified. All secreted MAbs were 
IgG class (IgGl, IgG2a and IgG2b) and were shown to recognize epitopes on the 
envelope protein by radioimmuno-precipitation assays (Table 3.1 and Figure 3.1).
3.3.2. Antigenic reactivities of the MAbs against a range of flaviviruses
The antigenic reactivities of the MAbs were characterized against a range of 
flaviviruses from different antigenic subgroups using IIF tests. The results are shown 
in Table 3.2.
Using the range of flaviviruses, the MAbs C17 and E46 were found to be JE virus 
type-specific and reacted with all strains of JE virus examined inclusive of JE vaccine 
(SA-14-2-8, SA-14-5-3, SA-14-14-2/PDK9 and SA-14-14-2/PHK) and wild-type JE 
viruses (SA-14 and Nakayama-original) but not other flaviviruses. Seven MAbs (C7, 
CIO, E15, E16, E32, E48 and E49) demonstrated reactivity only with the members 
of the JE subgroup. These seven MAbs recognized all the JE virus strains and the 
Murrey Valley encephalitis (MVE) virus. While they showed varying degree of cross­
reactivity with West Nile (WN) virus strains. For example, MAb C7 did not react 
with either of the two strains of WN virus; MAb E32 reacted with the Sarawak 
strain but not Egypt-101 strain, whereas, the MAb E48 exhibited the reverse 
reactivity pattern. Ten MAbs (C9, Cl l ,  C13, C23, C26, E4, E12, E43, E50, and 
E53) were found to be flavivirus intermediate reactive (i.e. they recognize some but
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TableS.l
Properties of C and E series monoclonal antibodies
MAbs ' isotype specificity gama-globulin * concentration
G7 IgG2a E protein 2.9
C9 IgG2a E protein 3.5
CIO IgG2b E protein 43
C ll IgGl E protein 3.0
C13 IgG2a E protein 5.0
C17 IgG2b E protein 2a
C23 IgG2b E protein 3.6
C26 IgG2b E protein 4.0
E4 IgGl E protein 3.1
E12 IgG2b E protein 2a
E15 IgGl E protein 3.5
E16 IgG2a E protein 3.9
E32 IgG2a E protein 3.7
E33 IgGl E protein 3.5
E43 ' lgG2a E protein 4.3
E46 IgG2a E protein 3.2
E48 IgG2a E protein 4.2
E49 IgG2b E protein 43
E50 IgGl E protein 5.0
E51 IgGl E protein 3.5
E53 IgGl E protein 3.2
E64 IgG2b E protein 2.9
*: Gama-globulin concentration was determined as mg/ml in ascitic fluid.
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Table3.2
Reactivities of C and E series MAbs in indirect immunofluorescence 
tests with a range of flaviviruses
MAbs 
Virus 8 0 S  S BO Ln 0\ hJ I 8 8 8 8
JE:
14-2/PDK9 4- 4* + 4- 4- 4- 4- 4* 4* 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4-
14-2/PHK 4- 4* 4- 4- 4- 4- -t- 4- 4- 4- 4- 4- 4- 4- 4- *i* 4- 4- •4 4- 4- 4-
2-8 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- •f 4- 4- 4-
5-3 4- 4- + 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- +
14 4- 4- -f *f- 4- 4- 4- 4- 4- 4* 4- 4- 4- 4- •t- 4- 4- 4- 4- *4 4- 4-
Naka. 4- 4- -f- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4—h 4- 4- 4- 4- 4- ■ 4- 4- 4-
MVE:
original
WN:
Sara.
ElOl.
YF:
Asibi
HoU.
Braz.
Dakar
DEN:
2-NG.
2-Jama.
TEE:
LGT-21
LGT-64
4- +  +  -H 4- 4- 4* 4- 4 - - H 4 - 4 - - k - H 4 - - t -  4-
- +  4* 4- 4- - 4-
- - 4- 4- - 4- 4"
4 - 4 - -  - - + - - f - t - - f 4 - - f
- - j - -  4 - -  +  4 - - f 4 - - + -
+ - + - - + 4" + -
4- - - "H - -F -{- -j- -
- 4- - - - - - + - - H
+  - - - 4- - - -|-
- * t -  - - 4 * 4 * 4 - -
4- 4- -+-
4 - 4 -  4-
4 - 4 - 4 -
4- 4- 4-
4 - 4 - 4 -  
4 - 4 - 4 -  
4- -+- -H
4- 4- *h
-f -b -f
4- -t- 4-
4- 4- -f
4* : positive reaction.
-: negative reaction.
Virus abbreviations are included in Chapter 2, Table 2.1.
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Figure 3.1 The viral protein specificity of MAbs as determined 
by radioimmunoprecipitation
B
N S 5  (P9®-
N S 3  (P77)-
E (p54). 
N S 1 (p 4Ql
actin
N S4a (p26). 
Pr«M (p23). 
N S 2 a  ( p i 9).
NS2b (pi 71
Track A: non-immunoprecipitated virus infected cell lysates
Track B: the E protein from the virus infected cell lysates
immunoprecipitated with MAb E64
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not all flaviviruses examined). It is interesting to note that six of these ten flavivirus 
intermediate reactive MAbs (C9, C13, C23, E4, E12 and E43) showed different 
cross-reactivity against three attenuated yellow fever (YF) vaccine strains, 17D-204- 
Holland, 17DD-Brazil, 17DD-Dakar and their wild-type parent strain Asibi. For 
example, MAb E43 reacted with the three vaccine strains but not the wild-type parent 
virus Asibi. MAb C23 recognized the parent and the vaccine derivative 17DD-Brazil 
but not the other two vaccine strains. MAbs E33, E51 and E64 recognized all 
flaviviruses examined.
3.3.3. Biological activities of the IMAbs
The biological activities of the C and E series MAbs were examined using PRNT and 
HAI assays with the vaccine virus SA-14-14-2/PDK9 (the immunogen) and the wild- 
type parent virus SA-14 grown in SW13 cells. The results are shown in Table 3.3.
Seven of the twenty-two MAbs elicited neutralizing (N) activity against the vaccine 
virus SA-14-14-2/PDK9 and/or the wild-type parent SA-14 virus. MAbs C l l ,  E43 
and E64 neutralized both the wild-type SA-14 and the vaccine derivative SA-14-14- 
2/PDK9 with the MAb C ll showing the highest N titre (a SNI of 2 against SA-14-14- 
2/PDK9 and 3 against SA-14). However, other four MAbs (E46, E15, E4 and E51) 
showed N activity against either the vaccine (the immunogen) or the wild-type parent 
viruses. MAbs E46 and E15 neutralized the wild-type parent SA-14 virus but not the 
immunogen virus SA-14-14-2/PDK9, whereas, i • i : , MAbs E4 and E5F 
elicited the reverse N activity.
All of the MAbs generated elicited HAI activity (except C7 and E50, which have 
not been tested). MAb CIS showed high HAI titre (640) against the parent virus
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Table3.3
Biological activities of C and E series MAbs tested against the immunogen virus 
SA-14-14-2/PDK9 and its wild-type partent virus SA-14
MAbs SA-14-14-2/PDK9 SA-14
HAI N HAI N
C17 320 - 320
E46 80 - 320 1.3
C7 ND - ND -
CIO 160 - 320
E15 80 - 160 1.0
E16 80 - 80 -
E32 320 - 320 -
E48 80 - 160 -
E49 160 - 160
C9 320 - 320
Cll 640 2.0 640 3.0
C13 40 - 640
C23 80 - ND
C26 160 - ND -
E4 40 1.0 160
E12 80 - - -
E43 320 1.2 640 0.8
E50 ND - ND -
E53 80 - 320 -
E33 320 - 160 -
E51 160 0.5 ND -
E64 640 1.0 640 1.0
HAI titre is expressed as the reciprocal of the highest dilution of MAbs, which inhibit 
haemagglutination of gander red blood cells by 4 HAUs of the virus, 
less than 20 was considered as negative (-).
N titre is expressed as serum neutralization index as described in Chapter 2, less than 0.5 
was considered as negative (-).
The virus examined was derived from S W13 cells and plaqued in LLC-MK2 cells.
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SA 14 but poor titre against the immunogen virus SA-14-14-2/PDK9 (40). In contrast, 
MAb E12 elicited HAI activity against the immunogen virus SA-14-14-2/PDK9 virus 
but not the wild-type parent strain SA-14. No other MAbs showed distinguishable 
HAI activity against the vaccine and the wild-type parent viruses.
3.4, Discussion
In this study, twenty-two E protein reactive MAbs were prepared against the vaccine 
strain of IE virus SA-14-14-2/PDK9 (grown in SW13 and C6-36 cells). The reactivity 
of these MAbs were characterized using indirect immunofluorescence (IIP) tests 
against a variety of flaviviruses from different antigenic complexes in the 
Flaviviridae. Plaque reduction neutralization tests (PRNTs) and haemagglutination 
inhibition (HAI) assays were used to investigate the biological activities of the MAbs. 
The properties of the MAbs are summarized in Table 3.4.
Four reactive patterns shown by the MAbs were identified. These are: IE virus 
type-specific, JE subgroup specific, flavivirus intermediate reactive and flavivirus 
group common. These results obtained from MAb studies support the previous 
antigenic classifications using polyclonal sera (de Madrid and Porterfield, 1974; 
Calisher et al., 1989), showing that JE viruses are antigenically close to the 
flaviviruses within the JE subgroup (JE-MVE-WN-SLE-KUN complex). In particular, 
twenty out of twenty-two MAbs cross-reacted with MVE virus. A similar observation 
has been reported by Kimura-Kuroda and Yasui (1986). These results were 
corroborated by the recently published data of the nucleotide and the deduced amino 
acid sequences of the E protein regions of MVE, WN, SEE and JE viruses in that JE 
viruses have the highest degree of amino acid homologies with MVE virus compared
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Table3.4
Summary of the properties of C and E series MAbs
MAbs isotype specificity HAI N
JE type: 
C17 IgG2b E protein + .
E46 IgG2a E protein + +
JE-subgroup:
C7 IgG2a E protein +
CIO IgG2b E protein + -
E15 IgGl E protein + +
E16 IgG2a E protein + -
E32 IgG2a E protein + -
E48 IgG2a E protein + -
E49 IgG2b E protein + -
flavivirus
intermediate:
C9 IgG2a E protein +
C ll IgGl E protein + +
C13 IgG2a E protein + -
C23 IgG2b E protein + -
C26 IgG2b E protein + -
E4 IgGl E protein + +
E12 Ig02b E protein + -
E43 IgG2a E protein + +
E50 IgGl E protein ND -
E53 IgGl E protein + -
flavivirus 
group common:
E33 IgGl E protein +
E51 IgGl E protein + +
E64 IgG2b E protein + +
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with other members in the JE subgroup (see Chapter 1).
Using these twenty-two MAbs, no vaccine strain specific " V ' & were identified 
when examined against both vaccine (SA-14-2-8, SA-14-5-3 and SA-14-14-2) and 
wild-type (SA-14 and Nakayama) virus strains. However, it could not be suggested 
that all the strains of JE virus examined were antigenically homologous before these 
strains are further analyzed with more MAbs. In the next chapter, more anti-JE virus 
MAbs will be included to perform comparative studies on these JE virus strains, 
particularly the wild-type parent strain and the three attenuated vaccine derivatives 
(SA-14-2-8, SA-14-5-3 and SA-14-14-2). Clearly, it is important to identify the 
epitopes, which are specific to the attenuated vaccine strains or the wild-type parent 
strain, since these epitopes may be significant in relation to the virulence and/or 
attenuation of JE virus.
In contrast to the wild-type and vaccine strains of JE virus, four strains of YF 
virus examined showed varying degree of cross-reactivity with the MAbs. The three 
vaccine strains, 17DD-Dakar, 17DD-Brazil and 17D-204-Holland, which were 
attenuated from the same wild-type parent strain Asibi (see review by Barrett, 1987), 
demonstrated different cross-reactivity patterns to one another and to their parent 
strain (Table 3.2). This result may indicate that the attenuation of the wild-type strain 
Asibi produces new epitopes on the attenuated vaccine derivatives. The antigenic 
variation among the three vaccine strains may be due to different manufacturing 
methods used by different manufacturers (17DD-Dakar was manufactured in Dakar, 
Senegal; 17DD-Brazil produced in Brazil and 17D-204-Holland manufactured in 
Holland.). It is unknown whether or not these antigenic variations are associated with 
the attenuation and/or immunogenicity of these YF vaccines. The antigenic
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heterogenicity among the 17D series vaccines 1. ''“ - -i . 1 in different parts of the 
world has also been observed by Barrett et al. (1989), Gould et al. (1989) and 
Buckley and Gould (1985).
The biological activities of the MAbs were examined using N and HAI assays with 
both the immunogen virus SA-14-14-2/PDK9 and the wild-type parent virus SA-14. 
All of the MAbs examined elicited HAI activity against the above viruses. A similar 
observation has also been reported by Kobayashi et al. (1985), who found that all 
MAbs prepared against the wild-type strain (Nakayama) of IE virus showed HAI 
activity the homologous virus strains. Whether or not these MAbs would also 
elicit HAI activity against heterologous flaviviruses, which were recognized by the 
MAbs in IIP tests, remains to be investigated. It is possible that such high induction 
of HAI antibodies by the virus may be associated with the clinical immunogenicity 
of this IE vaccine.
Seven out of twenty-two MAbs were found to have N activity. Four of them 
showed preferential N activity against either the immunogen virus SA-14-14-2/PDK9 
or the wild-type parent virus SA-14. This result indicates that the biological function 
of the same epitope on different viruses may be varied. Therefore, the present study 
suggests that care should be taken in the interpretation of the biological functions of 
the same epitope on different viruses. The r-globulin concentration of the ascitic 
fluids containing MAbs were determined as described in Chapter 2 and found to be 
similar (3-4mg/ml). Thus, the difference in the biological activity of the MAbs is 
unlikely due to the variation in the concentration of MAbs. In next chapter, the 
biological functions of epitopes on the E protein of the vaccine strains and their wild- 
type parent strain will be further analyzed and compared using more MAbs.
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Chapter 4
Comparative studies on the propagation, pathogenic and antigenic properties 
of the wild-type strain SA-14 of Japanese encephalitis virus and its 
attenuated vaccine derivatives: SA-14-2-8, SA-14-5-3 and SA-14-14-2
89
4.1. Introduction
As reviewed in Chapter 1, the vaccine strains of Japanese encephalitis (JE) virus: SA- 
14-2-8, SA-14-5-3 and SA-14-14-2/PHK, have proved to be safe and immunogenic 
in both laboratory tests and field trials (Huang, 1982; Liu, 1983; Yu et ah, 1988). 
Recently, the genomes of the SA-14-14-2 (PHK and PDK9)) and the wild-type parent 
strain SA-14 have been sequenced and compared (Nitayaphan et al., 1990; Aihara et 
a l,  1991). It was found that the vaccine derivative SA-14-14-2/PDK9 differed from 
the wild-type parent strain SA-14 by 45 nucleotides coding for 15 amino acid 
substitutions, while the SA-14-14-2/PHK differed by 57 nucleotides coding for 24 
amino acid changes (see Chapter 1, Section 1.9.2). Five of these amino acid 
substitutions were found in the envelope (E) protein and may be involved in the 
attenuation of the SA-14 strain of JE virus. However, due to the limited number of 
basic biological studies on the comparison of the wild-type parent strain and the 
attenuated vaccine derivatives, the understanding of the mechanism of attenuation and 
virulence of JE virus is limited. Therefore, from the standpoints of the characteriza­
tion of these vaccines and understanding of the molecular basis of the attenuation and 
virulence of JE virus, more comparative biological studies on the wild-type parent and 
its attenuated vaccine strains are required. The present work was initiated to 
investigate:
1) Comparison of the growth characteristics of the wild-type parent strain and its 
vaccine derivatives using in vitro cell systems to investigate whether or not the 
replication features, such as plaque morphology and temperature sensitivity (ts), are 
associated with attenuation and virulence.
2) Further examination of the pathogenicity of the wild-type parent virus and its
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vaccine derivatives using the immunocompromised mouse model to investigate the 
effect of host immune status on the attenuation and virulence of JE virus.
3) Antigenic comparison of the wild-type parent strain SA-14 and its three vaccine 
derivatives (SA-14-2-8, SA-14-5-3 and SA-14-14-2). To date, several research groups 
have prepared monoclonal antibodies (MAbs) against a number of wild-type strains 
of JE virus (see the review in Chapter 1 and references therein). At least eight E 
protein epitopes have been identified. However, none of them was identified to be 
wild-type specific as the previous workers did not include the attenuated variants of 
JE virus in their studies. Using MAbs prepared against the SA-14-2-8 virus. Fang and 
Chen (1988) briefly described one MAb specific for the vaccine strains SA-14-2-8 and 
SA-14-5-3 viruses. In this chapter, the antigenicity of both the wild-type parent and 
vaccine derivative strains of JE virus were analyzed, with the emphasis on the 
identification of the wild-type and vaccine specific epitopes, using panels of MAbs 
prepared against the above viruses.
4.2. Experimental procedures
4.2.1. Studies of the growth characteristics of the wild-type parent and 
its attenuated vaccine viruses
The incubation time for JE viruses to produce cytopathic effect (CPE), generate
virions, plaque production, and plaque morphology were used as parameters to
compare the growth phenotypes of the wild-type parent and its attenuated vaccine
viruses. The production of virions was determined by plaque assay in LLC-MK2 cells
as described in Chapter 2. The seed stock (see Chapter 2) of all the virus (except
where stated) was amplified once in Vero or LLC-MK2 cells. A multiplicity of
infection (m.o.i.) of 1 was used for all the propagation of the virus. Since the
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production of JE virus (as determined by pfus) is usually proportional to the degree 
of CPE (unpublished observation; Inoue, 1964), the virus was harvested depending 
on the CPE development (80% to 90%) and the virus yields were compared.
4.2.2. Pathogenicity studies
Mice were treated with sodium aurothiomalate (SATM) as described in Chapter 2. 
The virulence of the wild-type parent (SA-14) and the vaccine (SA-14-2-8, SA-14-5-3 
and SA-14-14-2) derivatives were examined in the SATM treated mice by 
intracerebral inoculation and compared to that in normal mice, which received PBS 
buffer only.
4.2.3. Antigenic studies
Monoclonal antibodies (MAbs) used in this study have been described in Chapter 2 
and Chapter 3. The details of the indirect immunofluorescence (IIP), haemagglutina­
tion inhibition (HAI) and neutralization tests were included in Chapter 2.
4.3. Results
4.3.1. Comparison of the growth characteristics of the wild-type parent 
strain SA-14 and its three vaccine derivatives;
SA-14-2-8, SA-14-5-3 and SA-14-14-2
The wild-type parent strain SA-14 and the vaccine derivatives (SA-14-2-8, SA-14-5-3
and SA-14-14-2/PHK and SA-14-14-2/PDK9) were examined and compared for their
ability to cause CPE], generate virions, plaque production and plaque morphology.
The results are summarized in Table 4.1.
It was found that the same degree (between 80% to 90%) of CPE produced by the
92
IIo *o y c
S  eo
IIü 00
1 3
U (D
g
II
£ 5Oû -o o u11
c/i O
I I
T)-
o
I
l lti
h« "Or
w
u
a ■?i
g w
u
w
ù
tü
U
g
s
»o
\q p p pVû VO Tf V")
es es es V) W-1
00 pVO VO x > «r> Ti­
P en
P P (N\o VO V)
Tt
^ n p PVO . VO S u-> VO
r - Tt
n N P rSo VO VO
Tf-
S
Q DC
es es
°? Tt
fS in r-( T—t
Tf- Tf t1.-4
<; <: 5 <: <
co co co co co
1
I 8i
es
o
H.
w
ù
t l l
* 3  '
of r e
■o a  y 
ë £
u
I
Iu
Ü o
’°  B
B
- J
03
: :
£§
"8
5
3
a  r
93
vaccine strain SA-14-14-2 virus (both PHK and PDK derivatives) in vertebrate 
(Vero, LLC-MK2, BHK21 and SW13) and invertebrate (C6-36) cell lines generally 
occured three days later than that of the wild-type parent and the other two vaccine 
viruses (SA-14-2-8 and SA-14-5-3) grown in the corresponding cells. The yield of 
infectivity of SA-14-14-2 (PHK and PDK9 derivatives) as determined by plaque assay 
in LLC-MK2 cells was between 1 and 2 Logio value lower than the other virus strains 
grown in the same cell lines. In addition, the SA-14-14-2 viruses produced 
homogeneous small plaques (approximately 1 mm in the diameter) in LLC-MK2 cells 
following upto 11 days incubation. In contrast, the parent and the other vaccine 
strains produced predominantly large plaques (between 3 and 4 mm in the diameter) 
after only 5 days incubation of the plaque assays. No phenotypic difference in above 
growth parameters was found between the parent strain SA-14 and the vaccine strains 
SA-14-2-8 and SA-14-5-3. SA-14-14-2 PHK and PDK9 derivatives exhibited the same 
growth characteristics.
4.3.2, Change of the growth characteristics after further passage of the 
vaccine virus SA-14-14-2 in mosquito C6-36 cells
Following further laboratory passages in continuous cell lines the SA-14-14-2 viruses
(both PHK and PDK9 derivatives) were examined for their growth characteristics as
described above. The results are shown in Figure 4.1 and 4.2.
The SA-14-14-2/PDK9 derivative maintained the growth properties as described 
in the previous Section 4.3.1 after passages in various continuous vertebrate cell lines 
(Figure 4.1). However, dramatic changes in the characteristics were observed 
following one passage of the SA-14-14-2 virus in the invertebrate mosquito cell line 
C6-36. First, the virus became more cytopathic, as determined by the incubation time
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Figure 4.1
Changes in the growth characteristics of the SA-14-14-2/PDK9 
vaccine virus following passages in various cell lines
SA-14-14-2/PDK9(seed) 
LLC-MK2 
SA-14-14-2/LLC-MK2—
SW13
SA-14-14-2/LLC-MK2/SW13-
.C:5
.V:4.3
- 1:11
- P : l
"C:4
■ V:5.4
■ 1:11
■P:l
Vero LLC-MK2 BHK21 06-36
1 r 1 r 1r
I I I I I f 'I’ "! n  SA.1414-2/LLÇ-MK2/SW13/C6-36
C V I P C V I P C V I P
4 5.0 11 1 5 4.5/ 11 1 3 5.1 11 1
V:5.9
C6-36 SW13
rm  rm  rm  rm
C V I P C V I P C V I P C V I P  
1 73 4 34  4 73 4 3 4  1 6.9 4 34  1 7.5 4 34
C: CPE, days post infection, 80-90% CPE occured. 
V: Virus output determined as Log g^ pfu/ml.
I: Incubation time for plaque production (days).
P: Plaque size determined by diameter (mm).
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Figure 4.2
Changes in the growth characteristics of the SA-14-14-2/PHK 
vaccine virus following passages in various cell lines
SA-14-14-2/PHK(seed)
I C6 36
SA-14-14-2/C6-36'
V:6.4
SW13
rm  rm  rm  r m
C V I P C V I P C V I P C V I P
1 73 4 3 4  4 7.6 4 34  1 63 4 3 4  1 7.5 4 34
C: CPE, days post infection, 80-90% CPE occured. 
V: Virus output determined as Log^gpfu/ml.
I: Incubation time for plaque production (days).
P: Plaque size determined by diameter (mm).
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for CPE production. After further passage into vertebrate (Vero, SW13 and L929) 
and invertebrate (C6-36) cell lines, same degree of CPE (between 80% and 90%) 
took three days less incubation than the preceding passage. Second, the yield of 
infectivity increased approximately by 2 Logio value as determined by plaque assay 
in LLC-MK2 cells. Third, although the virus still retained the same plaque 
morphology (the plaque size and incubation time for the plaque production as 
described in the previous section) following one passage in C6-36 cells, plaque assay 
of the virus following further passages of this mosquito cell grown SA-14-14-2 virus 
in above cell' (C6-36, Vero, SW13 and L929) showed that the virus produced large 
plaques with the diameter of 3-4 mm within 4 days. Similarly, the SA-14-14-2/PHK 
derivative was passaged once in the mosquito cells, and then underwent further cell 
passages as did the PDK9 derivative. The same dramatic changes in the characteris­
tics were observed (Figure 4.2). However, no such changes were found for the parent 
and the other two vaccine viruses (SA-14-2-8 and SA-14-5-3) following similar 
passage histories (data not shown).
4.3.3. Temperature sensitivity of the wild-type parent strain SA-14 and its 
vaccine derivatives: SA-14-2-8, SA-14-5-3 and SA-14-14-2 _
As described above, the SA-14-14-2 virus (both PHK and PDK9 derivatives) '' '
small plaque morphology before passaging in mosquito C6-36 cells. An in vitro
marker often associated with small plaque morphology is temperature sensitivity (ts).
Among dengue (DEN) viruses, both of these markers are often associated with
reduced animal virulence of the virus (Eckels et al., 1976). Thus, the two forms
(small and large plaque forms as described above) of the SA-14-14-2 and the other
two vaccine strains (SA-14-2-8 and SA-14-5-3) were examined for ts by comparing
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the efficiency of plating (e.o.p) at temperatures of 37°C and 39.5°C, and comparing 
to that of the parent virus strain SA-14. The results shown in Table 4.2 indicate that 
neither the vaccine nor the wild-type parent viruses are ts based on the e.o.p.
4.3.4. Pathogenicity of the wild-type parent and vaccine viruses in the mice 
immunocompromised with sodium aurothiomalate (SATM)
The pathogenicity of the wild-type parent strain and its three vaccine derivatives were
examined in both normal and immune compromised mice. The latter had been treated
with SATM as described in Chapter 2 to blockade the function of macrophage cells.
The results are shown in Table 4.3.
Following intracerebral (i.e.) inoculation of 100 pfus of the wild-type parent virus 
strain SA-14, both SATM treated and untreated mice died without showing difference 
in the mortality (100%) and average survival time (AST) (6.6 ±  0.2 days). All the 
vaccine strains caused no signs of the disease or death (the two mice suddenly died 
next day after inoculation of the SA-14-2-8 virus were not included as virus induced 
death) following i.e. inoculation of non-SATM treated adult mice with 10® pfus of the 
virus. In contrast, the vaccine viruses SA-14-2-8 and SA-14-14-2 (PHK and PDK9 
derivatives) caused lethal encephalitis in the mice pre-treated with SATM; all mice 
died with AST of approximately between 5 and 6 days. It is interesting to note that 
the SATM treated mice demonstrated shorter AST following i.e. inoculation with 10® 
pfus of SA-14-2-8 or SA-14-14-2 viruses than the mice challenged with 10  ^pfus of 
the wild-type parent strain SA-14. Unlike the SA-14-2-8 and SA-14-14-2 viruses, 
another vaccine virus SA-14-5-3 caused only sporadic death (1/8 mice) in SATM 
treated mice following i.e. inoculation with 10® pfu of the virus (Table 4.3). 
Compared with the non-SATM treated mice, the SATM treated mice showed
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Table4.2
Temperature sensitivity of the parent SA-14 and its vaccine virus 
derivatives; SA-14-2-8, SA-14-5-3, and SA-14-14-2
Virus
infectivity* at
e.o.p.
37°C 39.5°C
SA-14 7.1 73 1.6
SA-14-2-8 7.0 7.2 1.6
SA-14-5-3 63 6.6 1.2
SA-14-14-2/PDK9" 6.1 6.0 0.8
SA-14-14-2/PDK9’’ 73 7.1 0.6
SA-14-14-2/PHK" 6.4 6.4 1.2
SA-14-14-2/PHK‘* 73 7.6 1.2
*: Infectivity expressed as Lx)gioPfu/ml
a: Non-C6-36 cell passaged SA-14-14-2/PDK9 virus, which have small plaque morphology, 
b: C6-36 passaged SA-14-14-2/PDK9 virus, which have large plaque morphology, 
c: Non-C6-36 passaged SA-14-14-2/PHK virus, which have small plaque morphology, 
d: C6-36 passaged SA-14-14-2/PHK virus, which have large plaque morphology, 
e.o.p. : efficiency of plating.
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Table4.3
Pathogenicity of the wild-type parent SA-14 and the attenuated vaccine viruses 
SA-14-2-8, SA-14-5-3 and SA-14-14-2, in SATM treated and non-treated mice
Virus inoculum(LogioPfu)
SATM treated mice non-treated mice
mortality AST+.SEM mortality AST±SEM
SA-14 2 100%(10/10) 6.6+0.2 100%(9/9) 6.6±0.2
SA-14-2-8 5 100%(8/8) 5.1 ± 0 .2 12.5%(2/16*) NA
SA-14-5-3 5 12.5%(l/8) 9.0 ±0.0 0%(0/12) NA
SA-14-14-2/PDK9" 4 87.5%(7/8) 6.3±0.4 0%(0/10) NA
SA-14-14-2/PDK9*’ 5 100%(8/8) 5.9±0.6 0%(0/10) NA
SA-14-14-2/PHK" 4 75%(6/8) 6.1±0.8 0%(0/10) NA
SA-14-14-2/PHK‘* 5 100%(8/8) 5.8 ±0.2 0%(0/10) NA
control none 0%(0/5) NA 0%(0/5) NA
*: Two mice died suddenly next day after inoculation without encephalitic sighns were not counted, 
a: Non-C6-36 cell passaged SA-14-14-2/PDK9 virus, which showed small plaque morpholog)' (see Fig. 4.1). 
b: C6-36 cell passaged SA-14-14-2/PDK9 virus, which showed large plaque morohology (see Fig. 4.1). 
c: Non-C6-36 cell passaged SA-14-14-2/PHK virus, which showed small plaque morphology (see Fig. 4.2).
d: C6-36 cell passaged SA-14-14-2/PHK virus, which showed large plaque morohology (see Fig. 4.2). 
SATM control mice : inoculated with SATM only.
PBS control mice ; inoculated with PBS only.
NA; not applicable.
AST: averagesurvivaltime+.standard error of the mean (days).
100
lethargy, but no deaths or clinical signs of disease were observed.
4.3.5. Antigenic reactivity of the wild-type parent and its attenuated 
vaccine viruses with panels of monoclonal antibodies 
prepared against them
Six panels of monoclonal antibodies (MAbs) (totally 81 MAbs) prepared against the
JE virus vaccine strains, SA-14-14-2/PDK9 (C and E series) and SA-14-5-3 (T and
V series), and two wild-type strains, SA-14 (J series) and G8924 (K series), had been
preliminarily characterized into four reactive patterns with a range of flaviviruses in
indirect immunofluorescence (IIP) tests. Detailed information on these MAbs were
included in Chapter 2 and 3. In this chapter, these MAbs were further examined with
the wild-type parent (SA-14) and the vaccine derivatives (SA-14-2-8, SA-14-5-3 and
SA-14-14-2/PHK and SA-14-14-2/PDK9) using IIP tests.
Of the 81 MAbs examined, seven were found to distinguish between the wild-type 
parent and the attenuated vaccine viruses (Table 4.4). MAbs V23 and T60, generated 
against the vaccine virus SA-14-5-3, reacted with the vaccine strains (SA-14-2-8, SA- 
14-5-3, SA-14-14-2/PHK and SA-14-14-2/PDK9) only. While MAbs J44 (prepared 
against SA-14 virus), and KIO, K13, K39 and K43 (prepared against G8924 virus) 
recognized the wild-type viruses used as the immunogen, but not the vaccine 
derivatives. The vaccine and wild-type specificity of above MAbs were confirmed 
following the reaction with 12 other wild-type strains of JE virus (Table 4.4). The 
V23 and T60 MAbs showed no reaction with any of the wild-type viruses examined, 
whereas, MAbs KIO, K13, K39, K43 and J44 recognized all the wild-type viruses. 
None of other MAbs examined were able to distinguish the wild-type and the vaccine 
viruses (data not shown). No difference in antigenic reactivity was observed between
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Table 4.4
Antigenic reactivity of the wild-type parent SA-14 and its attenuated vaccine viruses 
SA-14-2-8, SA-14-5-3 and SA-14-14-2 in indirect immunofluoresence tests (IIP) with MAbs
Viruses*
MAbs
V23 T60 J44 KIO K13 K39 K43
vaccine strains: 
SA-14-2-8 + +
SA-14-5-3 .+ + - - - -
SA-14-14-2/PDK9^ + + - - - -
SA-14-14-2/PDK9'’ + + - - - - -
SA-14-14-2/PHie + + - - - - -
SA-14-14-2/PHK*’ + + - - - - -
wild-type strains:
SA-14 - - + + + + +
Beijing-1 - - + + + + +
Malaysia - - + + + + +
Thailand - - + + + + +
782219 - - + *f + + +
G8924 - - + + + + +
Indonesia - - 4- + + + +
Nepal - - + + + . + +
826309 - -■ + + + + +
Sarawak - - + + + + +
Taiwan - - + + + + +
Nakayama-O - - + + + + 4*
Nakayama-Y - - + + + + 4-
+: positive reaction. -: negative reaction.
SA-14-14-2/PDK9® : non-C6-36 cell passage, which has small plaque morphology (Fig. 4.1). 
SA-14-14-2^DK9'> : C6-36 cell passage, which has large plaque morphology (Fig. 4.1). 
SA-14-14-2/PHÎV : non-C6-36 cell passage, which has small plaque morphology (Fig. 4.2). 
SA-14-14-2/PHK*’ : C6-36 cell passage, which has large plaque morphology (Fig. 4.2).
*: Details of the viruses are given in Chapter 2, Table 2.2.
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the early non-C6-36 cell passaged and the late C6-36 passaged (as described in section 
4.3.2) SA-14-14-2 viruses in IIP tests (Table 4.4).
4.3.6. Biological activities of the wild-type and vaccine specific MAbs
The biological activities of the vaccine and wild-type specific MAbs described above 
were examined in haemagglutination inhibition (HAI) and neutralization (N) tests 
(Table 4.5). Neither of the vaccine specific MAbs (V23 and T60) elicited N activity 
and they were poor at HAI. Two (144 and K43) of the five wild-type specific MAbs 
showed N activity, while all elicited HAI to some extent.
4.3.7. Biological activities of the wild-type and vaccine common reactive MAbs
The biological activities of the MAbs, which did not distinguish the wild-type parent 
from the vaccine derivatives in IIP tests, were further analyzed in HAI and N tests. 
The results are shown in Table 4.6.
Two of the seven IB type specific MAbs were found to distinguish the wild-type 
parent virus from the vaccine derivatives in N test. MAb E 46 (prepared against the 
vaccine strain SA-14-14-2/PDK9) showed N activity only against the parent virus SA- 
14 but not the vaccine derivatives, whereas, the MAb K15 (prepared against the wild- 
type strain G8924) neutralized the vaccine but not the wild-type viruses. It is 
interesting to note that five out of the seven JE type specific MAbs (E46, K6, K15, 
K20 and K33) elicited N activity and two of them showed specific activity against the 
wild-type parent or the vaccine viruses.
Among the twenty-three JE subgroup reactive MAbs, MAb E15 showed specific 
N activity against the wild-type parent virus SA-14 only. None of other MAbs in this
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Table4.6
Biological activities of the wild-type and vaccine common 
reactive MAbs in HAI and N tests
x^irus SA-14 SA-14--2-8 SA-14-5-3 SA-14-14 -2/PDK9 SA-14-14 -2/PHK
m a Ù \ HAI N HAI N HAI N HAI N HAI N
JE-type
specific:
E46 320 13 160 - 160 - 80 - 320 ' -
K6 320 03 40 03 80 03 160 - 80 -
K15 320 - 80 0.8 160 1.2 160 0.8 160 1.0
K20 160 0.5 40 03 80 0.5 80 0.5 160 0.7
K26 160 - - - 40 - 160 - 80 -
K33 80 0.5 80 0.6 40 0.5 160 03 40 0.6
C17 320 . 40 160 . 320 80
JE subgroup 
specific:
E15 160 1.0 80 - 80 - 80 - 160 -
E16 80 - 80 - 80 - 80 - 80 -
E32 320 - 160 - 160 - 320 - 160 -
E48 160 - 80 - 80 - 80 - 40
E49 160 - 160 - 160 - 160 - 320 -
C7 ND ND - ND - ND - ND -
CIO 320 - 80 - 80 - 160 - 80 -
T2 40 - - - 40 - 40 - 40 -
T20 - - 40 - - - 40 - ND -
T65 - - 40 - - - 40 - ND -
T69 - - 40 - - - 40 - ND -
J41 80 - 160 - 160 - 80 - 160 -
J48 80 ND 160 ND 80 ND 160 ND 160 -
K2 40 0.8 40 03 40 0.5 160 13 320 ND
K8 160 - 80 - 80 - 80 - 40 -
K12 80 1.0 40 03 40 0.5 80 03 80 0.8
K14 160 - - - 80 - 80 - 160 -
K17 160 ND - ND 80 ND 80 ND 40 - ,
K23 160 160 - 160 - 320 - 80 -
K30 320 160 - 40 -
K32 40 - - -
K40 80 - 40 - 40 - 80 - 40 -
K44 160 - - -  ' - .  . 160 _ 80
continued on next page.
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Table 4.6. continued from the previous page,
\\iru s SA-14 SA-14-2-8 SA-14-5-3 SA-14-14-2/PDK9 SA-14-14-2/PHK
M A ^ \ HAI N HAI N HAI N HAI N HAI N
tlavivirus
intermediate;
C9 320 320 160
C ll 640 3.0 320 ND 320 ND 640 20 640 ND
C13 640 - - - - 13 40 - 320 -
T53 40 ■ - 80 - 80 - 80 - 160 -
T86 - - - - 40 - ,- - 40 -
C23 ND - ND - ND 80 - 40 -
C26 ND - ND - ND - 160 - 80 -
E4 160 - 640 640 - 40 1.0 40 0.8
E12 - - 80 80 - 80 - 80
E36 160 - 80 - 80 - 160 - 160 -
E43 640 0.8 80 - 80 - 320 1.2 80 0.8
E50 ND - ND - ND - ' ND - ND -
E53 320 - 40 80 - 80 - 160 -
K3 80 - 40 - 80 - 80 - 80 -
K4 - - - - 40 - 40 - 40 -
K5 160 - 80 - 80 - 80 - ND -
K7 640 - 160 - 160 - 160 - 320 -
K ll 40 0.7 40 0.8 80 2.4 160 0.5 40 1.0
K19 80 - - - - ■ - 160 - 80 -
K21 40 40 - 40 - 160 - 160 -
K24 160 - 40 - , 40 - 160 - 160 -
K28 80 - ND - ND - 80 - 160 -
K37 - - - 40 - 40 - 40 -
K38 320 - 160 - 160 - 320 - 80 -
K41 320 - - - - - 160 - 80 -
K42 160 - - - - 160 - 40 -
K45 80 - - - - 80 - 160 -
continued on next page.
106
Table 4.6. continued from the previous page,
SA-14 SA-14-2-8 SA-14-5-3 SA-14-14-2/PDK9 SA-14-14-2/PHK
M A b ^ H A I N H A I N H A I N H A I N H A I N
t l a v i v i r u s  
g r o u p  c o m m o n :
E33 160 160 160 320 160
E51 ND - ND 0 . 8 ND 0.7 160 0.5 ND ND
E64 640 1.0 320 - 320 640 1.0 320 0.8
V4 80 - 40 - 80 - 80 - 160 -
T81 40 - 40 40 - 40 - 40 -
J20 160 - 160 - 80 - 160 - 40 -
J42 - 0.5 - 0.7 - 0.5 - 0.5 - ND
J45 320 ND 160 ND 320 ND 320 ND 80 ND
K1 160 - 80 - 80 - 160 - 80 -
K9 80 - 40 - 80 - 160 160 -
K16 160 - 80 ■ - 80 - 160 - 80 -
K18 80 - 80 - 80 - 160 - ND -
K25 ND ND ND ND ND ND ND ND ND ND
K27 160 ND 40 ND 80 ND 80 ND 80 ND
K29 80 - 80 . - 80 - 160 - 40 - -
K36 ND - ND - ND - ND - ND
SA-14-14-2/PHK and PDK9 derivatives were used as the non-C6-36 cell passaged virus, 
which had small plaque morphology and derived from SW13 cells (see Fig. 4.1 and 4.2).
ND: not done.
HAI titres are expressed as the reciprocal of the highest MAb dilution, which inhibit 
4 HAU virus to HA gander red blood cells, less than 20 was considered as negative (-). 
N titres are expressed as SNI as described in Chapter 2, less than 0.4 was considered 
as negative (-).
All the viruses used were derived from SW13 cells and plaqued in LLC-MK2 cells.
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group distinguished the wild-type parent SA-14 virus from its attenuated vaccine 
derivatives in HAI or N tests. However, some of the MAbs did demonstrate 
specificity in the biological activities against individual viruses. For example, MAbs 
K30 and K44 had much higher HAI titre against the parent SA-14 and the vaccine 
SA-14-14-2 viruses (PHK and PDK9 derivatives) but no activity against the vaccine 
SA-14-2-8 and SA-14-5-3 viruses. Three out of these twenty-three MAbs (E15, K2 
and K12) showed N activity.
Twenty-seven flavivirus intermediate reactive MAbs ex hibited varied HAI and N 
activities dependent upon the virus-MAb combination being examined. The MAb C13 
neutralized the vaccine SA-14-5-3 virus only, while it had high HAI titre against the 
parent virus SA-14 but not the vaccines. MAb E4 showed specific N activity against 
SA-14-14-2 virus (PHK and PDK9 derivatives). MAb E43 neutralized both parent and 
the vaccine SA-14-14-2 (PHK and PDK9 derivatives) but not the other two vaccine 
viruses (SA-14-2-8 and SA-14-5-3). Five MAbs: C9, K19, K41, K42, K45, 
demonstrated HAI activity against SA-14 and SA-14-14-2 viruses only. Four out of 
the twenty-seven flavivirus intermediate reactive MAbs (C ll, C13, E43 and K ll) 
showed N activity. None of the MAbs in the group showed distinguishable biological 
activities against the wild-type parent or the attenuated vaccine viruses.
Of the seventeen flavivirus group reactive MAbs, only E51 elicited specific N 
activity against the vaccine viruses. E64 MAb had N activity against the SA-14 and 
SA-14-14-2 viruses but not the vaccine strains SA-14-2-8 and SA-14-5-3.
The MAbs, which exihibited specific N activity against the wild-type parent strain 
and vaccine derivatives or individual viruses, are summarized in Table 4.7. It should 
be noted that no difference in the biological activities of the MAbs against the two
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Table 4.7
Summary of the specificity of MAbs in N tests with the wild-type parent, 
itsatte nuated vaccine or individual viruses
\Mrus SA-14 SA-14-2-8 SA-14-5-3 SA-14-14-2/PDK9 SA-14-14-2/PHK
M A b ^ HAI N HAI N HAI N HAI N HAI N
JE-type
specific;
E46 320 13 160 160 80 320
K15 320 - 80 0 .8 160 1.2 160 0 .8 160 1.0
JE-subgroup
specific:
E15 160 1.0 80 80 80 160
flavivirus
intermediate:
C13 640 - - - - 1.5 40 - 80 -
E4 160 - 640 - 640 - 40 1.0 80 0 .8
E43 640 0 .8 80 80 - 320 1.2 320 0 .8
flavivirus
common:
E51 ND - ND 0 .8 ND 0.7 ND 0.5 ND 0 .8
E64 640 1.0 320 - 320 - 640 1.0 640 0 .8
The results are summarized from Table 4.6.
HAI titres are expressed as the highest MAb dilution, which inhibit HA, 
less than 20 considered as negative (-).
N titres are expressed as SNI as described in Chapter 2.
SA-14-14-2/PDK9 and PHK derivatives were used as non-C6-36 cell passaged virus, 
which showed small plaque morphology (see Fig. 4.1 and 4.2.).
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SA-14-14-2 derivatives (PHK and PDK9) was observed.
4.4. Discussion
In order to provide basic biological information for understanding the molecular basis 
of attenuation of JE virus, the propagation, pathogenic and antigenic characteristics 
of the wild-type strain (SA-14) and its attenuated vaccine derivatives (SA-14-2-8, SA- 
14-5-3 and SA-14-14-2/PHK and SA-14-14-2/PDK9) were examined and compared 
in this chapter.
The vaccine viruses SA-14-2-8 and SA-14-5-3 demonstrated very similar growth 
characteristics as the wild-type parent strain SA-14 in terms of the CPE production 
and yield of infectivity (determined by plaque assay) when grown in various cell lines 
(Table 4.1). Moreover, these two vaccine derivatives and the parent virus had similar 
plaque morphology following the same period of incubation for the plaque assay in 
LLC-MK2 cells. Therefore, these results indicate that none of the the in vitro growth 
characteristics correlate with the attenuated marker of these viruses. Another vaccine 
strain SA-14-14-2 (both PHK and PDK9 derivatives), which was developed from the 
SA-14-5-3 virus by further seven murine subcutaneous passages (SA-14-14-2/PHK) 
and nine passages in PDK cells (SA-14-14-2/PDK9), was found to have different 
growth characteristics to that of the parent and other two vaccine viruses. Firstly, the 
SA-14-14-2 virus required longer incubation time to produce a similar degree of CPE 
as the other viruses, while the yield of infectious virus : was lower. Secondly, the 
incubation time for the SA-14-14-2 viruses (PHK and PDK9 derivatives) to produce 
plaques in LLC-MK2 cells was much longer (11 days vs 5 days) and the plaque size 
was smaller than the parent and other two vaccine viruses. Presumably, such
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variations are due to the different replication times in the cell cultures. However, 
further studies are required to understand the molecular basis for such differences. 
It is unclear what role, if any, the difference in growth characteristics plays in the 
immunogenicity of the SA-14-14-2 vaccine as this vaccine virus has been proved to 
be more immunogenic than the SA-14-5-3 and SA-14-2-8 vaccines (see Chapter 1 and 
references therein).
The SA-14-14-2 (PDK9) virus maintained the growth characteristics as described 
in Section 4.3.1 following passage in various vertebrate continuous cell lines. 
However, although the virus still retained the plaque morphology after one passage 
in the invertebrate continuous mosquito C6-36 cell line, the growth characteristics in 
terms of CPE production and yield of infectious virus underwent dramatic changes 
and became very similar to that of the parent and other two vaccine virus when 
passaged into vertebrate (Vero, SW13 and L929) as well as the invertebrate cells (C6- 
36). Plaque assays showed that the above passaged SA-14-14-2/PDK9 virus had the 
plaque morphology very similar to the parent and other two vaccine viruses. The SA- 
14-14-2/PHK derivative also demonstrated the same changes following the similar 
passage histories. These results reflect that the gene(s) controlling the replication of 
the SA-14-14-2 virus have been markedly modified after the one passage in the 
invertebrate mosquito cells C6-36 (but not in the vertebrate cells) so that the resultant 
passage of the SA-14-14-2 virus could replicate more efficiently in the cells and to 
higher titres. Alternatively, these results may also suggest that the C6-36 cell 
modified SA-14-14-2 virus might become more cytopathic. It would be valuable for 
understanding the molecular basis for the virus replication to perform nucleotide 
sequence studies on the SA-14-14-2 viruses with these two different phenotypes.
I l l
Pathogenicity studies showed that this SA-14-14-2 virus still its attenuated
phenotype in mice, although dramatic changes in the growth characteristics of the 
virus occured. Thus, this result again indicates that the properties of the virus 
involved in in vitro replication are not associated in the attenuation of the virus. In 
addition, it also suggests that the attenuated phenotype of the SA-14-14-2 vaccine 
virus is stable.
The in vitro markers such as small plaque morphology and temperature sensitivity 
(ts) are often associated with the reduced animal virulence among dengue viruses 
(Harrison et al., 1977; Halstead et al., 1984). The results obtained in this study 
indicate that the attenuated SA-14 series vaccine viruses (SA-14-2-8, SA-14-5-3 and 
SA-14-14-2) are not ts and also have large plaque morphology (except non-C6-36 cell 
passaged SA-14-14-2 virus). Therefore, lack of the temperature-dependent restriction 
of the viral replication does not seem to be important for the attenuation of the SA-14 
JE virus. Lack of the ts phenotype, also the case for yellow fever 17D vaccines 
(Ledger et ah, personal communication), suggests that some form of the host 
restriction has occurred for these viruses. Both of these viruses have similar histories 
of extensive passage in hosts and host tissue that are not part of the nature infection 
cycle.
The mouse has been used as a very useful experimental animal model for the 
examination of the attenuated phenotype of the SA-14 series vaccines (Yu et al., 
1981; Huang, 1982). This study confirmed that the three vaccine viruses are not 
encephalitogenic in adult mice inoculated i.e. with a large dose of the virus. 
However, previous studies have shown that the vaccine viruses did cause fatal 
encephalitis in newborn immune immature mice. The virus also killed T (using
112
athymie mice) and B (using cytoxan treated mice) lymphocyte function compromised 
mice (Yu et aL, 1989; Fang and Chen 1989a). It was found that the vaccine viruses, 
SA-14-2-8 and SA-14-14-2 (both PHK and PDK9 derivatives), caused lethal 
encephalitis in macrophage cell function compromised (with SATM) mice with 100% 
mortality and shorter AST than the parent virus SA-14 following i.e. inoculation of 
10^  pfus of the virus. Another vaccine strain, SA-14-5-3, only caused sporadic deaths 
in the SATM treated mice. Interestingly, the wild-type parent virus SA-14 did not 
demonstrate enhanced virulence in terms of AST in the SATM treated mice. This 
result suggests that the normal function of macrophage does not affect the replication 
and invasion of this wild-type strain of IE virus into the CNS system. However, the 
relative pfu/LD^Q of the SA-14 virus was not examined. The shorter AST shown by 
the SATM treated mice i.c.inoculated with the SA-14-2-8 and SA-14-14-2 viruses 
could be due the larger inoculum than the wild-type parent viruses (10  ^vs 10  ^pfu). 
Taken together, it seems that the attenuation and virulence of this wild-type IE virus 
(SA-14) lies in two aspects: the pathogenicity to the target organ (CNS system) and 
the ability to overcome the host immune defence system. In addition, the present 
results also indicate that the degree of the attenuation of these three vaccine viruses 
is different in that the SA-14-5-3 is more attenuated than the other two viruses, at 
least in the adult mice system. This result may be in correlation with the observation 
by Yu et al. (see the Review by Huang, 1982 and references therein), who reported 
that the SA-14-5-3 vaccine had poorer immunogenicity than the SA-14-14-2 due to 
its over-attenuation. No virus samples were collected from the SATM treated mice 
killed by the SA-14-2-8 and SA-14-14-2 viruses. Therefore, it is not known whether 
or not the virus had reverted to virulence.
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In contrast to the IE viruses as discussed above, using i.e. inoculation of SATM 
treated adult mice, Gibson et al. (1990) found that the virulence of wild-type strain
Asibi of YF virus was enhanced, but the virulence of live attenuated 17Di > vaccine
€
virus was not affected. Thus, it may suggest that the effects of the host immune 
system on the IE viruses and YF viruses (both wild-type and attenuated vaccine 
viruses) are different. This variation may be due to the different tropism of JE and 
YF viruses. It is believed that SATM inhibits peritoneal macrophage lysosomal 
enzyme activity (Mehta and Webb, 1982). However, this mode of action is unlikely 
to explain the enhancement of the virulence of JE virus by i.e. inoculation. Since 
SATM converted i.e. inoculated JE vaccine viruses (SA-14-2-8, SA-14-14-2/PHK and 
PDK9) from avirulence to lethality, the drug might comp'-romise the host cellular 
immune responses leaving the JE vaccine virus replication in the brain unchecked.
As discussed above, no in vitro growth characteristics, e.g. CPE production, 
plaque morphology, ts, have been found to correlate with the virulence and 
attenuation of the SA-14 strain of JE virus. In a previous report. Fang and Chen 
(1988) briefly described a MAb prepared against the vaccine virus SA-14-2-8 which 
specifically reacted with the vaccine viruses (SA-14-2-8 and SA-14-5-3) but not the 
wild-type parent strain in IIF and HAI tests. In this study, antigenic analysis of the 
wild-type parent and the attenuated vaccine derivative viruses using six panels of 
MAbs (totally 81 MAbs) prepared against both attenuated vaccine (SA-14-14-2/PDK9 
and SA-14-5-3) and wild-type (SA-14 and G8924) strains of JE virus identified JE 
wild-type and vaccine specific epitopes. Two MAbs (V23 and T60) prepared against 
the vaccine virus SA-14-5-3 only recognized the vaccine viruses (SA-14-2-8, SA-14- 
5-3 and SA-14-14-2) but not any wild-type strains in IIF and HAI tests. While five
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MAbs (J44, KIO, K13, K39 and K43) prepared against the wild-type virus strains 
showed the reverse pattern of reaction. As reviewed in Chapter 1, Section 1.9.2, four 
amino acid substitutions are unique and identical to all the vaccine virus strains 
sequenced (SA-14-5-3, SA-14-14-2/PHK and SA-14-14-2/PDK9), while these four 
amino acids in the wild-type parent SA-14 virus were conserved in all wild-type 
strains of JE virus so far sequenced. Thus, the conservation of wild-type epitopes on 
all the wild-type JE virus strains examined was expected. The present results may 
suggest that these epitopes identified by the wild-type and vaccine specific MAbs have 
a role in the virulence and/or attenuation processes of the SA-14 series of vaccine 
viruses. Unfortunately, none of the wild-type or vaccine specific MAbs neutralized 
virus to a significant titre to generate MAb neutralization resistant variants to 
determine the amino acids constituting the epitopes and the possible role of these 
epitopes in the attenuation or virulence of this wild-type JE virus strain (SA-14). 
Therefore, with the available evidence, it cannot/eoncluded that these wild-type or 
vaccine specific epitopes are involved in the attenuated or virulent phenotypes rather 
than just being the antigenic markers of strains or substrains.
The wild-type and vaccine common reactive MAbs identified in IIF tests were 
further examined in biological assays (HAI and N) with the parent (SA-14) and 
attenuated vaccine viruses (SA-14-2-8, SA-14-5-3, SA-14-14-2/PHK and SA-14-14- 
2/PDK9). Four MAbs were found to distinguish the wild-type parent and the vaccine 
viruses from each other. MAbs E46 (JE-type specific in IIF test) and E15 (JE 
subgroup reactive in IIF test) neutralized the parent virus SA-14 but not the SA-14- 
14-2 (and SA-14-5-3 and SA-14-2-8) vaccine which the MAbs were prepared against. 
While MAbs K15 (JE-type specific) and E51 (flavivirus group reactive) showed the
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reverse N activity (Table 4.7). It is interesting to note that the MAbs E46 and E15 
(induced by the vaccine virus SA-14-14-2) had preferential neutralization of the wild- 
type parent virus (SA-14). A similar observation has been described by Schlesinger 
et al. (1983), who reported that some MAbs prepared against the 17D vaccine strain 
of YF virus showed N activity only against the wild-type parent strain Asibi, although 
they could recognize both viruses in other assays. Since both E46 and E15 reacted 
with the epitopes (identical or closely related) shared by the parent (SA-14) and the 
vaccine (SA-14-2-8, SA-14-5-3 and SA-14-14-2) viruses, the present results suggest 
that the biological function or the degree of the expression of the epitopes on the 
wild-type parent virus recognized by above MAbs could be different to that of the 
vaccine viruses. Alternatively, such preferential neutralization can also be due to the 
difference in the conformational structure of the E protein so that the interaction 
between the same MAb and the same epitope on different viruses would result in 
different biological consequences. These hypotheses can also be applied to the 
preferential N activity shown by other MAbs, e.g. C13, E4, E43, E64, which had 
specific N activity against the wild-type and one of the vaccines or one of the vaccine 
viruses only (Table 4.7). The similar preferential N activity with other anti-JE MAbs 
have also been observed among wild-type strains of IE virus in that the wild-type 
strains of IE virus could be distinguished by N activity (Sil and Wills unpublished 
observation). Thus, the present studies indicate that epitopes physically common to 
all IE viruses differ in their biological functions.
The specific N activities of the MAbs discussed above suggest that they may 
potentially be antigenic markers for identification of wild-type and attenuated vaccine 
strains of JE virus (in addition to the wild-type and vaccine specific MAbs described
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above). However, further investigation 45 required to confirm whether or not such 
specific N activities are associated (or correlate) with the virulence and attenuation 
of the SA-14 strain of JE virus. For example, N study with other wild-type strains 
of JE virus, detailed epitope mapping of the E protein will be very useful to answer 
this question. Moreover, the preferential neutralization of the wild-type parent strain 
SA-14 by the MAbs generated against the vaccine virus SA-14-14-2/PDK9 suggests 
that this antigenic relationship between the vaccine and its wild-type parent strain 
might relate to its effectiveness as a live JE virus vaccine.
In serological studies using immune sera or ascitic fluid produced against 
flaviviruses, N tests are generally the most specific for the immunizing strain and 
related flaviviruses (de Madrid and Porterfield, 1974; Monath, 1990). The results 
described in this chapter support the above observation at epitope level. First, five out 
of seven JE-type specific and three out of twenty-three JE subgroup reactive MAbs 
showed N activity and three of them (E46, K15 and E15) distinguished the parent 
virus from the vaccine derivatives. In contrast, four out of twenty-seven and three out 
of seventeen in flavivirus intermediate and flavivirus group reactive MAbs 
respectively demonstrated N activity. Secondly, most of the HAI MAbs showed cross 
activity with both the wild-type parent and the vaccine viruses. While most of the 
MAbs, which distinguish wild-type and vaccine viruses, or the individual viruses, had 
N activity, although some MAbs demonstrated limited specificity in HAI assays.
No difference in the growth characteristics, pathogenicity and antigenic phenotypes 
between the SA-14-14-2/PHK and SA-14-14-2/PDK9 derivatives were observed in 
this study. These results support the observation made by Eckels et al. (1988), who 
reported that the adaption of SA-14-14-2/PHK in PDK cell cultures did not result in
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detectable phenotypic (plaque size) and genome (analysed using oligonucleotide 
fingerprints) changes for this virus clone. However, further comparative studies are 
required to examine the immunogenicity of these two different derivatives of SA-14- 
14-2 virus.
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Chapter 5
Generation and analysis of Japanese encephalitis virus monoclonal antibody 
neutralization resistant variants from the wild-type parent strain SA-14 
and its vaccine derivative viruses: SA-14-5-3 and SA-14-14-2
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5.1. Introduction
The biological properties of haemagglutination (HA), neutralization (N) and passive 
protection of flaviviruses have been found to reside on the envelope protein (Brinton, 
1986). To date, although the physical structure of the JE virus E protein and the 
spatial location of epitopes on this protein have been examined by several groups 
(Kimura-Kuroda and Yasui, 1983; 198^; Cecelia etal., 1988), studies on the specific 
biological functions of the epitopes are limited.
Generation of antigenic variants of viruses has been used as a very useful method 
to investigate the biological functions of the epitope both in vivo and in vitro. The 
selection of antigenic variants depends upon the virus population being heterogeneous, 
including virions either lacking certain E protein epitopes or with the epitope of the 
altered biological function. Accordingly, MAbs with specific biological activities 
against particular epitopes allow the selection of the antigenic variants in the virus 
population with the physically or functionally altered epitopes recognized by the 
MAb. The best method to generate antigenic variants is by selection with MAbs that 
elicit neutralizing activity. Consequently, generation of variants that replicate in the 
presence of neutralizing MAbs will be the variants with, in theory, only one mutation 
in the epitope recognized by the selecting MAb.
In the previous chapter, the results showed that the E protein epitopes of the wild- 
type parent (SA-14) and its vaccine derivatives (SA-14-2-8, SA-14-5-3 and SA-14-14- 
2/PDK9) exhibited varied degree of reactivity with the MAbs in PRNT and HAI 
assays. Therefore, in this chapter the biological functions of these epitopes were 
further examined by generation of MAb neutralization resistant (MAb^) variants from 
the wild-type parent and its vaccine derivative viruses.
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5.2. Experimental procedures
5.2.1. Neutralizing (N) MAbs
For selection of MAb^ variants, the MAb with the SNI of greater than four is 
prefered. However, as shown in the previous chapter, only a few MAbs elicited N 
activity against the virus examined and most of those N MAbs had a SNI of less than 
three. Thus, the MAbs giving the highest SNI were chosen to generate MAb^ 
variants. The details of the N MAbs used in this study are shown in Table 5.1.
5.2.2. Selection of MAb^ variants
The detailed procedure for the selection of MAb^ variants is described in Chapter 2. 
Briefly, a MAb was incubated with a virus at room temperature for 45 minutes and 
then titrated in plaque assays and the reduction in infectivity titre compared to the 
control. The potential MAb^ variants were selected by picking plaques and amplifying 
in cell culture. Then, they were confirmed to have lost the epitope recognized by the 
MAb in PRNT and IIF tests with the appropriate MAbs using the techniques 
described in Chapter 2.
5.2.3. Examination of the biological properties of the MAb^ variants
The growth charateristics of the selected MAb^ variants, such as their ability to 
produce CPE, virus plaque production and plaque morphology, were examined as 
described in Chapter 4. The HA activity of the MAb^ variants was examined using 
the method included in Chapter 2.
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Table 5.1
Properties of the monoclonal antibodies (MAbs) used to 
generate MAb neutralization resistant variants
MAbs specificity SA-14 SA-14-2-8 SA-14-5-3 SA-14-14-2/PDK9
N HAI N HAI N HAI N HAI
C ll flavivirus
intermediate
3.0 640 ND ND ND ND 20 640
C13 flavivirus
intermediate
- 640 - - 13 - 40
K2 JE subgroup 0.8 40 0.5 40 1.0 40 0.5 160
K ll flavivirus
intermediate
0.7 40 0.8 40 24 80 0.5 160
K15 JE subgroup 320 0.8 80 1.2 160 0.8 160
N.B. Results are summarized from Table 4.6, Chapter 4.
N: The titre is expressed as serum neutralization index as described in Chapter 2.
HAI: The highest MAb dilution which inhibited haemagglutination of 
gander red blood cells by 4 HAUs of the virus.
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5.2.4. Pathogenicity study of the MAb^ variants
The pathogenicity of the selected MAb^ variants was examined in female outbred TO 
mice (described in Chapter 2) by intracerebral (i.e.) inoculation (20ul). The mortality 
and average survival time were calculated as described in Chapter 2.
5.3. Results
5.3.1. Generation of MAb^ variants
As shown in Table 5.1, MAb C ll neutralized the parent SA-14 and the vaccine 
derivative SA-14-14-2/PDK9 to SNIs of 3.0 and 2.0 respectively. While MAbs C13, 
K2, Kl l ,  and K15 neutralized the vaccine virus SA-14-5-3 to a higher SNI than the 
parent and the other two vaccine viruses. Thus, MAb C ll was used to generate 
MAb^ variants from the parent virus strain SA-14 and the vaccine SA-14-14-2/PDK9. 
While MAbs C13, K2, K ll and K15 were used to produce MAb^ variants from the 
vaccine virus SA-14-5-3.
The putative MAb^ variants were plaque picked from the PRNTs as described in 
Chapter 2. Two plaques were picked each from SA-14 and SA-14-14-2/PDK9 viruses 
from the PRNTs with MAb C ll and were designated SA-14/C11^\ SA -14/Cll^ and 
SA-14-14-2/PDK9/Cll^' and SA-14-14-2/PDK9/Cll^ respectively. Similarly, the 
SA-14-5-3 virus plaques were selected from the PRNTs with MAbs: three for C13, 
two for K2, three for K ll and two for K15. These were designated SA-14-5-3/C13^\ 
SA-14-5-3/C13^, SA-14-5-3/C13'^, SA-14-5-3/K2^\ SA-14-5-3/K2^, SA-14-5- 
3 /K ll^ \ SA-14-5-3/K1F, SA-14-5-3/Kll^, SA-14-5-3/K15^' and SA-14-5-3/K15^ 
respectively (Table 5.2).
All the putative MAb^ variants were amplified in SW13 cells and harvested
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Table 5.2
PRNTs of the selected potential MAl^ variants 
with the appropriate MAbs which selected them
MAbR
variants
CPE*
Logiopfti/mf
SNI
without MAb with MAb
SA-14/Cll^ 13 1.2 0.1
SA-14/Cll^ - 1.0 1.1 -0.1
SA-14 + 7.0 4.0 3.0
SA-14-14-2/PDK9/Cll^ - 1.7 13 0.2
SA-14-14-2/PDK9/Cll^ ■ - 13 1.2 0.1
SA-14-14-2/PDK95 -f 6.9 4.8 21
SA-14-5-3/C13^ + 6.9 5.7 1.2
SA-14-5-3/C13^ + 6.7 5.7 1.0
SA-14-5-3/C13^ + 6.9 5.8 1.1
SA-14-5-3 + 7.1 5.6 1.5
SA-14-5-3/K2^ + 6.7 6.6 0.1
SA-14-5-3/K2^ + 6.7 6.9 -0.2
SA-14-5-3 + 7.1 6.0 1.1
SA-14-5-3/Kll^ + 6.5 63 0.0
SA-14-5-3/Kll^ + 7.0 7.2 -0.2
SA-14-5-3/Kll^ 7.1 6.9 0.2
SA-14-5-3 -i- 7.1 4.7 2.4
SA-14-5-3/K15R1 ,+ 73 63 1.0
SA-14-5-3/K15R2 + 15 6.0 1.5
SA-14-5-3 + 7.1 5.9 1.2
+: Infectivity titres are determined by plaque assay in LLC-MK2 cells.
*: CPE was produced in SW13 cells.
$: The SA-14-14-2/PDK9 used was C6-36 passaged and had large plaque 
morphology (see Chapter 4, Fig. 4.1 ).
SNI: serum neutralization index.
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depending on the degree of CPE (90%) or five days post infection, whichever was 
the shorter time. The putative MAb^ variants were then titrated, with and without the 
selecting MAb, using plaque assays in LLC-MK2 cells. As can be seen in Table 5.2, 
the SA-14 and SA-14-14-2/PDK9 Cll^ variants showed very low infectivity titres and 
no CPE after being amplified in SW13 cells. In contrast, all the SA-14-5-3 MAb^ 
variants derived from MAbs C13, K2, K ll and K15 were amplified to a high titre 
in SW13 cells.
The above amplified potential MAb^ variants were examined by PRNTs with the 
appropriate MAbs used to select them (Table 5.2). It was found that the SA-14 and 
SA-14-14-2/PDK9 Cll^ variants, the SA-14-5-3 MAb^ variants derived from MAbs 
K2 and K ll were either not neutralized or poorly neutralized by the appropriate 
MAbs in comparison to their parent viruses. In contrast, three SA-14-5-3 plaque 
picked virus clones from MAb C13 and two from the K15 were still neutralized by 
the appropriate MAbs to a similar extent as the parent virus.
5.3.2. Indirect immunofluorescence (HF) tests of the putative MAb^ variants
In addition to the confirmation of the putative MAb^ variants with PRNTs, IIF tests 
were used to identify the physical changes of the epitopes on the selected MAb^ 
variants with the appropriate selecting MAbs, together with the vaccine (V23 and 
T60) and the wild-type (KIO, K13, K39, K43 and 144) specific MAbs. The results 
are shown in Table 5.3.
All the potential vaccine MAb^ variants (SA-14-14-2/PDK9/C11 ,^ SA-14-5- 
3/C13\ K2^, Kll^ and K15^) retained their reactivity with the two vaccine specific 
MAbs (V23 and T60) but did not react with any of the wild-type specicific MAbs.
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Table 5.3
IIF testsof the selected potential MAlf variants with the 
appropriate MAbs, vaccine and wild-type specific MAbs
MAb^ appropriate 
variants selectingMAb
vaccine specific wild-type specific
V23 T60 K ll K13 K39 K43 J44
SA-14/Cll^ 4- 4- 4- 4- 4-
SA-14/Cll^ - - - 4- 4- 4- . 4- 4-
SA-14 4- - + 4- 4- 4- 4-
SA-14-14-2/PDK9/Cll^ - 4- 4" - - - - -
SA-14-14-2/PDK9/Cll^ - . 4- 4- . - - - - -
SA-14-14-2/PDK9 -f 4- 4- - - - - .
SA-14-5-3/C13^ + 4- 4-
SA-14-5-3/C13^ -f- 4- 4- - - - ■ - -
SA-14-5-3/C13^ 4- 4- 4- - - • - - -
SA-14-5-3 4- 4- 4- ' - - - - -
SA-14-5-3/K2^ . 4- 4-
SA-14-5-3/K2^ - 4- 4- - - - - -
SA-14-5-3 4- 4- 4- - - - - . -
SA-14-5-3/Kll^ 4- 4- 4- - - _
SA-14-5-3/Kll^ 4- 4- .4- - - - -
SA-14-5-3/Kll^ 4- 4- 4- ■ - - - -
SA-14-5-3 + 4- + . - - - - -
SA-14-5-3/K15R1 4- 4- + - - -  . - _
SA-14-5-3/K15R2 4- 4- + - - - -
SA-14-5-3 4- 4- + - - - -,
+: positive reaction, 
negative reaction.
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Similarly, the wild-type parent virus SA-14 Cll^ only reacted with the five wild-type 
specific MAbs (KIO, K13, K39, K43 and J44) but not with the two vaccine specific 
MAbs. In the last section, it had been shown that the MAbs Cl l ,  K2 and K l l  did not 
neutralize their appropriate MAb^plaque picked virus clones (SA-14/Cl 1 ,^ SA-14-14- 
2/PDK9/Cll^, SA-14-5-3/K2^ and SA-14-5-3/K1F). In the IIF tests, it was found 
that the C ll (SA-14/C11^^“ ‘*®2 ^nd SA-14-14-2/PDK9/Cll^^“ ‘*^) and K2 (SA-14-5- 
3/K2R1 “ d R2^  MAb^ variants did not react with the appropriate MAbs used to select 
them. In contrast, MAb K ll still recognized all the three selected virus clones (SA- 
14-5-3/ Kl l ^^’ The SA-14-5-3 virus clones plaque picked from the PRNTs 
with MAbs C13 and K15, which were still neutralized by the appropriate MAbs (see 
last section), were recognized by the corresponding MAbs in IIF tests. Thus, it 
suggests that the epitopes recognized by MAbs C13 and K15 on the plaque selected 
SA-14-5-3 viruses were not altered either physically or functionally and were 
excluded from further examination.
5.3.3. Growth characteristics of the MAb^ variants
As mentioned in Section 5.3.1, the MAb Cll^ variants derived from the wild-type 
parent strain SA-14 and its vaccine derivative SA-14-14-2/PDK9 replicated poorly in 
SW13 cells. Thus, the growth characteristics of the variants were examined by 
propagating the virus in different cell lines and comparing to that of the appropriate 
parent virus. Due to the poor infectivity titre of the MAb Cl l^ variants (between 1.0 
to 1.7 Logio pfu/ml), a multiplicity of infection (m.o.i.) of 1 0 '^ ^ ^  used in this 
study.
As can be seen in Table 5.4, no CPE was observed following infection of the cells
127
c
"C
P £
U
2
I
I
Ü
u
Z
z.'”
}i
I
'È a>
m
u
z."
i - i
w
u
i l.£
s
I
1
V) On .—( If)
' +
:
• +
I I S
S S 5v| v|
• +
s
<NJ VO
1—t r—> lO
r-4
TH r-4
y y
D" rr It
<: < <:
(Z) w w
5
tNj n  V)
r-i 1-4 1/1
I t +
s
S S
vl v|
• +
I  I  s
+
$
2 2
y
I
I
y  
2 2II
i i
8
i
L
if
Æ  C3
Ï Î
t  £
5  I
w
■Sc1o•o
2 eg
O
>
.2
1 3<D
'S
*s
CiP
c rw
128
(SW13, LLC-MK2, Vero and C6-36) with the MAb Cll^ variants (derived from both 
SA-14 and SA-14-14-2/PDK9 viruses). Coincident with this, it was found that the 
virus infectivity titre was low ranging between < 1.0 to 1.7 Logio pfu/ml. In contrast, 
using the same m.o.i. (10'^^ the parent viruses (SA-14 and SA-14-14-2/PDK9) 
produced CPE in above cells and the infectivity titre was generally between 4 to 5 
Logio higher than their appropriate MAb Cll^ variants. Moreover, the MAb Cl l^  
variants demonstrated small plaque morphology in comparison with the large plaques 
produced by the parent viruses.
The SA-14-5-3 MAb^ variants generated from the PRNTs with MAbs K2 and K ll 
were also examinednhe alteration in their growth characteristics. It was found that all 
the SA-14-5-3 MAb^ variants maintained the growth characteristics similar to the 
parent SA-14-5-3 virus in terms of the above parameters (Table 5.5)
5.3.4. Haemagglutination (HA) activity of the MAb^ variants
The HA activity of the SA-14, SA-14-14-2/PDK9, and SA-14-5-3 MAb^ variants 
were examined using gander red blood cells (RBCs) as described in Chapter 2. Due 
to the low infectivity titre of the C ll MAb^ variants, both the parent and the variants 
were amplified once more in SW13, LLC-MK2, Vero and C6-36 cell to increase the 
infectivity titre.
As can be seen from Table 5.6, the SA-14 and SA-14-14-2/PDK9 C ll  MAb^ 
variants, whose infectivity titre was still low (ranging from < 1.0 to 1.7 Logjo pfu/ml) 
after being amplified once more in above cell lines, showed no detectable HA 
activity. In contrast, the parent viruses grown in SW13 (with infectivity titre of 10  ^^  
pfu/ml for SA-14, 10^  ^pfu/ml for SA-14-14-2/PDK9) and C6-36 (with infectivity
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titre of 10^  ^pfu/ml for SA-14 and 10^   ^pfu/ml for SA-14-14-2/PDK9) cells had HA 
titres between 64 and 256 per 50 ul. No HA activity was observed for the above 
viruses grown in Vero or LLC-MK2 cells. All the SA-14-5-3 MAb^ variants showed 
no HA activity despite high infectivity titres following growth in the above cell lines. 
As with the SA-14 and SA-14-14-2/PDK9 viruses, the parent virus of the SA-14-5-3 
MAb^ variants grown in SW13 and C6-36 cells (but not the virus grown in Vero or 
LLC-MK2 cells) elicited HA activity with titres between 256 and 512 per 50 ul.
5.3.5. Pathogenicity of the MAh^ variants
The pathogenicity of the selected MAb^ variants were examined in adult mice using 
intracerebral inoculation as described in Chapter 2. The results were shown in Table 
5.7.
Due to the low infectivity titre of the SA-14 and SA-14-14-2/PDK9 MAb Cll^ 
variants, the mouse can only be i.e. inoculated with 0.2 pfu/20ul of the virus. As can 
be seen in Table 5.7, neither the parent viruses (SA-14 and SA-14-14-2/PDK9) nor 
their MAb Cll* variants caused deaths, or sickness, in the mice inoculated i.e. with
0.2 pfu of the virus. The parent SA-14-14-2/PDK9 viruses did not kill mice following
1.e. inoculation of 10  ^ pfus, whereas, the mice challenged i.e. with 100 pfus of the 
parent SA-14 virus died with 100% mortality and an average survival time of 6.6 ±  
0.2 days. Presumably, the avirulence of the parent SA-14 virus when inoculated i.e. 
with 0.2 pfu was due to the low dose of the inoculum.
Following i.e. inoculation of 10^  pfus of both the parent SA-14-5-3 virus and its 
K2 and K ll MAb^ variants, the mice showed no signs, of disease or deaths (Table 
5.7).
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Tables?
Pathogenicity of the MAt^ variants for adult mice following i.e. inoculation
MAb^variants inoculum*
(pfus)
No. of dead
Mortality
(%,)
AST
No. of inoculated
SA -14/C lf 0.2 0/10 <10 NA
SA-14/Clf^ 0.2 0/10 ^10 NA
SA-14* 0.2 0/10 <10 NA
SA-14* 100 10/10 100 6.6 ± 0 .2
SA-14-14-2/PDK9/Cll^ 0.2 0/10 J<10 NA
SA-14-14-2/PDK9/Cll^ 0.2 0/10 <10 NA
SA-14-14-2/PDK9* 0.2 0/10 :<10 NA
SA-14-14-2/PDK9* 100,000 0/10 <10 NA
SA-14-5-3/K2^ 100,000 0/10 <10 NA
SA-14-5-3/K2^ 100,000 0/10 <10- NA
SA-14-5-3/Klf^ 100,000 0/10 <10 NA
SA-14-5-3/Klf^ 100,000 0/10 <10 NA
SA-14-5-3/Klf^ 100,000 0/10 <10 NA
SA-14-5-3* 100,000 0/10 <10 NA
AST: average survival time± standard error of the mean. 
* : The appropriate parent control virus.
AfA-
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5.4. Discussion
In this study, MAbs were used to generate antigenic variants from both the wild-type 
parent strain SA-14 and its vaccine derivatives (SA-14-5-3 and SA-14-14-2/PDK9).
The MAb^ variants of the vaccine virus SA-14-5-3 were selected using N MAb 
K2 (JE subgroup specific) and K ll (flavivirus intermediate reactive). In IIF tests, the 
K2 MAb failed to recognize its MAb^ variants, whereas, MAb K ll still showed 
reactivity with the MAb^ variants prepared against it. Therefore, this result suggests 
that the amino acids constituting the K2 epitope have altered, while the resistant 
neutralization phenotype of the K ll MAb^ variant may be due to a functional change 
of the epitope only.
All the SA-14-5-3 K2^ and Kll^ variants maintained the antigenic markers of the 
parent vaccine virus in that they only reacted with the two vaccine specific MAbs 
(V23 and T60) but with none of the wild-type specific MAbs (KIO, K13, K39, K43 
and J44) as described in the last chapter. However, further studies are required to 
investigate what physical or functional changes, if any, that affect the other epitopes 
on the E protein of the K2^ and K11 MAb^ variants. In pathogenicity tests, it was 
found that the K2^ and K11^  variants retained the attenuated phenotype following i.e. 
inoculation with the a large dose (10  ^pfus) of the virus. Thus, the alteration of these 
two epitopes (K2 and K11) do not seem to be important for the attenuated phenotype 
of this vaccine virus.
No differences in the growth characteristics were observed between the parent SA- 
14-5-3 virus and its K2^ and Kll^ variants in terms of CPE production, infectivity 
titre, and plaque morphology following propagation in various cell lines. Thus, it can 
be presumed that the physical alteration of the K2 epitope or the functional change
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of the K ll epitope played no significant role in the virus replication in relation to the 
above phenotypes. Biological assays showed that the SA-14-5-3 K2^ and Kll^ 
variants have lost HA activity and this loss of HA activity was not recovered 
following further passage in cell cultures. This result indicates that the epitopes 
recognized by MAbs K2 and K ll are associated with the HA activity of the virus. 
The similar observation has been made by Holzmann et al. (1989), who reported that 
the HA activity of a MAb^ variant generated from tick-borne encephalitis virus 
decreased significantly, but was not absent, in comparison to that of the parent virus. 
It is unclear what role, if any, these epitopes (K2 and Kl l )  play in the 
immunogenicity of the SA-14-5-3 vaccine.
In contrast to their MAb^ variants, the parent viruses (SA-14, SA-14-5-3 and SA- 
14-14-2/PDK9) did show HA activity after being grown in SW13 and C6-36 cells. 
However, no HA activity was found for the virus grown in Vero and LLC-MK2 
cells, although the infectivity titres indicated that there were enough antigen available 
to elicit HA activity with respect to the results obtained in SW13 and C6-36 cells. 
This observation indicates that the HA activity of JE virus is host cell (from which 
the virus derived) dependent to some extent. Enveloped viruses, such as flaviviruses, 
are hybrid entities composed of structures that are specified by the virus as well as 
by the host cells. Although the primary amino acid sequence of the virus envelope (E) 
protein is virally encoded, the pattern of glycosylation and the composition of 
carbohydrate and lipids, which are important to the conformational structure of the 
virus envelope, are specified by host enzymes. It has been shown that flaviviruses 
derived from different types of cells contained the phospholipid composition similar 
to that of the host cells (Trent and Naeve, 1980). Therefore, it may be presumed that
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flavivirus envelopes derived from different host cells could have different 
conformational structures. This result indicates that the host cells play a significant 
role in modifying the biological activities, such as HA activity, of flaviviruses. Thus, 
the loss of HA activity by the SA-14-5-3 K2^ and Kll^ variants as discussed above 
could be due to the co-effects of the physical and/or functional alterations of these 
epitopes and the host cell modification. If this is the case, it would be interesting to 
investigate what cell lines, if any, could restore the HA activity to the SA-14-5-3 
MAb^ variants.
The Cl l^ variants were generated from the wild-type parent strain (SA-14) and 
its vaccine derivative (SA-14- 14-2/PDK9) viruses. IIF tests showed that the selected 
Cl l^ variants had lost their reactivity with the MAb Cl l .  Therefore, it indicates that 
the amino acids constituting the C ll epitope have altered. The SA-14 and SA-14-14- 
2/PDK9 Cl variants retained their reactive patterns with the vaccine (V23 and T60) 
and the wild-type (KIO, K13, K39, K43 and J44) MAbs. However, due to the 
extremely low infectivity titre of the Cll^ variants, it was not possible to examine 
whether or not this alteration of the C ll epitope is associated with any changes in the 
pathogenicity of the wild-type (SA-14) and the vaccine (SA-14- 14-2/PDK9) viruses. 
It is conceivable that the in vivo N test involving the wild-type parent virus SA-14 
would be very useful to identify the function of this epitope in relation to the 
pathogenicity.
In one of the author’s previous studies (unpublished observation), it was found that 
this C ll epitope could elicit passive protection against tick-borne (Langat virus strain 
TP21) and mosquito-bome (WN virus strain Sarawak (IE subgroup)) flavivirus 
infections. The Cl l^ variants generated from the above two viruses, which have lost
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the C ll epitope as determined in IIF test, were found to replicate so poorly (as found 
for JE virus) in various cell lines that the pathogenicity study was unsuccessful. 
Dunster et al. (1990) reported that highly attenuated WN Sarawak virus by passage 
in HeLa cells lost reactivity with this MAb in N test, although the C ll  epitope was 
still detected in IIF test. Interestingly, this HeLa cell attenuated WN Sarawak virus 
could replicate to high titres in various cells. Thus, it may be reasonable to 
hypothesize that both the physical structure and the function of this C ll  epitope could 
be very important for the virus pathogenicity.
It is interesting and surprising that the SA-14 and SA-14-14-2/PDK9 Cl 1  ^variants 
(and the previously generated Langat TP21 and WN Sarawak Cll^ variants) showed 
defective growth characteristics in various cell lines compared to that of their 
respective parent viruses. This defective growth phenotype correlates with the 
physical alteration (loss) but not the functional change of this C ll epitope. To the 
author’s knowledge, such MAb^ variants defective in replication has not been 
described before. If this defective replication phenotype is the consequence of the 
physically altered C ll epitope on the E protein, it may be presumed that the 
impediment of the virus replication happens in the early stage of the virus replication 
cycle, such as virus attachment and penetration, or the late stage, e.g. the virion 
assembly and release, since the E protein is associated with such processes. However, 
with the available evidence, it cannot be excluded that this defective replication 
phenotype is the result of the mutation outside of the E gene and the loss of the C ll 
epitope is just a coincident antigenic marker. Clearly, nucleotide sequence studies will 
aid in understanding the molecular basis for such a replication defective phenotype.
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Chapter 6
Attenuation of wild-type Japanese encephalitis viruses 
by passage in HeLa cells
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6.1. Introduction
As reviewed in the Chapter 1, the attenuation of JE viruses could only be obtained 
by repeated prolonged passages in primary cell cultures. The genomes of RNA 
viruses evolve at a high mutation rate, therefore, many nucleotide changes can occur 
as a result of such long passaging. Comparison of the nucleotide sequence of the 
wild-type JE virus strain SA-14 and its attenuated vaccine SA-14-14-2/PHK and 
PDK9 derivatives yielded equivocal results (Aihara et aL, 1991; Nitayaphan et aL, 
1990), as the large number of passages separating the attenuated variants from the 
wild-type parent resulted in 57 for SA-14-14-2/PHK and 45 for SA-14-14-2/PDK9 
nucleotide changes, many of which are probably not associated with the attenuation 
and/or virulence of the virus. Therefore, an alternative approach would be to analyse 
the attenuation of JE virus that can be achieved after very few passages in cell 
culture. This should contribute to elucidation of attenuating mutations in the virus 
genome.
During the 1960s, it was demonstrated that only six sequential passages of the 
wild-type yellow fever (YF) virus (strain Asibi) in HeLa cells resulted in the 
attenuation of the virus for monkeys so that the virus lost its ability to cause 
viscerotropic disease (Hardy, 1963; Hearn etal., 1965; Converse etal., 1971). More 
recently, Barrett et al. (1990) have confirmed and extended this work, showing that 
the wild-type Asibi virus was attenuated for both monkeys and mice following six 
passages in HeLa cells. Furthermore, they demonstrated that the Asibi HeLa p6 virus 
was antigenically different to the non-HeLa passaged parent virus. A similar 
observation has also been reported for West Nile (WN) viruses (Dunster et al. , 1990).
JE and WN viruses are in the same subgroup of the Flaviviridae, and share a high
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degree of homology both as antigens and at the nucleotide level (see Chapter 1, 
Section 1.9.1). Therefore, it is reasonable to investigate whether or not JE viruses can 
be attenuated by few passages in HeLa cells. In this chapter, four wild-type strains 
of JE virus were passaged in HeLa cells in an attempt to attenuate the virus for adult 
mice. Using monoclonal antibodies (MAbs), the HeLa and non-HeLa passaged JE 
viruses were examined for changes in the viral envelope protein that may be related 
to attenuation and/or virulence of the virus. Moreover, the immunogenicity of HeLa 
cell attenuated JE virus was examined.
6.2. Experimental procedures
6.2.1. Viruses
Four wild-type strains of JE virus SA-14, Beijing-1, Nakayama-original (Nakayama- 
O) and 826309 were passaged in HeLa cells. The details of the viruses were 
described in Chapter 2. Prior to this study, each virus was amplified once in Vero 
and C6-36 cells. The three SA-14 series vaccine strains (SA-14-2-8, SA-14-5-3 and 
SA-14-14-2/PDK9) were also passaged in HeLa cells to compare with the HeLa cell 
passage of the wild-type strains. To investigate the proposal of Dunster et aL (1990) 
that the HeLa cell attenuation of arboviruses would be vector and tissue tropism 
dependent, a mosquito-bome neurotropic alphavirus, Semliki Forest Virus (SFV) 
strain TS + , was used as a control to compare with the mosquito-bome neurotropic 
flavivirus examined in this chapter. Details of this vims were included in Chapter 2.
6.2.2. Pathogenicity studies
Adult mice are highly sensitive to JE vimses and are the animal model of choice to
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study JE viruses (Monath, 1990). In this study, female outbred TO mice (described 
in Chapter 2) were used to determine the virus virulence. Mice were challenged by 
intracerebral (i.e. 20ul), intraperitoneal (i.p. lOOul) or intranasal (i.n. 20ul) routes. 
Following inoculation, the mice were observed for a period of upto 21 days and, 
where possible, the LD50, average survival time (AST) and/or mortality rate were 
calculated (see Chapter 2) as the index to measure the degree of the virus virulence.
6.2.3. Immunogenicity studies
Female inbred Balb/c mice (see Chapter 2) were used to examine the immuno­
genicity of the virus investigated in this work. Mice were immunized intraperitoneally 
with 10^  pfu of the virus. Blood samples were collected from the heart on day 14 and 
28 post inoculation respectively. Red blood cells were removed by centrifugation and 
the remaining serum was incubated at 56°C for 30 mins to inactivate any complement 
elements. The neutralizing antibody titre of the serum was determined using 100 pfu 
N test as described in Chapter 2 with the homologous and heterologous virus strains.
6.2.4. Antigenic studies of the HeLa passaged JE virus 
with monoclonal antibodies (MAbs)
The antigenicity of the JE virus investigated in this chapter was examined using the
indirect immunofluorescence test (IIF) as described in Chapter 2 with a panel of JE
wild-type and vaccine specific MAbs (see Chapter 4).
6.3. Results
6.3.1. Passage of wild-type strains of JE virus in HeLa cells
Wild-type strains of JE virus, SA-14, Beijing-1, Nakayama-0 and 826309, and the
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alphavirus SFV TS+ were used to infect HeLa cells as described in Chapter 2. The 
results are shown in Table 6.1. No cytopathic effects (CPE) were observed until the 
fifth passage of the SA-14 strain in HeLa cells at a low m.o.i. (0.1). This lack of 
CPE was accompanied by a low infectivity titre in the supernatant of infected cells. 
In contrast, when using a high m.o.i. (5), all four strains of JE virus produced 
significant CPE throughout all HeLa cell passages. Coincident with this, the 
infectivity titre of each HeLa cell passaged virus remained at a high level, except for 
the SA-14 virus, whose infectivity titre decreased at passage 5 and 6. The infectivity 
titre of HeLa cell passaged JE virus was determined by plaque assay using both LLC- 
MK2 and HeLa cells. No significant difference was found in the two cell systems in 
relation to the virus titre detected (Table 6.2).
In plaque assays, all four wild-type parent strains of JE virus contained a mixture 
of virions giving large and small plaque morphologies. In contrast, the virus 
harvested after one passage in HeLa cells was predominantly large plaque in 
morphology. This plaque morphology was maintained during the subsequent passages 
in HeLa cells.
Similarly, the alphavirus SFV TS+ was also passaged six times in HeLa cells 
using a m.o.i. of 5. The biological characteristics of this virus following passage in 
HeLa cells were very similar to that of the JE viruses described above (Table 6.1).
6.3.2. Haemagglutination activity of the HeLa and non-HeLa passaged JE  viruses 
The haemagglutination activity of the HeLa and non-HeLa passaged JE viruses was 
assayed using gander red blood cells (RBCs) as described in Chapter 2. The results 
are shown in Table 6.3. The four non-HeLa passaged wild-type strains of JE virus,
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which had infectivity titres approximately between 10 -^10  ^ pfu/ml and HA titres 
between 32-128, were found to have no detectable HA activity after a single passage 
in HeLa cells. This loss of HA activity was maintained throughout the HeLa cell 
passages. Although this loss of HA activity could be attributed to too little antigen 
available for some JE HeLa cell passaged viruses, e.g. the HeLa passaged SA-14 
virus derived from low m.o.i., there was no detectable HA activity for the other 
HeLa cell passaged JE viruses, even though, the majority of the infectivity titres were 
higher than the non-HelLa passaged parent virus. The non-HeLa cell passaged SFV, 
which had the infectivity titre of 10® pfu/ml and the HA titre of 128, also lost HA 
activity following a single passage in Hel^ cells (Table 6.3).
6.3.3. Passage of the JE vaccine strains, SA-14-2-8, SA-14-5-3 
and SA-14-14-2/PDK9 in HeLa cells
Each of the SA-14 series vaccine strains was passaged six times in HeLa cells at a
m.o.i. of approximately 5. The results (Table 6.4) show that the SA-14-2-8 and SA-
14-5-3 viruses are very similar to the wild-type JE viruses (high m.o.i. passages, see
Table 6.1) in that the virus produced significant CPE following all HeLa cell passages
accompanied with a high degree of infectivity titre as determined by plaque assays in
LLC-MK2 cells. In contrast to the wild-type strains, which completely lost HA
activity following a single passage in HeLa cells, the vaccine strains (SA-14-2-8 and
SA-14-5-3) were still able to agglutinate the gander RBCs after one passage in HeLa
cells, although the HA ability was markedly diminished. Compared with the non-
HeLa passaged virus, which had a HA titre of 128, the HA titres of the SA-14-2-8
and SA-14-5-3 HeLa pi viruses reduced to 8 and 16 respectively. No HA activity was
detected for the both viruses from HeLa p2 onwards. No CPE was observed after
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passage of the vaccine strain SA-14-14-2/PDK9 in HeLa cells. Coincident with this, 
it was found that there was a significant reduction in the virus infectivity titre 
following the first HeLa cell passage (reduced from HeLa pO 10^  ®'® ° pfu/ml to the 
103.0-3.2 pfu/ml of the HeLa pi) as determined by plaque assays using both LLC-MK2 
and HeLa cells (Table 6.4). This low infectivity titre was maintained throughout the 
subsequent HeLa cell passages. All the HeLa cell passaged SA-14-14-2/PDK9 viruses 
were found to have no detectable HA activity.
6.3.4. Virulence of HeLa cell passaged JE viruses for adult mice
The neuroinvasiveness and neurovirulence of four HeLa cell passaged wild-type 
strains of JE virus and the SFV were determined and compared to that of the non- 
HeLa passaged parent virus in adult mice (Table 6.5). The results showed a variation 
in the virulence between the different isolates of JE virus examined and also between 
the parent and HeLa p6 viruses. Six sequential HeLa cell passages of JE virus, strain 
Nakayama-0, resulted in significant attenuation of the virus. The pfu/LD^o ratio of 
the non-HeLa passaged virus was 1(P ® following intranasal (i.n.) inoculation of the 
mice. After six HeLa cell passages, the pfu/LD^o was greater than 10^ ®. Thus, the 
Nakayama-0 HeLa p6 virus was attenuated at least 3,500 fold. Similarly, the strain 
826309 also showed a marked attenuation after six passages in HeLa cells. The 
pfu/LDjo of the HeLa p6 826309 was at least 100 fold higher than the non-HeLa cell 
passaged parent virus (10"^  ® versus > 10^  ®). In contrast, Beijing-1 strain remained as 
virulent for mice after six HeLa cell passages as the parent virus. No significant 
alteration in the average survival time and LD50 were observed between the parent 
and the HeLa p6 viruses. Similar to the Beijing-1 strain of JE virus, the TS+ strain
148
Table 6.5
Neuroinvasiveness and neurovirulence of HeLa and non-HeLa 
passaged wild-type JE viruses for adult mice following i.n. inoculation
Virus strains HeLapassage Lo^opfu/LDso
AST
(+SEM )
0 >5.0 NA
SA-14*
6 >3.0 NA
0 >5.0 NA
SA-14*
6 ±3.0 NA
Beijing-1
0 4.4 83+0.4
6 43 9.1+03
0 2.8 117+0.7
Nakayama-O
6 ± 6 3 NA
826309
0 43 10.2 + 0.4
6 ± 63 NA
0 33 8.9+0.5
SFV
6 3,6 5.9+0.6
a: Average survival time ±the standard error of the mean. 
*: low m.o.i. passaged SA-14 virus.
S: high m.o.i. passaged SA-14 virus.
NA: Not applicable.
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of SFV was not attenuated following six passages in HeLa cells as measured by the 
LD50 after i.n. inoculation of the mice (Table 6.5). Interestingly, the mice inoculated 
i.n. with the SFV HeLa p6 virus showed a shorter survival time (5.9±0.6 days) 
compared to the mice inoculated with the non-HeLa cell passaged parent virus 
(8.9+0.5 days). As reported previously (Huang, 1982), the SA-14 strain had very 
poor peripheral virulence and was completely avinilent (i.e. no clinical manifesta­
tions of the disease were observed.) following i.n. inoculation of adult mice. 
Therefore, it was not possible to determine the neurovirulence of either the HeLa or 
the non-HeLa passaged virus by this peripheral route of challenge.
To examine the attenuation process, the intermediate HeLa cell passaged 
Nakayama-0 viruses was inoculated into adult mice as above. The results (Table 6.6) 
show that the virus exhibited significant attenuation characteristics after a single 
passage in HeLa cells, and did not kill mice following i.n. inoculation of 10^  pfu, 
whereas the parent virus did. This attenuated phenotype was maintained on the 
subsequent HeLa cell passages.
Since the virus was only administered by a peripheral route above, it was 
considered possible that the attenuation of the Nakayama-0 virus was solely due to 
the reduced neuroinvasiveness rather than the neurotropic virulence of IE virus (e.g. 
the wild-type SA-14 virus has poor neuroinvasiveness but high neurotropic 
virulence.). To answer this question, the viruses were inoculated into adult mice by 
the intracerebral (i.e.) route (Table 6.7). The Nakayama-0 pO virus was completely 
lethal for the mice following i.e. inoculation of 10 pfu of the virus. In contrast, the 
pi and p6 viruses, which had been shown to be avinilent by i.n. inoculation of the 
mice, were highly attenuated, even following the inoculation of 10  ^pfu of virus into
150
Table6.6
Neuroinvasiveness and neurovirulence of the intermediate 
HeLa cell passaged Nakayama-O viruses following i.n. inoculation
HeLapassage
moculum
(Lo^oPiu)
Virulence
ASTsurvivors
mortality (%)total inoculated ( +SEM)
0 4 1/8 88 117 + 0.7
1 6 8/8 <115 NA
2 6 8/8 <115 NA
3 6 ND ND NA
4 6 8/8 <115 NA
5 6 8/8 <115 NA
6 6 8/8 ±115 NA
NA: Not applicable, ND: Not done.
AST: average survival time ±  standard error of the mean.
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Table6.7
Neurovirulence of HeLa and non-HeLa passaged SA-14 and 
Nakayama-O strains of JE virus following i.e. inoculation
Virus HeLapassage
inoculum
(Logjopfu)
survivors
Virulence
mortality (%)LD 50 AST(+SEM )total inoculated
SA-14 0 20 1/17 <20 6.6,4- 0.2
6* 20 0/10 100 <20 6.5+0.2
6* 20 0/10 100 <20 .6.5+03
Nakayama-O 0 1.0 0/10 100 <1.0 6.5+0.1
1 5.0 6/6 0 ±5.0 NA
6 5.0 13/14 7 ±5.0 7.0+0.0
NA: not applicable.
*: low m.o.i. passaged S A-14 virus.
$: high m.o.i. passaged SA-14 virus.
AST: average survival time+standard error of the mean.
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the mouse brain, and only caused sporadic deaths. Due to the poor peripheral 
virulence (or neuroinvasiveness) of the strain SA-14, the neurovirulence of non-HeLa 
and HeLa passaged SA-14 virus (both derived from low and high m.o.i.) were 
determined following i.e. inoculation. It was found that both the HeLa pO and p6 
viruses were lethal for the mice following i.e. inoculation of 100 pfu. No difference 
in the average survival time was observed between the parent pO and the p6 viruses 
(Table 6.7). Moreover, no infectious virus, detectable by plaque assays ( < l(f 
pfu/ml), was found in the pooled brain samples collected from the mice inoculated 
i.e. with the pi and p6 viruses following 6/7, 14 or 21 days of the infection, whereas, 
high titre virus was recovered from the mouse brain inoculated with the pO virus 6/7 
days post inoculation (Table 6.8).
6.3.5. Effect of passaging JE HeLa p6 viruses in mosquito 
C6-36 cells on the HA activity
The mosquito C6-36 cells consistently produce high HA titres of JE viruses
(unpublished observation). All the JE HeLa p6 viruses (both the virulent and the
attenuated) and the SFV were passaged once in the C6-36 cells at a m.o.i. of 5 (with
the exception of SA-14 and SA-14-14-2/PDK9 HeLa p6 viruses, which only had the
infectivity titre of 10^ "^  pfu/ml and 1(P  ^pfu/ml respectively.). The results in Table
6.9 show that all the viruses, after five days of inoculation, could grow in C6-36
cells to a similar high titre as that propagated in HeLa cells apart from the SA-14 and
SA-14-14-2/PDK9 viruses, whose infectivity titres increased upto 10^   ^ pfu/ml and
10^  ° pfu/ml respectively. It was found that all the HeLa p6 viruses (JE viruses and
the SFV) regained the HA activity after a single passage in the mosquito cells. SA-14-
14-2/PDK9 virus, which still had a lower infectivity titre (10  ^° pfu/ml) after
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Table 6.8
Recovery of the virus from mouse brains 
inoculated with the Nakayama-O HeLa pO and p6 viruses
virus infectivity recovered^
HeLa inoculum No. of
passage (Log,„pfu) brainsamples* j j zid.p.i.
0 1 5 7.4 NA NA
1 5 3 <20 ± 2 0 ± 2 0
6 5 3 <20 ± 2 0 ± 2 0
6 + CEFpl 5 5 ± 2 0 <2.0 ± 2 0
control‘s none 5 ± 2 0 ± 2 0 ± 2 0
*: pooled samples, each brain was homogenized in 1 ml PBS. 
a: Infectivity titre expressed as Log jq pfu/ml.
b: control mice i.e. inoculated with PBS. 
d.p.i.: Days post inoculation.
NA: Not applicable as mice had died.
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Table 6.9
HA activity of HeLa cell passaged JE viruses after being grown in mosquito cells C6-36
virus
HeLap6 HeLa p6/C6-36 p i
infectivity HAU l^êlO(pfu/HAU)/ml infectivity HAU
1^ 810  
(pfu/HAU)/ml
Nakayama-O 8.1 <2 >65 8.7 512 4.7
826309 83 <2 >6.7 7.9 256 4.2
Beijing-1 83 <2 >6.1 8.6 256 4.9
SA-14 5.4 <2 >.3.8 7.6 128 4.2
SA-14-2-8 82 <2 >i6.6 8.5 128 5.1
SA-14-5-3 7.6 <2 >6.0 85 256 4.8
SA-14-14-2
(PDK9)
29 <2 >13 5.0 <2 >3.4
SFV 8.1 <2 >.65 85 512 4.8
Infectivity: expressed as Table 6.1. 
HAU: expressed as Table 6.3.
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one passage in C6-36 cells than the other HeLa p6 viruses, was still unable to 
agglutinate the gander RBCs.
6.3.6. Effect of passaging Nakayama-O HeLa p6 virus 
in other cell lines on the virulence
It has been shown above that the HeLa cell passaged JE viruses could regain the HA
activity following a single passage in mosquito C6-36 cells. The question remained
as to whether or not the loss of HA had any bearing on the attenuation of the JE
viruses for mice. It was possible that the recovery of the HA activity by passaging
the attenuated virus in mosquito or other cell cultures would cause a reversion to
virulence. In an attempt to answer this question, the attenuated HeLa p6 Nakayama-O
virus was passaged in the mosquito cell line C6-36(same as above), three continuous
vertebrate cell lines (Vero, SW13 and LLC-MK2), and primary chicken embryo
fibroblast (CBF) cell culture. The virulence and HA activity of the Nakayama-O
HeLa p6 virus grown in the above cell cultures were determined (Table 6.10).
The virus infectivity titre determined by plaque assays showed that the virus yield 
was roughly equal for each of the cell cultures examined. No alteration in plaque 
morphology was observed (i.e. the HeLa cell passaged virus maintained a large 
plaque morphology). After a single passage in the mosquito and the CEE cells, the 
HA ability of the Nakayama-O HeLa p6 virus was recovered. However, the virus still 
had no detectable HA activity after one passage in the other cell cultures, even 
though, the virus was propagated to a similar high infectivity titre as that harvested 
from the mosquito and the CEE cells. Adult mice were inoculated with 10^  pfu of the 
virus grown in above cell cultures by i.n. route. The results in Table 6.10 show that 
the Nakayama-O HeLa p6 virus passaged in C6-36,CEE (HA positive) and LLC-MK2
156
Table 6.10
Virulence and HA activity of Nakayama-O HeLa 
p6 virus after being grown in other cell lines
HeLa
passage
route of^ 
inoculation
virulence
AST
(+SEM )
HA
activitsurvivors mortality (%)total inoculated
0 i.n. 1/8 88 117+0.7 +
6 i.n. 8# <12 NA -
6-HC6-36pl i.n. 8/8 <12 NA +
6 + Vero pi i.n. 4/8 50 9.7+0.4
6 +  SW13pl i.n. 2# 75 10.3+0.3 -
6-f-LLC-MK2pl in. 8# <12 NA -
6-f-CEFpl i.n. 10/10 <10 NA +
i.c. 10/10 <10 NA
+: positive.
-: negative.
NA: not applicable.
#: mice were inoculatediQ  ^pfu by the i.n. route.
AST: average survival time+standard error of the mean.
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(HA Negative) cells remained as avirulent as the HeLa p6 virus, whereas, the Vero 
and SW13 passaged virus (HA negative) reverted to virulence to different degrees, 
with 50% and 75% mortality respectively. I.c. inoculation of 10^  pfu of the CEF 
passaged Nakayama-O HeLa p6 virus into adult mice also demonstrated that the virus 
was avirulent. Furthermore, no infectious virus was found in brains sampled from the 
mice on day 6/7, 10 and 14 post inoculation (Table 6.8).
6.3.7. Reactivity of HeLa and non-HeLa passaged JE  viruses with 
a panel of JE  wild-type and vaccine specific MAbs
The HeLa and non-HeLa passaged IE viruses were examined by indirect immuno­
fluorescence (IIF) tests with a panel of IE wild-type cind vaccine specific MAbs that 
had been described in Chapter 4. The results are shown in Table 6.11.
Of the five wild-type specific MAbs, K13 and K39 failed to recognize the 
attenuated Nakayama-O and 826309 HeLa p6 viruses but were still reactive with the 
Beijing-1 and SA-14 HeLa p6 viruses, which remained as virulent as the non-HeLa 
passaged parent viruses. The other three wild-type specific MAbs, KIO, K43, and 
144, recognized the virulent HeLa p6 IE viruses as well as the attenuated Nakayama- 
O HeLa p6 derivative. One vaccine specific MAb, V23, reacted with the Nakayama- 
O and 826309 HeLa p6 viruses but not the other HeLa cell passaged wild-type IE 
viruses, whereas, another MAb, T60, did not recognize any HeLa cell passaged 
viruses examined in this study. Further examination of the intermediate HeLa cell 
passaged Nakayama-O viruses showed that MAbs K13 and K39 only recognized few 
infected cells at the first HeLa cell passage and became completely negative with the 
second passage. On the other hand, the vaccine specific MAb V23 appeared to 
become reactive with some of the virus infected cells from the first passage and
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recognized all infected cells from the second passage onwards.
6.3.8. Temperature sensitivity (ts) of HeLa and non-HeLa passaged JE  viruses 
The high virulent strains of JE virus has been shown to be more resistant to heat than 
the low virulent strains (Huang, 1982). The HeLa and non-HeLa cell passaged JE 
viruses were examined for temperature sensitivity (ts) by incubating the virus in 
plaque assays at 37°C and 39.5°C. The results in Table 6.12 show that both the HeLa 
(including the virulent and the attenuated) and the non-HeLa passaged JE viruses were 
not ts as the virus exhibited a similar infectivity titre at the optimal temperature 37°C 
as well as the supraoptimal temperature 39.5°C.
6.3.9. Inununogenicity of the attenuated Nakayama-O HeLa p6 virus
The immunogenicity of the live attenuated Nakayama-O HeLa p6 virus for adult 
I -  - J Î J mice was examined and compared to that of the 13-propiolactone (BPL) 
inactivated HeLa pO and p6 viruses by a single i.p. inoculation with 10^  pfu of virus. 
The Nakayama-O HeLa p6 virus had received one further passage in CEF cell culture 
before use. The procedure for immunizing mice and testing the serum for antibody 
has been described in Section 6.2.3.
The results in Table 6.13 show that the neutralizing (N) antibody response to the 
live attenuated Nakayama-O HeLa p6 virus could be detected 14 days post 
immunization (d.p.i.) with the N antibody titre of 20 against both the HeLa and non- 
HeLa passaged homologous virus. The N antibody titre increased to 160 (against the 
HeLa pO virus) and 80 (against the HeLa p6 virus) by 28 d.p.i.. In contrast, the 
inactivated Nakayama-O HeLa p6 and pO viruses did not induce detectable N antibody
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Table 6.13
N and HAI antibody responses of mice immunized 
with either live or inactivated HeLa p6/CEF pi viruses 
compared to the inactivated non-HeLa passaged parent virus
serumsamples No. of mice *
Nakayama-O pO 
N HAI
Nakayama-O p6 
N HAI
live HeLa p6/CEF
14 d.p.i. 1 20 320 20 320
28 d.p.i. 1 160 160 80 160
inactivated HeLa p6/CEF 
14 d.p.i. <20 320 <20 160
28 d.p.i. <20 160 <20 80
inactivated HeLa pO
14 d.p.i. <20 160 <20 80
28 d.p.i. <20 <20 <20 <20
live HeLa p6/CEF^ 
14 d.p.i. 5 320 1280 320 1280
28 d.p.i. ND NA NA NA NA
*: Mice used are inbred Balb/C except where stated, 
a: TO mice used for the previous virulence test.
N and HAI: the titres are expressed as the reciprocal of the dilution of the antibody 
inhibiting 100 pfu (N test) or 4 HAU (HAI test) against homologous virus strains.
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response ( < 20) after either 14 or 28 days of immunization. However, haemagglutina- 
tion inhibition (HAI) tests showed that the serum collected on 14 d.p.i. did contain 
HAI antibodies with the titre of 320/160 (induced by inactivated HeLa p6 virus) and 
160/80 (induced by inactivated HeLa pO virus). By 28 d.p.i. the HAI antibody titre 
decreased slightly to 160/80 (inactivated HeLa p6 virus serum sample) and less than 
20 (the inactivated HeLa pO virus serum sample) when examined against the 
corresponding Nakayama-O HeLa p6 and pO viruses. Similarly, the HAI antibody 
response induced by the live HeLa p6 virus also decreased with the titre decline from 
320 (14 d.p.i.) to 160 (28 d.p.i.). A pooled serum sample (from 5 mice) was 
collected from the outbred TO mice inoculated i.c. with the live Nakayama-O HeLa 
p6 virus for the virulence test described previously (Section 6.3.3) on 14 d.p.i.. It 
was interesting to note that the N antibody titre (320) and the HAI titre (1280) were 
much higher than the corresponding single serum sample collected from one inbred 
Balb/C mouse 14 days after i.p. immunized with the virus (Table 6.13).
The serum N activity induced by the live attenuated Nakayama-O HeLa p6 virus 
was further examined against heterologous IE virus strains (Table 6.14). It was found 
that the N antibody titre of the serum sampled 14 d.p.i. varied when tested against 
different wild-type isolates of IE virus, ranging from less than 20 (e.g. the Taiwan 
strain and Indian strain G8924) to 80 (e.g. the Malaysian strain, Thai strain and 
Indian strain 782219). It was noted that the serum could neutralize some of the 
heterologous strains (examples above) to a higher titre (80) than the homologous 
viruses HeLa pO and p6 (20). At 28 d.p.i. the N antibody titre against all the wild- 
type isolates examined increased to between 80 and 160. Thus, the titre increased by 
2 to 8 fold by 28 d.p.i. in comparison with the serum collected on 14 d.p.i.,
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Table6.14
Cross N activity of the serum produced by mice immunized with 
the live Nakayama-O HeLa p6 virus tested against different JE virus strains
Virus Neutralizing antibody titre*
strains serum a serum b serum c
Malaysia 80 160 >320
Thailand 80 160 >320
782219 80 160 NT
G8924 <20 160 320
Indonesia 40 160 320
Nakayama-
Yoken
40 160 >.320
Nepal 20 160 320
826309 40 160 320
SA-14 20 80 >320
Sarawak 40 160 _>320
Taiwan <20 80 >320
Beijing-1 20 160 ^320
Nakayama-O
HeLapO
20 160 320
20 80 320
* : the reciprocal of the serum dilution which neutralized 50% of the virus, 
a: The serum sampled on day 14 post i.p. immunization from inbred Balb/c mice.
b: The serum sampled on day 28 post i.p. immunization from inbred Balb/c mice, 
c: The serum sampled on day 14 from the outbred TO mice inoculated i.c. 
with the virus.
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depending on the strains of JE virus examined. Again, the pooled antiserum sample 
collected from the TO mice 14 d.p.i. (described above) showed a much higher N titre 
( > 320) against all the wild-type isolates of JE virus than the corresponding single 
serum sample obtained from the Balb/C mouse (<20 to 80).
6.4. Discussion
In this chapter, four wild-type strains of JE virus (SA-14, Beijing-1, Nakayama-O and 
826309) were passaged six times in HeLa cells to investigate whether or not, as 
previously reported for YF and WN viruses (Hardy, 1963; Hearn, et ah, 1966; 
Converse, et ah, 1971; Barrett, et ah, 1990; Dunster, et ah, 1990), they can become 
significantly attenuated. Female TO outbred strain mice were used as an animal 
model to determine the virulence of the viruses.
Following i.n. inoculation of the virus into mice, it was found that the prototype 
strain, Nakayama-O, and an Indian strain 826309 of JE virus were significantly 
attenuated following six passages in HeLa cells. In contrast, the Beijing-1 and SA-14 
HeLa p6 viruses remained as virulent as the non-HeLa passaged parent viruses 
following i.n. (Beijing-1) and i.c. (SA-14) inoculation into mice (since the SA-14 
virus has very poor peripheral virulence, the i.c. inoculation is the only reliable 
challenge route to determine the virus virulence (Huang, 1982)).
The prototype strain Nakayama-O, which is the basis of the currently used 
inactivated IE vaccine, was selected for further analysis. The virulence of different 
HeLa cell passaged Nakayama-O virus was determined by both i.n. and i.c. inocula­
tion of virus into mice. It was found that the neurovirulence and/or neuroinvasiveness 
of the Nakayama-O virus were significantly reduced following a single passage in
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HeLa cells, in comparison to that of the non-HeLa passaged parent virus (Tables 6.6 
and 6.7). In addition to the markedly reduced neurovirulence, no infectious virus was 
recovered from the mouse brain inoculated with the attenuated viruses (HeLa p i and 
p6). This result suggests that the HeLa cell attenuated Nakayama-O virus may not be 
able to infect brain tissues or may only cause a transient infection.
By examination of all the HeLa cell passages of the Nakayama-O virus (HeLa p l- 
p6) and the 826309 HeLa p6 virus with a panel of IE wild-type specific and vaccine 
specific MAbs, it was observed that the attenuation of IE Nakayama-O and 826309 
viruses was accompanied with antigenic changes in the viral envelope (E) protein. 
The IE wild-type specific MAbs (K13 and K39) recognized the virulent non-HeLa 
cell passaged parent virus but not the attenuated HeLa p6 virus. While one vaccine 
specific MAb (V23) reacted with the vaccine strains (SA-14-2-8, SA-14-5-3 and SA-
14-14-2/PDK9) as well as the IE Nakayama-O an^826309 HeLa p6 viruses. Thus,^26
the wild-type epitope(s) recognized by MAbs K13 and K39 on the E protein have 
been lost and one vaccine specific epitope recognized by MAb V23 gained during the 
passages of the Nakayama-O and 826309 viruses in HeLa cells. Further studies 
showed that the loss of wild-type epitope(s) and the acquisition of a vaccine specific 
epitope occurred at the first HeLa passage of the Nakayama-O virus and became 
stablised from the second passage onwards. This would suggest that as few as two 
passages of the IE Nakayama-O virus in HeLa cells will engender the attenuation of 
the virus with acquisition of two biological markers: 1) the significantly reduced 
neuroinvasiveness and neurovirulence for mice; 2) loss of the wild-type epitope(s) and 
gain of a vaccine specific epitope. Whether or not the wild-type epitope(s) 
(recognized by MAbs K13 and K39) and the vaccine specific epitope (recognized by
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MAb V23) are functionally or physically linked in some way is not known. Similarly, 
it cannot be excluded that these antigenic changes are co-incidental with the 
attenuation. Nonetheless, it appears possible that the latter marker, i.e. the antigenic 
changes, may have a significance in determining the former marker (attenuation), 
since attenuated variants derived by two different processes all shared these antigenic 
similarities (i.e. the passage of the wild-type strain SA-14 virus through primary 
hamster kidney cell cultures to produce the attenuated vaccine viruses, SA-14-2-8, 
SA-14-5-3 and SA-14-14-2/PDK9, and the passage of the Nakayama-O virus through 
HeLa cells as described in this chapter.). However, it should be noted that although 
both the HeLa pi and p6 viruses are highly attenuated for mice, the wild-type 
epitope(s) recognized by MAbs K13 and K39 are still partly detected in the HeLa p i 
virus infected cells, whilst they completely disappeared from the p6 virus. Similarly, 
the vaccine specific epitope (V23) was only expressed in some of the HeLa p i virus 
infected cells in comparison with the subsequent passages and the SA-14 series 
vaccines. Therefore, further studies are necessary to investigate what role, if any, 
alterations in these E protein epitopes play in the attenuation of the JE viruses. 
Unfortunately, the MAb V23 does not neutralize the virus and K13 and K39 
neutralize very poorly. Thus, MAb neutralization resistant variants could not be 
generated to examine these epitopes in detail.
The HeLa cell attenuated Nakayama-O viruses are biologically similar to the 
attenuated vaccine derivatives from the wild-type SA-14 strain by passage in primary 
hamster kidney cells (as described in the chapter 4) in relation to the two biological 
markers discussed above. However, the attenuated SA-14 variants (SA-14-2-8, SA-14- 
5-3 and SA-14-14-2/PDK9) were produced by passage of the wild-type SA-14 virus
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in primary hamster kidney cells and required upto 100 passages before a highly 
attenuated mutant was selected. It is not known if the Nakayama HeLa p6 virus has 
lost the mosquito-competence as the SA-14 vaccine derivatives have done (Yu, 
personal communication). It was reported that 45 nucleotide (15 amino acid) 
differences separate the wild-type SA-14 virus from its SA-14-14-2/PDK-9 vaccine 
derivative (Nitayaphan et al., 1990), while 57 nucleotide (24 amino acid) differences 
to that of the SA-14-14-2/PHK derivative (Aihara et al., 1991). However, those 
nucleotide changes specifically involved in attenuation and/or virulence remained to 
be identified. In contrast, as few as two passages in HeLa cells generated the 
attenuated Nakayama-O virus with the similar markers as the attenuated SA-14 
variants. Therefore, it would be expected that fewer nucleotide changes are 
determinants of the attenuation of IE virus. It is conceivable that some changes would 
be in agreement with the nucleotide sequencing studies for the SA-14 and its SA-14- 
14-2 vaccine derivatives. Such sequence studies remain to be undertaken in the future.
The wild-type strains, Beijing-1 and SA-14, were not attenuated following six 
passages in HeLa cells. No antigenic alteration was observed between the HeLa and 
non-HeLa passaged viruses. Huang (1982) pointed out that different wild-type strains 
of JE virus varied in their degrees of neuroinvasiveness and neurovirulence. The 
present results showed that the molecular basis for the attenuation of different strains 
of JE virus may be very different. These two JE virus strains have been classified as 
separate immunotypes from the Nakayama-O and 826309 strains (M. Wills, personal 
communication). However, it is not known whether or not such antigenic differences 
would confer the variation on the virulence and/or attenuation of different JE virus 
strains.
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The mosquito-borne neurotropic alphavirus SFV also remained as virulent as the 
parent virus for adult mice after six passages in HeLa cells. Murphy et al. (1955) 
reported that the Venezuelan equine encephalitis virus, another mosquito-borne 
neurotropic alphavirus, showed a lowered pathogenicity for mice following upto 65 
HeLa cell passages. Thus, HeLa cell attenuation is not common to all mosquito-bome 
viruses. It is possible that the SFV would require more passages (than 6) in HeLa 
cells before it could be attenuated for mice. On the other hand, it is also possible that 
the SFV may not be able to be attenuated or even may become more virulent after 
passages in HeLa cells due the species and/or strain differences. For example, the 
mice inoculated with the SFV HeLa p6 virus showed a y shorter survival
time (5.9 days) compared to the mice challenged with the non-HeLa cell passaged 
virus (8.9 days) (P<0.01).
Plaque assays showed that all the four wild-type parent strains of IE virus 
contained a mixture of virus particles giving both large and small plaque 
morphologies. While after a single passage in HeLa cells, the virus was predomi­
nantly of large plaque morphology. This suggests that a modification on the virus 
plaque morphology or selection of the virus variants of large plaque morphology 
occurred during the passage process in HeLa cells. However, it is unlikely that the 
attenuation of the IE virus (Nakayama-O and 826309) by passage in HeLa cells is due 
to such effects. Firstly, the significant attenuation was observed following a single 
HeLa cell passage, hence populations of the attenuated variants accummulated by a 
selective enrichment of pre-existing avirulent mutants would probably not high enough 
to overwhelm the virulent virus particles. Secondly, the HeLa cell passaged Beijing-1 
and SA-14 viruses remained as virulent as the non-HeLa passaged parent viruses,
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although they have also obtained the predominant large plaque morphology after one 
passage in HeLa cells. Thirdly, the non-HeLa passaged parent virus of mixed plaque 
morphologies did not show any traces of reactivity in IIF tests with the vaccine 
specific MAb V23, which is one of the biological markers acquired by the HeLa cell 
attenuated Nakayama-O virus. Fourthly, by plaque purifying a large plaque from the 
wild-type yellow fever virus strain Asibi population, Barrett et al. (1990) 
demonstrated that the purified virus did not have the attenuation characteristics, such 
as, reduced virulence and antigenic changes, in comparison to the attenuated HeLa 
p6 virus, which acquired the predominant large plaque morphology. Therefore, the 
attenuation of the IE virus by passage in HeLa cells probably occurred as a result of 
the attenuating pressure exerted by HeLa cells on the virus genome rather than the 
selective enrichment of a pre-existing avirulent mutant. Such a selection pressure may 
be multifactoral including the selection of viruses that can infect HeLa cells as well 
as undergoing the replication cycle in HeLa cells.
The loss of HA activity of both the attenuated (Nakayama-O and 826309) and the 
virulent (Beijing-1 and SA-14) HeLa cell passaged IE viruses occured at the first 
passage. This indicates that the biological function of the HA epitopes on the E 
protein of IE viruses may have been modified by HeLa cells so that they lost the 
ability to agglutinate gander RBCs. Following a single passage in an invertebrate cell 
line, C6-36, and CEF cells (only the Nakayama HeLa p6 virus was passaged in this 
primary cell culture.), the HeLa cell passaged virus regained the HA activity. In 
contrast, such a function could not be recovered after the virus had been grown in 
vertebrate cell lines, i.e. Vero, LLC-MK2 and SW13. Although the virulent HeLa 
cell passaged IE viruses, Beijing-1 and SA-14, also lost their HA activity, it was
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unclear whether or not such modification on the HeLa cell passaged Nakayama-O 
virus was linked to the attenuation. Examination of the pathogenicity of C6-36 and 
CEF cell grown HeLa cell passaged Nakayama-O virus, which has restored HA 
ability, showed that the attenuation characteristics appeared to be stable. Interestingly, 
after one passage in Vero or SW13 cells, the HeLa cell attenuated Nakayama-O virus 
showed various degrees of reversion to virulence, albeit the virus was HA negative. 
Therefore, based on the present study, it can be proposed that the HA activity of IE 
viruses examined does not associate with the attenuation and/or the virulence when 
assayed using gander RBCs (It has been reported that the HA and haemolytic activity 
of IE viruses were related to the neurovirulence when assayed using one-day-old 
chick RBC system (Huang, 1982, and references therein.)). Whether or not such loss 
and regain of HA activity and the reversion to virulence occurred at a genetic level 
is not known. In addition, it is also unclear whether or not this reversion to virulence 
is in correlation with the loss of the vaccine specific epitope recognized by MAb V23 
and regain of the wild-type specific epitope(s) recognized by MAbs K13 and K39. 
Further work is required to be done to elucidate the molecular basis for attenuation 
of IE virus in HeLa cells.
The temperature sensitivity (ts) is one of the important biological markers used for 
identification of attenuated virus strains (Kantoch, 1978). Dunster et al. (1990) 
reported that the HeLa cell attenuated WN-Sarawak virus acquired ts and this 
acquisition of ts was associated with the attenuation characteristics of the virus. The 
experiments performed in this study showed that the HeLa cell attenuated IE viruses 
(Nakayama-O and 826309) were not ts. Also, it has been shown previously (Chapter 
4) that the SA-14 series vaccine strains (SA-14-2-8, SA-14-5-3 and SA-14-14-2) were
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not ts. Therefore, these two different attenuation processes of JE viruses did not 
require/ / a ts mutation. In addition, the present study also suggests that the molecular 
basis for the HeLa cell attenuation of JE viruses can be very different to that of WN 
virus, if the ts mutation of the HeLa cell passaged WN-Sarawak virus is directly 
linked with the attenuation.
In comparison with the wild-type strain of JE virus, two interesting charateristics 
were observed following passage of the SA-14 series vaccine strains in HeLa cells. 
First, the vaccine viruses (SA-14-2-8 and SA-14-5-3) lost HA activity after two HeLa 
cell passages, whilst, the wild-type virus strains lost HA activity following only a 
single passage in HeLa cells. Second, the vaccine strain SA-14-14-2/PDK9 grew very 
poorly in HeLa cells in contrast to the other two vaccine strains and the wild-type 
isolates of JE virus. However, it is unclear what role, if any, the attenuation traits 
and/or the selection pressure exerted by HeLa cells play in such variation between the 
vaccine strains and the wild-type strains of JE virus.
The attenuation of JE viruses by passage in HeLa cells expands the current 
knowledge of HeLa cell attenuation of flaviviruses showing that not only the 
viscerotropic (e.g. YF) and pantropic (e.g. WN) but also a neurotropic flavivirus can 
be attenuated by very few passages in HeLa cells. However, since the neurotropic 
tick-borne flaviviruses, Langat and louping ill, were not attenuated following passage 
in HeLa cells (Dunster et oL, 1990), it would appear that only mosquito-bome 
flaviviruses could be attenuated by this process. A common biological marker 
acquired by the HeLa cell attenuated flaviviruses is the antigenic changes on the 
envelope (E) protein (Table 6.15 and references therein). Similar to the attenuated JE 
viruses described in this chapter, it was observed that wild-type strains of YF virus:
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Asibi (Barrett et a l,  1990), FVV (Dunster, personal communication) and B4.1 (Sil, 
personal communication) attenuated following passages in HeLa cells lost some of the 
wild-type specific epitopes and gained a vaccine specific epitope. Similarly, the 
significant attenuation of the WN-Sarawak virus following six passages in HeLa cells 
was accompanied by alteration of a neutralizing epitope on the E protein (Dunster, 
et ah, 1990). Therefore, it is likely that such antigenic changes on the virus surface 
proteins, mainly the E protein, play a significant role in determining the attenuation. 
This observation further suggests that the E protein gene is one of the major 
determinants of the attenuation of flaviviruses following passage in HeLa cells.
The following points are of particular interest in relation to HeLa cell attenuation 
of flaviviruses (see the summary in Table 6.15). Firstly, not all flavivirus species 
examined to date can be attenuated by as few as six passages in HeLa cells. For 
example, it was found that DEN-2 virus, the neurotropic tick-borne flaviviruses 
louping ill and Langat remained as virulent as the non-HeLa passaged parent viruses 
after six passages in HeLa cells (Dunster et ah, 1990). Secondly, not all strains of 
the same species can be attenuated following passage in HeLa cells. As mentioned 
above, unlike the Nakayama and 826309 strains of JE virus, the neurovirulence of 
HeLa cell passaged Beijing-1 and SA-14 JE virus strains was not reduced in 
comparison to the non-HeLa cell passaged parent virus. The similar observation has 
been made for the wild-type YF virus strain Dakar 1279 (Sil, personal communica­
tion). Thirdly, significant attenuation occurred after the different number of HeLa cell 
passages depending on the particular virus species and/or strains examined. For
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example, the JE virus strain Nakayama and YF virus strain FVV became significantly 
attenuated after a single passage in HeLa cells, whereas, the similar extent of 
attenuation was observed after three passages for YF virus strain Asibi, six passages 
for WN virus strain Sarawak. Fourthly, the resultant attenuation of the virus 
following passage in HeLa cells is challenge route dependent, in spite of the fact that 
all flaviviruses possess a neurotropic virulence for mice (Monath, 1990). HeLa cell 
passaged JE virus strain Nakayama and WN virus strains Smithbum and E-101 were 
shown to be attenuated by both peripheral (i.n. and/or i.p.) and intracerebral (i.c.) 
challenge routes. In contrast, HeLa cell passaged YF virus strain Asibi and FVV and 
WN virus strain Sarawak were shown to be avirulent following peripheral inoculation 
but not by the i.c. route. This challenge route dependent attenuation indicates that the 
HeLa cell attenuation of flaviviruses for mice is varied in that some flaviviruses such 
as JE virus strain Nakayama and WN-Smithburn were attenuated in neurotropic 
virulence (may be neuroinvasiveness as well), whilst, some viruses were only 
attenuated in the neuroinvasiveness, e.g. YF Asibi, WN-Sarawak.
Following a single immunization of mice with the live HeLa cell attenuated 
Nakayama-O virus (grown in chicken embryo fibroblast cells), it was found that the 
neutralizing (N) antibody could be detected on 14 days post immunization (d.p.i.). 
The serum sampled on 28 d.p.i. showed that the titre of N antibody increased. In 
contrast, the mice immunized with the inactivated Nakayama-O HeLa p6 and the non- 
HeLa passaged parent virus (HeLa pO) did not exhibit detectable N antibody response 
either 14 days or 28 days after the single immunization with the virus. It was 
interesting that the serum (14 d.p.i.) did contain HAI antibodies with a titre similar 
to that induced by the live HeLa p6 virus. Unlike the N antibody, the HAI antibody
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titre decreased in the serum collected 28 d.p.i., particularly the serum from the mice 
immunized with the inactivated HeLa pO virus (Table 6.13). Thus, this observation 
indicates that the immune response to the JE virus examined in this work occured in 
two phases: 1) primarily the HAI antibody response (observed approximately 14 
d.p.i.); 2) mainly the N antibody response (observed roughly 28 d.p.i.). Moreover, 
the live Nakayama-O HeLa p6 virus could induce a better N antibody response than 
the corresponding inactivated virus (N antibody response to the inactivated virus was 
not detectable.)
A pooled serum sample collected from the outbred TO mice 14 days after i.c. 
inoculation with the same live virus as above was found to contain a much higher titre 
of N and HAI antibodies than the corresponding single serum sample from the Balb/C 
mouse. The following reasons may be responsible for such results. First, the genetic 
differences, particularly the MHC variation, between the outbred TO strain mice and 
the inbred Balb/C mice could significantly determine the immune response to the JE 
virus examined. Alternatively, the individual difference among the outbred TO mice 
may affect the pooled results considerably, whilst, such individu#! variation is 
minimized by using the inbred mice, although the sample was singled. Thirdly, 
probably the most important reason appeared to be the different inoculation route. 
The i.c. inoculation of the TO mice directly introduced the virus into the circulation 
system, whereas, the i.p. immunization of the Balb/C mice could not. Apparently, 
this difference could affect immune efficacy significantly.
Further examination of the immune efficacy of the live Nakayama HeLa p6 virus 
showed that the virus could induce a good level of neutralizing antibodies against 
different geographical isolates of JE virus (Table 6.14). Moreover, it was found that
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the N antibody titres of the serum sampled after 14 days immunization varied from 
20-80 when tested against different JE virus strains, whilst the serum collected on the 
day 28 post immunization neutralized the different JE virus strains not only to a 
greater but also similar extent (80-160). This results further suggest that the 
attenuated virus has induced an early and a late immune responses in mice. Again, 
the pooled serum sample from the TO mice showed a much greater N activity against 
all the heterologous virus strains examined than the serum from the Balb/C mouse 
after the same period of time of immunization. Although the results presented here 
are limited, e.g. only the single inbred mouse sample was analyzed, it seems that this 
HeLa cell attenuated Nakayama-O strain would be a good candidate for a live JE 
vaccine. In particular, the stability of the attenuated phenotype following passage in 
CEF cells is encouraging for the potential use of this virus as a candidate vaccine as 
CEF cells are approved by the World Health Organization for the production of live 
attenuated virus vaccine. Further studies, especially the in vivo immuno-protection 
study, are required to characterize this attenuated Nakayama-O variant for a live 
vaccine production.
In conclusion, the studies described in this chapter provide a good model system 
with which to analyze the molecular basis for attenuation and virulence of JE viruses 
and to develop a live JE virus vaccine.
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Chapter 7
Comparison of receptor binding activity of wild-type JE virus strains to their 
attenuated variants using mouse brain cell membrane receptor preparations
178
7.1. Introduction
Japanese encephalitis (JE) is an infectious disease affecting the central nervous system 
(CNS). Immunocytochemical studies in fatal human cases showed that JE viruses 
only infected neurones, with no evidence for glial cell infection (Johnson et ah, 
1985). Therefore, it is thought that the focusing of infection and damage to neurones 
in the CNS system by the virus (in other words, the CNS tissue tropism of the virus) 
accounts for the pathology and the clinical manifestations of JE. The attachment 
domain of the viral attachment protein (VAP), e.g. the E protein for flaviviruses, and
the host cell receptors for the virus, which are ’   ^ believed to be on CNS
neurone cells, are two major determinants of the host range and the tissue tropism of 
the virus (Lentz, 1990). Consequently, it is of primary importance for understanding 
molecular aspects of virus virulence to investigate the first event in the virus infection 
of the cell, i.e. the attachment step of the virus replication cycle.
The process of viral entry involves specific viral-associated glycoproteins as well 
as target cell binding sites and receptors (Fuller and Spear, 1987). It has been 
demonstrated for dengue and West Nile viruses that the F^  portion of anti-virus 
antibodies coating the virus interacts with cell surface F^  receptors, cross-linking 
virions to the cell surface and facilitating the uptake of the virus-antibody complex 
into cells (Halstead, 1988; Cardosa, 1986; Peiris et a l ,  1981). However, no specific 
cellular receptors have been described for any of the flaviviruses. In contrast, several 
other viruses have been shown to use binding sites for known physiological ligands. 
For examples, rhinovirus, the aetiological agent responsible for common cold, enters 
cells by means of the cell adhesion molecule ICAM-1 (Greve et al., 1989); human 
immunodeficiency virus (HIV) responsible for acquired immune deficiency syndrome
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(AIDS), primarily uses the CD4 glycoprotein molecule (Dalgleish et ah, 1984); 
Epstein-Barr virus infects B lymphocytes by means of the C^ d complement receptor 
(Fingeroth et ah, 1984); rabies virus infects neurone cells through a neurotransmitter 
receptor, the acetyl choline receptor (Lentz et ah, 1982); reovirus enters through a 
neurotransmitter receptor, the B-adrenergic receptor (Co et ah, 1985) and vaccinia 
virus can enter the cell by first interacting with the epidermal growth factor (EGF) 
receptor (Eppstein et ah, 1985).
Using the crude adult mouse brain tissue homogenate. Fang and Cheng (1989b) 
performed an original study on JE virus binding activity showing that the attenuated 
vaccine strains, SA-14-2-8 and SA-14-5-3, had a lower binding ability than the 
virulent wild-type parent strain SA-14. It was, therefore, postulated that the 
attenuation of the JE virus was partly due to the lower binding ability of the 
attenuated strains so that they could not kill mice even following intracerebral (i.c) 
inoculation of a large dose of the virus.
In this chapter, in order to confirm and extend the above observation, and further 
to establish a system to investigate the receptor sites for JE viruses, the attachment 
activity of JE virus to neurone cells was assessed using the mouse brain cell 
membrane receptor preparations, which are currently being used to study 
neurotransmitter receptor systems (Middlemiss and Fo zard, 1983). The binding 
kinetics of wild-type strain SA-14 and attenuated strains of JE virus was investigated. 
Using a panel of selected neurotransmitter antagonists and monoclonal antibodies 
prepared against JE viruses, studies were performed to elucidate the cell receptor site 
for the virus binding and the virus binding domain (epitope) on the E protein of JE 
virus.*
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7.2. Experimental procedures
7.2.1. Viruses
The details of the viruses used in this study were described in Chapter 2. Prior to this 
study, each virus was amplified once in mosquito C6-36 cells except the reovirus 
type-3 and poliovirus type-1, which were cultivated in L-929 and Vero cells 
respectively,.
7.2.2. Virus receptor binding assay
I. Binding kinetics assay: the details of the procedure for virus-receptor 
binding assay were described in Chapter 2; the sample was collected at intervals of
1 . 2 . 3 .  4, 5, 10, 20, 30, 40, 50, and 60 mins of incubation time, in every binding 
kinetics assay; the tests were performed at 4°C, 26°C and 37°C respectively. The 
protein concentration in the membrane receptor preparation was 20 ■ ; . 7ml.
n. Constant virus and various receptor concentration binding assay: the 
concentration of virus preparation used was 10^   ^ pfu/ml; the membrane receptor 
preparation was used at 2-fold serial dilution and the resultant protein concentrations 
were:^ 40/ 7ml, 2 0 r  /ml, 10/^^ /ml, 5 / ^  7ml, 2 . 5 / ^  J/ml and 1.25
{, 7ml.
in. Constant receptor and various virus concentrations binding assay: in 
this experiment, the receptor concentration was used at the protein concentration of 
20 " "ml in the membrane receptor preparation; the virus preparation was used at 
10-fold serial dilution ranging from 10^  or 10^  pfu/ml to 10^  pfu/ml.
rV. Neurotransmitter antagonist blocking virus receptor binding assay: the 
detailed procedure was described in Chapter 2; the antagonists used were described
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Table 7.1
Neurotransmitter antagonist ligands used in this study
antagonist
ligand
selectivity of 
neurotransmitter system
atropine
spiperone
muscanmc
cholinergic
dopamine (D 2 ) 
serotonin (5HT2>5HTi)
(-)-propranolol
(±.)-SKF83566
serotonin (5HTi) 
B-adrenergic
dopamine (Dj)
5-aminovaleric
acid
(-)-bicuculine
GABA-B
GABA-A
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in Table 7.1.
V. MAb blocking viral attachment domain binding assay: a panel of MAbs 
possibly representing six different epitopes on the E protein of JE virus was used to 
identify the epitope which may be involved in the virus receptor binding, including: 
the wild-type specific MAbs K-10, K-13, K39 and J-44, vaccine-specific V-23, JE 
type-specific K-6, JE subgroup specific K-8, a flavivirus intermediate reactive K-41, 
and flavivirus-group specific K-9; the MAb N-3 prepared against Coxsackievirus type 
A9 was used as a negative control. Due to the limitation of the method, MAbs with 
neutralizing activity can not be used. Prior to incubation with the membrane receptor 
preparation, the virus was incubated with MAbs at room temperature for 45 mins as 
the N tests as described in Chapter 2.
7.3, Results
7.3.1. Binding activity of JE  viruses to crude mouse brain tissue homogenates
The wild-type JE virus strain SA-14 and its attenuated vaccine derivatives: SA-14-2-8, 
SA-14-5-3 and SA-14-14-2/PDK9, were examined for their binding activity to the 
crude mouse brain tissue homogenate (MBTH) at 4°C, 26°C and 37°C. Viruses were 
incubated with the MBTH for 1 hour. Following incubation, the MBTH was pelleted 
and the quantity of the virus binding to the MBTH was determined by comparison of 
the infectivity present in the supernatant to that in a control sample, which was 
incubated with cell growth medium only. The degree of binding was expressed as a 
binding index (BI) as described in Chapter 2. The results are shown in Table 7.2.
After incubation with the MBTH at 37°C and 26°C, most of the wild-type strain 
SA-14 virus bound to the mouse brain tissue as determined by 1.3 Logjo reduction in
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the virus infectivity titre (termed as binding index (BI) 1.3, equivalent to 95% of the 
virus bound to the MBTH) in comparison to the control test, in which the virus was 
preincubated with the cell growth medium. Following incubation at 4°C, the SA-14 
virus only bound to the MBTH by a BI of 0.3 (50% binding). In contrast to the wild- 
type parent virus strain SA-14, the vaccine derivatives (SA-14-2-8, SA-14-5-3 and 
SA-14-14-2/PDK9), which were highly attenuated in their neurotropic virulence for 
mice, exhibited much lower binding activity to the mouse brain tissue with the BI 
between -0.1 to 0.2 at all the temperatures (Table 7.2). The negative control virus, 
poliovirus type-1, which does not infect the brains of adult mice, did not bind to the 
MBTH preparation.
7.3.2. Binding ability of JE  virus as determined using 
continuous cell lines: Vero and C6-36
To compare with the binding ability of JE virus to the in vivo tissue-MBTH (see the
previous section), the binding ability of JE virus to the laboratory continuous cell
lines, Vero and C6-36, was examined at 26°C as described in Chapter 2. A single cell
suspension was used in this study. Mosquito cells C6-36, were triturated off from the
cell culture flasks, while, Vero cells were trypsinized or scraped from the flasks. The
ratio of the number of cells to virus (pfus) was approximately 10-100:1 depending on
the virus examined. The results are shown in Table 7.3.
In contrast to the MBTH, no significant difference in the virus binding ability to 
above continuous cell lines was observed between the wild-type parent SA-14 and its 
three attenuated vaccine derivative viruses. However, a remarkable difference was 
found between the degrees of JE virus binding to the trypsinized and the scraped Vero 
cells. The JE viruses bound to the trypsinized Vero cells very poorly with Bis
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bewteen 0.1 (20%) and 0.3 (50%), compared to virus binding to the scraped Vero 
cells of Bis between 0.7 (80%) and 1.0 (90%).
7.3.3. Receptor binding activity of JE viruses to mouse 
brain membrane receptor preparations
Wild-type and attenuated strains of JE virus were studied for their receptor binding
activity using the mouse brain cell membrane receptor preparation (MRP) as
described for neurotransmitter receptor binding studies by Middlemiss and Fo zard
JIU
(1983). The virus was incubated with the MRP at protein concentration 20f / /ml 
for 60 mins at 26°C. The results are shown in Table 7.4.
Unlike the crude MBTH (see Section 7.3.1), five wild-type and four attenuated 
strains of JE virus were found to bind to the MRP, although the vaccine strain, SA- 
14-5-3, bound to a less degree (with the BI of 0.8) than the other viruses. In contrast, 
no binding activity was observed for the poliovirus type-1, and very slight binding 
(with the BI of 0.2) for the reovirus type-3. Semliki Forest virus strain TS +  , a 
neurotropic alphavirus, also bound with a BI of 1.3 indicating that the binding to the 
MRP is not unique to JE viruses. It is interesting to note that JE viruses of different 
infectivity titre (concentration), e.g. Sarawak (10^  ^ pfu/ml) and Nakayama (10^ -^  
pfu/ml) strains, were bound to similar degrees with Bis of 1.3 and 1.2 respectively.
7.3.4. Receptor binding activities of JE viruses to various tissue MRPs
The receptor binding activities of the wild-type strain SA-14 and its attenuated 
vaccine strain SA-14-14-2/PDK9 were further examined using the MRPs made from 
various tissues: mouse brain, mouse liver, rat brain and monkey liver, and compared 
to that of the wild-type strain Asibi of YF virus. The detailed procedure of the
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Table 7.4
Receptor binding ability of viruses
to mouse brain cell membrane receptor preparations
virus virus +  Tris virus + R BI percentage of binding
wild-type 
JE virus:
SA-14 6.5* 5.0 15 97%
Nakayama 65 53 1.2 94%
Sarawak 75 6.2 13 95%
Beijing-1 6.2 4.8 1.4 96%
826309 7.0 5.4 1.6 97%
attenuated 
JE virus:
SA-14-2-8 6.5 4.7 1.8 98%
SA-14-5-3 7.0 6.2 0.8 84%
SA-14-14-2/PDK9 7.4 63 1.1 92%
Nakayama-O HeLa p6 6.8 5.6 1.2 94%
othervirus:
SFV-TS-h 6.8 55 1.3 95%
reovirus type-3 6.4 6.2 0.2 37%
poliovirus type-1 65 6.8 -0.3 -50%
* : infectivity titre expressed as Logjo pfu/ml.
R: mousebrain membrane receptor preparations. 
BI: binding index.
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binding assay was included in Chapter 2. The protein concentration of the above 
MRPs and the incubation time were same as the previous Section 7.3.3. The results 
are shown in Table 7.5.
Both the wild-type SA-14 and attenuated SA-14-14-2/PDK9 strains of JE virus 
bound to the MRPs made either from mouse or rat brains to similar degrees with Bis 
between 1.0 to 1.5 (90% to 97% binding). In contrast, these two JE virus strains 
bound to the mouse or monkey liver MRPs to a much less degree with Bis between 
0.1 to 0.4 (21% to 60% binding). The viscerotropic flavivirus, YF virus strain Asibi, 
showed much higher binding ability to the above liver MRPs than the JE virus with 
a BI of 1.1 (mouse liver) and 1.3 (monkey liver). The YF virus also bound to the 
mouse brain MRP, although to a less degree than the JE virus with a BI of 0.8 (84% 
binding).
7.3.5. Statistical analyses of the plaque and vims receptor binding assays 
In this study, plaque assays were used as the measurement to determine the degree 
of virus receptor binding activity. Thus, it was essential to investigate the 
reproducibility and reliability of this assay. The statistical analysis of the plaque assay 
data obtained from the control test in the virus receptor binding kinetics assay(at 
26°C, see Figures 7.1b, 7.2a, b and c, and 7.3a and b) is shown in Table 7.6. All the 
six sets of plaque assay data (with the sample size of 12) showed that the plaque assay 
performed in this study is reproducible with the standard error of mean (SEM) of 
0.01 (except Nakayama-HeLa p6 (Figure 7.3b), SEM of 0.02) and reliable with the 
P value less than 0.001. The statistical analysis process is detailed in the Appendix.
Similarly, the method of virus receptor binding assay employed in this study was
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Table 7.6
Reproducibility and reliabiltiy of plaque assays
virus
statistical^— 
parameter
SA-14 SA-14-2-8 SA-14-5-3 SA-14-14-2
Nakavama-O
HeLapO HeLap6
N 12 12 12 12 12 12
mean 6.45* 6.49 7.00 6.42 734 6.92
SEM 0.01 0.01 0.01 0.01 0.01 0.02
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
N.B. Data were taken from the control tests in the binding kinetics 
study at 26° C (in Figure 7.1b, 7.2a, b and c, and 7.3a and b.) 
Nisamplesize.
SEM: standard error of the mean.
*: infectivity titre expressed as Log 10 pfu/ml.
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Table 7.7
Reproducibility and reliability of virus receptor binding assays
virus
stalls ticai^^^ parameter
SA-14 SA-14-5-3
C R BI C R BI
range of 
samples 6.26* 5.00 1.26 7.12 6.27 0.85
6.42 4.95 1.47 6.85 6.13 0.72
635 5.10 1.25 6.95 6.26 0.69
6.41 4.90 151 7.20 630 0.90
6.23 4.90 133 6.90 6.30 0.60
6.43 5.25 1.18 7.05 5.93 1.12
6.10 5.00 1.10 7.10 6.35 0.75
6.27 4.95 132
N 8 8 8 7 7 7
mean 631 5.00 131 7.02 6.22 0.80
SEM 0.04 0.04 0.04 0.05 0.05 0.05
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
N.B. Results were obtained on separate occasions.
N: sample size.
SEM; standard error of the mean.
C: control, virus incubated with Tris.
R: virus incubated with the membrane receptor preparation.
BI: binding index as described previously.
*: infectivity titre expressed as Logiopfu/ml.
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statistically analyzed using JE SA-14 and SA-14-5-3 virus strains as examples (Table 
7.7). Sets of collected virus receptor binding data from separate occasions using same 
protocols (with sample size of 8 for SA-14 virus and 7 for SA-14-5-3 virus) showed 
that the SEM of the virus binding assay was 0.04 for the SA-14 virus and 0.05 for 
the SA-14-5-3 virus. The P value was less than 0.001. Therefore, this would indicate 
that the technique of the virus binding assay is reproducible and reliable. In addition, 
the difference in the degree of the receptor binding activity between the SA-14 virus 
(with the average BI of 1.30) and the SA-14-5-3 virus (with the average BI of 0.80) 
was statistically significant with the P value less than 0.001.
7.3.6. Receptor binding kinetics of the SA-14 strain at different temperatures.
The receptor binding kinetics of the SA-14 strain of JE virus to the mouse brain cell 
MRP was assessed at 4°C, 26°C, and 37°C. It can be seen from Figure 7.1 (a, b, c, 
and d) that the majority of the binding at all three temperatures occured very rapidly 
within the first minute of incubation. The virus bound to the MRP with the BI of 1.3 
at 37°C, 1.2 at 26°C and 1.0 at 4°C after 1 minute incubation. The binding was 
essentially completed after 30 mins incubation. By reaching the equilibrium binding, 
the BI increased to 2.0 at 37°C, 1.5 at both 26°C and 4°C. Therefore, the BI of the 
virus at 37°C is 0.5 I-ogio higher than that at 26°C and 4°C. A summary of the 
binding kinetics of SA-14 virus at the three temperatures is shown in Figure 7. Id.
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Figure 7.1a The receptor binding kinetics of the SA-14 strain at 37°C
I
I
10
10
Virus + MRP 
Virus + Tris
10
10
10 15 20 25 30 35 40 45 50 55 6050
Time (Minutes)
Virus+ MRP: The virus was incubated with the mouse brain membra nâ/ 
receptor preparation 
Virus+Tris: The virus was incubated with Tris buffer, pH 7.4.
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Figure 7.1b The receptor binding kinetics of the SA-14 strain at 26°C
-o
Vims + MRP 
Virus + Tris
13-
10 15 20  25 30 35 40 45 50  55 6050
Time (Minutes)
Virus+ MRP: The virus was incubated with the mouse brain membra: nC, 
receptor preparation 
Virus+Tris: The virus was incubated with Tris buffer, pH 7.4
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Figure 7.1c The receptor binding kinetics of the SA-14 strain at 4°C
i 
I
Virus + MRP 
Virus + Tris
10 15 20 25 30 35 40 45  50 55 6050
Time (Minutes)
Virus4-MRP: The virus was incubated with the mouse brain membrane 
receptor preparation 
Virus+Tris: The virus was incubated with Tris buffer, pH 7.4.
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Figure 7. Id The summary of the receptor binding kinetics of the SA-14
strain at three different temperatures: 37°C, 26°C and 4°C
2.4-
2.2
2.0
1.8
I
® 0.8
SA-14 (370  
SA-14 (26C) 
SA-14 (4C)0.4
0 .2 -
0.0 H F
20 25 30 35 40 45 50 55 60
Time (Minutes)
The results were summarized from Figure 7.1a, b and c.
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7.3.7. Receptor binding kinetics of vaccine strains:
SA-14-2-8, SA-14-5-3 and SA-14-14-2/PDK9
The receptor binding kinetics of the attenuated vaccine strains(SA-14-2-8, SA-14-5-3
and SA-14-14-2/PDK9) were examined at 26°C and compared to that of the wild-type
parent strain SA-14. The results are shown in Figure 7.2a, b, c and d.
After 1 min incubation, the SA-14- 14-2/PDK9 virus bound to the MRP only with 
a BI of 0.1. The degree of the binding then increased to a BI of 0.4 following 5 mins 
incubation and 1.0 by 10 mins (Figure 7.2c and d). The binding of the SA-14-2-8 
virus increased from a BI of 0.8 after one minute to 1.3 after 10 mins incubation 
(Figure 7.2a and d). In contrast, the wild-type parent strain SA-14 reached a similar 
degree of binding (a BI of 1.2) within the first minute of incubation. Therefore, the 
initial binding rate of the vaccine strains: SA-14-2-8 and SA-14-14-2/PDK9, is slower 
than that of the parent strain SA-14. Interestingly, when the binding was essentially 
completed (i.e. the maximum level of binding) by 30 mins of incubation, the wild- 
type parent virus SA-14 bound less than the vaccine strain SA-14-2-8 (Bis of 1.5 vs 
1.8 respectively), although the SA-14 virus bound to a greater extent than the vaccine 
strain SA-14-14-2/PDK9 (Bis of 1.5 vs 1.0 respectively). Following 10 mins 
incubation, the SA-14-5-3 virus reached the maximum binding with a BI of 0.8 
(Figure 7.2b and d). Thus, the SA-14-5-3 virus bound to the MRP to a lesser degree 
than either the parent SA-14 strain or the other two vaccine strains SA-14-2-8 and 
SA-14-14-2/PDK9.
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Figure 7.2a The receptor binding kinetics of the SA-14-2-8
strain at 26°C
I
1
■o-
10 ®
Virus + MRP 
Virus + Tris
10 15 20 25 30  35 40 45  50 55 6050
Time (Minutes)
Virus4-MRP: The virus was incubated with the mouse brain membrane 
receptor preparation.
Virus+Tris: The virus was incubated with Tris buffer, pH 7.4.
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Figure 7.2b The receptor binding kinetics of the SA-14-5-3
strziin at 26°C
3 ,
^  10
-o
Virus + MRP 
Virus + Tris
20 25 30  35 40 45  50 55 60
Time (Minutes)
Virus+ MRP: The virus was incubated with the mouse brain membrane 
receptor preparation.
Virus+Tris: The virus was incubated with Tris buffer, pH 7.4.
20 0
Figure 7.2c The receptor binding kinetics of the SA-14-14-2/PDK9
strain at 26°C
Î
f
Vims + MRP 
Vims + Tris
20 25 30 35 40 45  50 55
Time (Minutes)
Virus4-MRP: The virus was incubated with the mouse brain membrane 
receptor preparation.
Virus+Tris: The virus was incubated with Tris buffer, pH 7.4.
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Figure 7.2d Comparison of the receptor binding kinetics of the 
SA-14 and its attenuated vaccine derivative 
strains: SA-14-2-8, SA-14-5-3 and 
SA-14-14-2/PDK9 strains at 26°C
2.4-
2.2
2.0
1.8
I
-o
bû 1 -2  “
c 10"*#4 ■
®  0.8 -
-o-
0.6 -
0.4 SA-14
SA-14-2-8
SA-14-5-3
SA-14-14-20.2
0.0
1 0 15 20 25 30 35 40  45  50 55 6050
Time (Minutes)
The results were summarized fron Figures 7.1b, 7.2a, 7.2b and 7.2c.
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7.3.8. Receptor binding kinetics of the virulent Nakayama-O HeLa pO
and its attenuated HeLa p6 derivative virus
The receptor binding kinetics of the virulent Nakayama-O HeLa pO and its attenuated
derivative HeLa p6 viruses were examined and compared using the same method as
the comparison of the wild-type SA-14 virus and its attenuated vaccine derivative
viruses at 26°C. The results are shown in Figure 7.3a, b and c.
Generally, the attenuated Nakayama-O HeLa p6 virus (Figure 7.3b) demonstrated 
similar binding kinetics as the SA-14-14-2/PDK9 virus (Figure 7.2c). While the 
virulent Nakayama-O HeLa pO showed similar receptor binding rate as the wild-type 
SA-14 virus. The Nakayama-O HeLa p6 virus bound very poorly in the first 3 
minutes of incubation with Bis between 0.1 and 0.3, then the degree of binding 
gradually increased to the maximum by 30 minutes with a BI of 1.1. The Nakayama- 
O HeLa pO virus, however, bound to a BI of 0.8 after one minute of incubation. The 
maximum binding was obtained by 10 minutes with a BI of 1.2. Thus, the virulent 
Nakayama-O HeLa pO virus has a faster initial binding rate than its attenuated HeLa 
p6 derivative, whereas, the maximum degree of binding is generally the same (Bis 
of 1.1 vs 1.2).
7.3.9. Quantitative relationship between the protein concentration in the 
mouse brain MRP and the degree of the virus binding
The degree of IE virus (strain Sarawak) receptor binding was assessed with the
mouse brain MRP of protein concentration ranging from 1.25/ 7ml to 40^. /ml.
The results are shown in Table 7.8 and Figure 7.4.
It was found that the virus bound to the MRP to a similar degree with Bis between
1.1 to 1.2 at protein concentrations of 40 and 20p ./ml respectively (Table 7.8).
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Figure 7.3a The receptor binding kinetics of the Nakayama-O
strain at 26°C
10®
Virus + MRP 
Virus + Tris
10 ®
10 15 20 25 30 35 40 45 50 55 6050
Time (Minutes)
Virus+MRP: The virus was incubated with the mouse braine membrane 
receptor preparation.
Virus+Tris: The virus was incubated with Tris buffer, pH 7.4.
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Figure 7.3b The receptor binding kinetics of the Nakayama-0
HeLa p6 virus at 26°C
virus + MRP 
Virus + Tris
B
a -6D.
>
u
aa
10
10 15 20 25 30 35 40 45 50 55 6050
Time (Minutes)
Virus4-MRP: The virus was incubated with the mouse brain membrane 
receptor preparation.
Virus+Tiis: The virus was incubated with Tris buffer, pH 7.4.
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Figure 7.3c Comparison of the receptor binding kinetics of the
Nakayama-0 and its attenuated Nakayama-0
KeLa p6 viruses at 26°C
1.4
1.2 - -e-
1.0
0.8
"5 0.6 -
0.4- HeLapO
HeLap6
0.2 -
10 15 20 25 30 35 40 45 50 55 600 5
Time (Minutes)
The results were summarized from Figures 7.3a and b.
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Table7.8
Quantitative relationship between
the protein concentration and the degree of virus binding
proteinConcentration
Sarawak strain
C R BI percentage of binding
40 7.4* 6.2 12 94%
20 7.4 63 1.1 92%
10 7.4 6.6 0.8 84%
5 7.4 7.0 0.4 60%
25 7.4 7.1 0.3 50%
1.25 7.4 73 0.1 20%
0.00 7.4 7.4 0.0 0%
C: control, virus incubated with Tris only.
R: virus incubated with the membrane receptor preparation. 
BI: binding index.
*: infectivity titre expressed as Logiopfu/ml.
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Figure 7.4 Quantitative r -  _ i : ; between the
protein concentration and the
degree of virus binding
£•o 0.8 -
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0.6 -"O
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0.4 -
0.2
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25
The protein concentrations in the MRP were used as 1.25, 2.5, 5, 10, 20 and 
4 0 ^  . . / m l  
W  brUv,
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While the extent of the virus binding decreased proportionally from a BI of 1.1 to 0.1 
following 2-fold dilution steps of the protein concentration from 20 fmol/ml to 1.25 
fmol/ml (Table 7.8 and Figure 7.4). Thus, the saturating protein concentration in the 
MRP for JE virus binding is between approximately 10 fmol/ml and 20 fmol/ml.
7.3.lO.Quantitative relationship between the virus concentration 
and the degree of the virus receptor binding
As described in Section 7.3.3, JE viruses of 10-fold different infectivity titre bound
to the mouse brain MRP to a similar extent. Therefore, it was interesting to
investigate the quantitative relationship between the virus concentration and the degree
of the virus receptor binding. The SA-14 and Nakayama-0 viruses, with infectivity
titres of 10^  ° pfu/ml and 10^  ^pfu/ml respectively, were diluted in 10-fold steps. The
degree of receptor binding of each virus dilution was examined using a MRP of
protein concentration, 20^ 7ml. The results are shown in Table 7.9.
All the five SA-14 virus dilutions (from 10® to 10"^ ), with the corresponding virus 
concentration ranging from 10^  ® to 10^  ^pfu/ml, bound to the MRP with a similar BI 
between 1.0 to 1.3. The similar pattern of results was also observed by assessing the 
receptor binding of different dilutions of Nakayama-0 virus (Table 7.9). Therefore, 
when 20 /ml protein concentration is used, the degree of JE virus receptor 
binding remains constant regardless of the virus concentration.
The receptor binding activity of the residual virus, which escaped from the virus- 
receptor binding reaction (obtained from the 10® dilution), was examined by re­
incubation with a fresh MRP. It was found that this residual virus essentially did not 
bind to the fresh MRP with BI of 0.1 for the SA-14 virus and 0.0 for the Nakayama- 
O virus.
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Table 7.9
Quantitative relationship between
the virus concentration and the degree of virus binding
virus SA-14 Nakayama-O
dilution^X
C R BI percentage of binding C R BI
percentage 
of binding
lOP 6.0" 4.7 13 95% 7.7 63 1.2 94%
10*^ 5.0 4.0 1.0 90% 6.8 5.8 1.0 90%
10*^ 4.0 29 1.1 92% 5.8 4.6 1.2 94%
10'^ 3.0 20 1.0 90% 4.7 3.6 1.1 92%
10'^ 21 1.0 1.1 92% 3.6 28 0.8 84%
10'^ ND ND NA NA 28 1.7 1.1 92%
residual*
virus 4.8 4.7 0.1 20% 53 5.5 0.0 0%
C: virus incubated with Tris.
R: virus incubated with the membrane receptor preparation. 
BI: binding index.
*: residual virus was harvested from virus (lOP) 
plus receptor preparation supernatant.
a: infectivity titre expressed as Lx)^opfu/ml.
ND: not done; NA: not applicable.
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7.3.11.BiochemicaI identification of the receptor site 
for JE viruses on mouse brain cells
The receptor site for JE viruses on the mouse brain cells was investigated using virus
receptor binding inhibition assays with neurotransmitter receptor selective antagonist
ligands.
Prior incubation of the mouse brain MRP with the dopamine D2 and 5-hydroxy- 
tryptamine (5-HT) 5HT2 antagonist spiperone (10 um) was found to prevent the 
binding of the wild-type SA-14, but not the vaccine SA-14-14-2/PDK9 strain of JE 
virus to the MRP (Table 7.10). This inhibition was found to be specific for the D2 
and 5-HT2 receptors, since ligands for other receptors did not block the binding. 
None of the ligands examined prevented the binding of the vaccine strain SA-14-14- 
2/PDK9 virus (Table 7.10). Further examination with other strains of JE virus 
showed that the receptor binding of the wild-type Nakayama-0 strain was blocked 
after pre-incubation of the MRP with spiperone, while the other two vaccine strains 
(SA-14-2-8 and SA-14-5-3) and the attenuated Nakayama-0 HeLa p6 viruses were not 
prevented from binding to the spiperone bound MRP (Table 7.11).
7.3.12.Quantitative relationship between spiperone concentration 
and the degree of blockade of JE virus receptor binding
The degree of blockade of JE virus (Nakayama-0 strain) receptor binding by
spiperone was assessed using the mouse brain MRP pre-incubated with serial 10-fold
dilutions of spiperone ranging from lOum to 1pm. The protein concentration in the
MRP used was 2(X' /ml. The results are shown in Table 7.12 and Figure 7.5.
The control, in which the virus was incubated with the MRP only, showed that the
virus bound with a BI of 1.4, i.e. approximately 96% of the virus bound to the
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Table 7.10
JE virus binding to the membrane receptor preparation 
pre-treated with various neurotransmitter ligands
^ ^ \v ir u s SA-14 SA-14-14-2/PDK9
l i g a n d ^ - s ^ V+(Tris+L) V +(R +L ) BI percentage of binding V+(Tris+L) V +(R +L )
control* 63" 53 1.0 90% 7.1 6.4 0.7 80%
atropine 6.4 53 1.1 92% 7.2 6.2 1.0 90%
spiperone 63 63 0.0 0 % 7.2 6.5 0.7 80%
(-)-propranolol 6.3 5.4 0.9 87% 7.1 6.1 1.0 90%
5-aminovaleric
acid 6.4 5.6 0.8 84% 7.1 63 0.8 84%
(+)-SKF83566 6.2 5.4 0.8 84% 6.9 5.9 1.0 90%
(-)-bicuculine 63 5.2 1.1 92% 7.0 6.0 1.0 90%
*: Control test, virus incubated with Tris buffer or the receptor preparation only.
V+ (Tris4-L): virus incubated with Tris buffer, which was pre-incubated with the 
appropriate ligand solution for 15 mins at 3T C 
V+ (R+L): virus incubated with the membrane receptor preparation, which was 
pre-incubated with appropriate ligand solution for 15 mins at 37° C.
BI: binding index.
a: infectivity titre expressed as Logjo pfu/ml.
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Table 7.11
Inhibition effects of spiperone on both wild-type 
and attenuated strains of JE virus binding to 
the membranereceptor preparation
virus control* test®
V+Tris V +R BI percentageofbinding V+(Tris+L) V +(R +L ) B I;
percentage
ofbinding
SA-14 63^ 53 1.0 90% 63 53 0.0 0%
Nakayama-O 63 53 1.2 94% 63 6.4 0.1 20%
SA-14-2-8 6.5 5.2 13 95% 6.6 53 13 95%
SA-14-5-3 6.1 53 0.6 75% 6.0 53 0.7 80%
SA-14-14-2/PDK9 7.1 6.4 0.7 80% 7.1 6.5 0.6 75%
Nakayama-O
HeLap6 63 5.4 0.9 87% 6.2 5.4 0.8 84%
poliovirus
type-1 6.5 6.8 -0.3 -50% 63 6.5 0.0 0%
*: control test, virus incubated with Tris buffer (Tris) or receptor 
preparation (R) only.
a: test group, virus incubated with Tris buffer or the membrane receptor preparation, 
which were pre-incubated with ligand (L) spiperone solution, (V+ (Tris 4-L)) 
and (V4-(R4-L)).
b: infectivity titre expressed as Lo^q pfu/ml. 
BI: binding index.
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Table 7.12
Quantitative relationship between the concentration of spiperone and the degree 
of JE virus strain Nakayama-O binding to the membrane receptor preparation
spiperone
concentration V-H(Tris4-L) V-f(R+L) BI
percentage 
of binding
control* 63" 4.9 1.4 96%
lOuM 6.0 5.9 0.1 20%
luM 6.1 5.9 0.2 37%
lOOnM 6.1 6.0 0.1 20%
lOnhl 6.2 5.2 1.0 90%
Inflfl 6.2 5.2 1.0 90%
100pm 6.2 4.7 13 97%
10pm 6.2 4.8 1.4 96%
ip ë 6.2 4.7 13 97%
*: control tests: virus incubated with Tris or the membrane receptor 
preparation plus the ligand dissolvant i.e. 0.2% citric acid.
L: ligand spiperone.
R: themouse membrane receptor preparation.
BI: binding index.
a: infectivity titre expressed as logjopfu/ml.
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Figure 7.5 Quantitative relationship between spiperone concentration and 
the degree of JE virus strain Nakayama-0 binding to 
the membrane receptor preparation
2.0
1.6
1.4
1.2
0.8
0 .6 -
0.4-
0.2
0.0
Spiperone Concentration
The spiperone concentrations were used as 10-fold dilutions: IpM, lOpM, 
lOOpM, InM, lOnM, lOOnM, luM and lOuM, corresponding to the values on 
the X axis: 1, 2, 3, 4, 5, 6, 7, and 8 respectively.
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MRP,. In contrast, the Bis were between between 0.1 and 0.2 when the MRP was 
pre-incubated with spiperone at concentrations ranging from lOum to lOOnm. In other 
words, approximately, between 60% and 70% of the virus was prevented from 
binding to the spiperone bound MRP at these ligand concentrations (lOum to lOOnm). 
However, as the ligand was further diluted' from lOOnm to 1pm, the degree of the 
virus binding increased from the BI of 0.1 (20%) to 1.5 (97%), which was virtually 
the same degree of the binding as the control test (96%). Therefore, the spiperone 
concentration required to saturate the JE virus receptor binding site was 
approximately between lOOnhl and lOnM using a MRP containing a protein 
concentration of 20^ , /ml.
7.3.13.Identification of the viral attachment epitope with MAbs
The viral attachment domain was investigated using a panel of MAbs representing at 
least six different epitopes on the E protein: wild-type specific epitope (K-10, K-13, 
K39 and J-44); vaccine specific epitope (V-23); JE-type specific epitope (K-6); JE 
subgroup specific epitope (K-8); flavivirus intermediate epitope (K-41) and flavivirus- 
group specific epitope (K-9). After incubation with the wild-type SA-14 and vaccine 
SA-14-2-8 and SA-14-14-2/PDK9 strains of JE virus, none of the MAbs examined 
was found to prevent the virus from binding to the mouse brain MRP (Table 7.13).
7.4. Discussion
The neurotropism of JE virus plays a major role in causing the clinical manifestations 
and histopathological changes associated with JE. Therefore, analysis of the CNS 
tissue tropism of this virus is a key part to the understanding of the molecular basis
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of the virus virulence and/or attenuation. It is believed that the infection of CNS 
neurones by JE viruses is initiated by the attachment (via the E protein, which acts 
as the viral attachment protein for flaviviruses (Brinton, 1986) ) of the virus to a 
receptor site on the surface of the neurone cells. In this study, the receptor binding 
activity of both wild-type and attenuated strains of JE virus was investigated using a 
membrane receptor preparation (MRP) made from adult mouse brain cells. Initial 
experiments confirmed Fang and Cheng’s observation (1989b) showing that the wild- 
type, but not the vaccine, strains of JE virus bound to the crude mouse brain tissue 
homogenate (MBTH) (Table 7.2). However, both wild-type and attenuated vaccine 
strains of JE virus bound to the mouse brain MRP (Table 7.4).
The binding of JE virus to the mouse brain MRP was shown to be specific. 
Firstly, the negative control virus, poliovirus type-1, whose receptor sites is only 
found on primate animal cells, did not bind to the MRP made from mouse brains. 
Also, reovirus type-3 (Bearing strain), which is avirulent for adult mice, bound to the 
MRP poorly compared with JE viruses. Secondly, JE viruses showed preferential 
binding activity to the mouse brain MRP preparation compared to the equivalent liver 
(mouse and monkey) preparation. In contrast, the viscerotropic flavivirus, YF virus 
(strain Asibi) demonstrated binding ability to the liver (mouse and monkey) and the 
mouse brain MRPs (Table 7.5). Thirdly, the degree of JE virus binding was constant 
regardless of the virus concentration when a high protein concentration of the MRP 
was used. Fourthly, the residual virus which escaped from the virus-receptor binding 
reaction was shown to be defective to bind to the fresh MRP (Table 7.9). Therefore, 
these results suggest that the JE virus binding is mediated by the specific interaction 
between the E protein and the specific receptor molecules.
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The above observations also indicate that a small fraction (approximately 5-10%) 
of JE virus, which is defective or less effective in receptor binding, exists in the JE 
virus population, as this virus did not bind even after 60 mins incubation with the 
fresh MRP. It is not clear whether this small fraction of the virus originally exists in 
the virus population or resulted from the effects caused by the MRP. It has been 
reported that a highly attenuated mutant could be isolated from the residual virus that 
escaped from the binding to the crude MBTH (Fang and Chen, 1989c). Clearly, more 
studies, especially pathogenic studies on this small fraction of JE virus that escaped 
binding to the mouse brain MRP, are required. If this small fraction of the JE virus, 
which is defective or less effective in binding to neurone cells, naturally occurs in the 
wild-type JE virus population, it will be very important to study it both from point 
of views of understanding the virus virulence and the virus evolutionary history. It 
is conceivable that the proportion of this fraction of virus in the virus population of 
different JE virus strains may contribute to the ratio of apparent to inapparent 
infections in humans.
The degree of the virus receptor binding was found to be in linear proportion to 
the protein concentration in the MRP below a protein concentration of 20f  Jml. 
It has been reported that only one collision in 10^  between viruses and their target 
cells lead to permanent attachment (Longberg-Holm and Philipson, 1981). Therefore, 
it can be assumed that a large concentration of receptor sites is necessary to maintain 
a high frequency for the virus to find their binding sites. At this concentration, the 
absolute number of the receptor sites may be much higher than the the number of the 
virus particles in order to reach the maximum degree of binding and binding rate. 
Further studies are required to characterize such a quantitative relationship between
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the virus and receptor site in the binding process.
Both wild-type and attenuated strains of JE virus were found to bind to the mouse 
brain MRP (Section 7.3.3). This result does not agree with the initial studies with the 
MBTH preparation, which showed that the binding ability of the vaccine strains of 
JE virus, SA-15-2-8, SA-14-5-3 and SA-14-14-2/PDK9, was much lower than that 
of the wild-type parent strain, SA-14, (Fang and Cheng, 1989b; Section 7.3.1). The 
following hypotheses can be proposed to explain the inconsistency between these 
results. Firstly, the wild-type and attenuated strains may have different receptor sites 
on the brain neurone cells. Secondly, the difference in the mouse brain preparation 
used to assess the JE virus binding activity affects the degree of the presentation and 
spatial orientation of the cell receptor sites to the virus. Thirdly, the kinetics of the 
binding of wild-type and vaccine strains was different indicating different affinity for 
the receptors. Finally, the density of the receptor for the wild-type and vaccine strains 
of JE virus may be different and that the receptor for the vaccine virus in the crude 
MBTH may be masked.
The attachment of JE virus to continuous cell lines was investigated. No significant 
difference in the virus binding ability to Vero and C6-36 cells was found between the 
wild-type parent SA-14 and its three attenuated vaccine derivative viruses (SA-14-2-8, 
SA-14-5-3 and SA-14-14-2/PDK9). This result supports the observation in Chapter 
4, which had shown that the in vitro replication characteristics examined did not 
correlate with the attenuated markers of these viruses. However, it was found that the 
JE virus did not bind to the trypsinized Vero cells as efficiently as to the scraped 
Vero cells. Thus, it suggests that the JE virus binding sites on Vero cells may be 
trypsin labile or are altered in conformational structure following treatment of the cell
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surface with trypsin.
The receptor binding kinetics of the SA-14 strain was studied at 4°C, 26°C and 
37°C respectively. It was found that the virus binding to the mouse brain MRP had 
little temperature dependence. However, as reported by Fang and Chen (1989b) and 
the observation in Section 7.3.1 (Table 7.2), the JE virus binding to the crude MBTH 
was temperature dependent in that the virus only showed binding activity at 37°C and 
26°C but not at 4°C. Dimmock (1982) pointed out that there was a reduction in the 
rate of attachment of some viruses, e.g. rhinoviruses, to cell cultures at a 
subphysiological temperature. This was attributed to the need for receptors to diffuse 
laterally through cell membranes. Thus, the functional activity of the receptor site on 
the intact live cells (in the crude MBTH), which can be influenced by the 
physiological state of the cell, may be temperature dependent. In contrast, such 
temperature effects on the MRP (subcellular) are much less. Therefore, it seems that 
the specific binding interaction between the VAP and the receptor site may be 
temperature independent, whereas, the natural attachment of the virus to the cells can 
be markedly affected by the temperature due to temperature dependent factors 
involved in the binding process in vivo.
The binding kinetics of the three attenuated vaccine strains: SA-14-2-8, SA-14-5-3 
and SA-14-14-2/PDK9, and attenuated Nakayama-0 HeLa p6 variant were shown to 
be different to that of their wild-type parent strains SA-14 and Nakayama HeLa pO. 
SA-14-5-3 virus bound to a less extent, while the SA-14-2-8, SA-14-14-2/PDK9 
and Nakayama-0 HeLa p6 viruses bound to a similar degree as their appropriate 
parent strains, but at a lower initial binding rate, particularly, SA-14-14-2/PDK9 and 
Nakayama-0 HeLa p6. Therefore, the result suggests that the vaccine strains may
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have shifted to different receptor sites due to the amino acid changes (see Chapter 1, 
Section 1.9.2) in their VAP, i.e. the E protein (Nitayaphan et oL, 1990).
It has been shown that vaccine strains did not kill immune mature adult mice 
following intracerebral (i.c) inoculation and the virus was eliminated from the brain 
rapidly (Chen et al., 1983). However, these vaccine derivatives cause fatal 
encephalitis in immune immature and/or immune compromised mice following i.c. 
inoculation (Chen et a l ,  1989; Yu et al., 1988 and Chapter 4). The mortality of the 
encephalitis caused by the SA-14-2-8 and SA-14-14-2/PDK9 virus in the immune 
compromised mice could reach nearly 100%, while the SA-14-5-3, which had reduced 
binding than the other two vaccines and the parent virus, only killed mice sporadically 
(see Chapter 4). These results suggest that the attenuated vaccine strains of JE virus 
do have binding sites on the neurone cells and potentially can replicate in them. 
However, the attachment and/or further replication may be sensitive to the normal 
host immune surveillance.
In this study, it was found that the antagonist spiperone for the neurotransmitter 
dopamine D2 and 5-hydroxytryptamine 5-HT2 subtype receptors specifically blocks 
the binding of the wild-type, but not the attenuated variants (SA-14 series vaccines 
and Nakayama-0 HeLa p6) of JE virus to the mouse brain MRP. This inhibitory 
effect on wild-type JE virus binding was found to be specific for the dopamine D2 
and/or 5-HT2 receptor subtype since ligands for other receptors (muscarinic, G ABA, 
5-HTj and dopamine D J were without such effect. None of the ligands examined 
prevented binding of the SA-14 series vaccine strains and Nakayama-O HeLa p6 
derivative of JE virus to the MRP. This observation implicates that a dopamine 
and/or 5-HT neurotransmitter subtype receptor may act as a binding site on neurone
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cells for wild-type JE viruses but not for the attenuated strains. This is further 
supported by the observation showing that the degree of blockade of wild-type JE 
virus (Nakayama-O) binding to the mouse brain MRP decreased as the ligand 
spiperone was diluted from lOOnlti to IpM. It will be very useful to do more studies 
to determine the of spiperone with respect to this protein concentration of the 
MRP, which will aid in understanding the detailed kinetics of wild-type JE virus 
binding to the mouse brain receptor.
The genomes of the wild-type SA-14 and the attenuated vaccine strains SA-14-5-3 
and SA-14-14-2/PDK9 have been sequenced and compared (see Chapter 1, Section 
1.9.2). Five amino acid substitutions on the E protein were indentified between each 
vaccine strain and their wild-type parent virus. Based on the results achieved in this 
chapter, it appears that the molecular basis for the attenuation of the wild-type strains 
of JE virus may be partly due to one or more of these the mutations in the E gene 
(i.e. the flavivirus attachment protein) so that the attenuated virus strains are unable 
to bind such functionally important receptors. A similar observation has been reported 
for Sindbis virus, an alphavirus, in that the a-adrenergic antagonist 
phenoxybenzamine specifically inhibited the attachment of a neurovirulent but not of 
an avirulent strain of Sindbis virus to a rat neural cell line (Longberg-Holm and 
Philipson, 1981). Moreover, this result may also explain the different binding activity 
between the wild-type and the attenuated vaccine strains of JE virus discussed above.
The binding of the virus to such functionally important neurotransmitter receptors 
can initiate two-fold pathological consequences. Firstly, the binding of the VAP to 
its receptor site may lead to infection, which will cause physical damages to the brain 
tissue (Johnson et al., 1985). Secondly, the virus particles could act as a ligand to
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initiate the transfer of a signal to the interior of the neurone cells by the attachment 
to the physiological receptors and result in disorder of the regulatory system. For 
example, wild-type JE virus particles may act as an agonist or antagonist to compete 
with dopamine for the dopamine D2 receptor. Neuropsychiatrie sequelae of JE include 
Parkinsonism, which is caused by the deficiency in the dopamine biosynthesis 
pathway. Clinical treatment of Parkinson’s disease patients with L-dopamine lead to 
an increase in the density of dopamine D2 receptor (Seeman, 1981). Therefore, it is 
possible that the JE virus infection of neurones via dopamine D2 receptor may 
contribute to the neuropsychiatrie sequelae seen in patients who survived JE. In fact, 
several previous studies have already shown that viral encephalitis could affect some 
important neurotransmitter metabolism. For example, mice infected with the 
Venezuelan equine encephalomyelitis virus (an alphavirus) showed a significant 
decrease in the G ABA content but an increase in dopamine concentration in the brain 
tissue, meanwhile, the activity of related enzymes were affected (Levine gr ah, 1981; 
Bonilia et ah, 1980 Bonilia et ah, 1975). Therefore, it is reasonable to presume that 
the clinical manifestations of JE may be partly due to the similar disorder of 
neurotransmitter metabolism. Clearly, the in vivo study of the relationship between 
the JE virus infection and the neurotransmitter disorder will be very informative for 
understanding the details of JE pathology, and provide further evidences of the 
interaction between the virus and the receptor for it.
Antibodies against the region of the viral coat protein thought to be involved in 
the binding to the receptor have been shown to block the attachment of the virus 
(Lentz, 1990.). The relationship between the antigenic epitope and the virus receptor 
binding domain on the E protein was analyzed using a panel of MAbs, which
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represent at least six different epitopes, i.e. the wild-type specific, vaccine specific, 
type specific, subgroup specific, flavivirus intermediate specific and flavivirus group 
specific epitopes. Unfortunately, due to the limitation of the method used in the 
present study, neutralizing MAbs cannot be used. The result obtained using above 
non-neutralizing MAbs indicated that none of these epitopes examined is related to 
the viral binding domain. Dimmock (1984) stated that in most cases the antibody 
which can block the viral binding domain can also be neutralizing in the in vitro 
neutralization assay system (but not vice versa). For example, immunization of 
animals with synthetic peptides corresponding to the binding domain of the VPl 
polypeptide of foot-and-mouth disease virus resulted in production of neutralizing 
antibody (Fox et al., 1989.). Therefore, it is necessary for identification of the viral 
binding domain to include neutralizing MAbs in such a study. However, it is 
noteworthy that the wild-type and vaccine specific MAbs examined did not block 
either wild-type or vaccine virus strains binding to the mouse brain receptor 
preparation. These results indicate that . the emergence of the vaccine specific 
epitope(s) and loss of wild-type epitope(s) may be not linked with the shift of the 
virus receptor, although both are caused by the same mutation in the gene, i.e. the 
amino acid substitutions in the E protein.
Overall, the present study described a novel approach to study the interaction of 
the viral attachment protein with the cell receptor. The results obtained using this 
method indicate that the mutation in the JE virus attachment protein, i.e. the E 
protein, resulted in the shift of the virus receptor and this may be part of the 
molecular determinants of virulence and/or attenuation of JE virus. However, further 
modifications are required to improve the system, e.g. introducing radiolabelling
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techniques into the present method will greatly facilitate further and precise 
identification of the virus receptor site and the viral binding domain on the JE virus 
E protein.
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Chapter 8 
General Discussion
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In this thesis, studies on the comparative virology of wild-type and attenuated strains 
of JE virus have been described, with the aim of finding correlations between 
biological characteristics, nucleotide and deduced amino acid sequences, and virulent 
and/or attenuated phenotypes of the virus.
In antigenic studies, both PHK cell culture attenuated SA-14 series vaccine viruses 
(SA-14-2-8, SA-14-5-3, and SA-14-14-2/PHK and PDK9 derivatives) and HeLa cell 
attenuated Nakayama-0 and 826309 variants were distinguished from their 
appropriate virulent wild-type parent virus strains by E protein reactive MAbs.
Five MAbs (KIO, K13, K39, K43 and J44) were found to be specific for wild-type 
strains of JE virus and two MAbs (V23 and T60) specific for the attenuated vaccine 
strains (SA-14-2-8, SA-14-5-3, and SA-14-14-2/PHK and PDK9). Nucleotide and the 
deduced amino acid sequence data have shown that four amino acid substitutions in 
the E protein (numbers, 107, 138, 176 and 279, see Chapter 1, Section 1.9.2) are 
unique and identical to the vaccine strains (SA-14-5-3 and SA-14-14-2/PHK and 
PDK9 derivatives). These four respective amino acids in the E protein of the wild- 
type parent strain SA-14 are conserved in all wild-type strains of JE virus so far 
sequenced (Nitayaphan et a l ,  1990; Aihara et a l ,  1991). Thus, this strongly 
indicates that one or more of these four amino acid substitutions (positions: 107, 138, 
176 and 279) are involved with the acquisition of the antigenic marker of attenuation 
(i.e. the epitopes recognized by the vaccine specific MAbs V23 and T60) and the 
conservation of the antigenic marker of virulence (i.e. the epitopes recognized by the 
wild-type specific MAbs, KIO, K13, K39 and K43). Similarly, the simultaneous 
acquisition of the vaccine specific epitope recognized by MAb V23 and loss of the 
wild-type specific epitope(s) recognized by MAbs K13 and K39 by the attenuated
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HeLa p6 viruses (Nakayama-0 and 826309 HeLa p6 viruses) further suggest that 
these amino acid substitutions are the determinants of the antigenic markers of 
attenuation and virulence of JE virus. Further analysis of the hydrophilicity predicts 
that amino acids at positions 138 (Glu->Lys) and 279 (Lys-^Met) are located on the 
external, hydrophilic surface of the E protein and may constitute the wild-type and/or 
vaccine specific epitopes.
Consequently, further studies to compare the nucleotide sequences of the HeLa and 
non-HeLa cell passaged JE Nakayama-0 and 826309 viruses, particularly the E gene, 
to that of the SA-14 and its attenuated vaccine derivatives including the SA-14-2-8 
virus (see Chapter 1, Section 1.9.2) will greatly aid in mapping the genetic basis 
associated with such antigenic markers. It has been reported that the HeLa cell 
attenuated YF virus strain Asibi also gained the equivalent antigenic marker of 
attenuation and virulence identified for YF virus. The gain of a vaccine specific 
epitope and loss of the wild-type specific epitope were identified on the E protein of 
17D vaccines and the HeLa cell attenuated viruses (Barrett et al., 1990b and 1990c). 
Taken together, it appears likely that the amino acid substitutions in the E protein 
which lead to emergence of the antigenic markers correlating with virulent and/or 
attenuated phenotypes play an important role in the molecular basis of the attenuation 
and/or virulence. However, further studies are required to clarify the significance of 
such amino acid substitutions in the E protein in relation to virulence and/or 
attenuation of JE virus. The recent contribution of flavivirus infectious clones (YF, 
Rice et al., 1989; DEN, Lai et al., 1991; JE, Sumiyoshi, personal communication) 
will enable site-directed mutagenesis of E protein amino acids to be undertaken and 
the effects of such alterations studied in vivo.
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The amino acid substitutions in the E protein not only can cause the physical 
changes (i.e. the emergence of the vaccine specific epitope and loss of the wild-type 
specific epitope as discussed above), but may also result in conformational and 
functional alterations of epitopes on the E protein. This was supported by the 
observation that some MAbs showed preferential N activity against the wild-type 
parent SA-14 or its attenuated vaccine derivatives (Table 4.7). It is unclear whether 
or not such conformational and/or functional changes are related to the attenuation or 
virulence of the JE virus (SA-14). Further investigations, such as including the HeLa 
cell attenuated Nakayama-0 and 826309 viruses, are necessary to elucidate the 
correlations, if any, between these antigenic characteristics and attenuation and/or 
virulence of JE virus.
Patterns of reactivity of MAbs, which distinguish the wild-type parent virus strains 
from their attenuated derivative viruses or distinguish individual virus strains as 
described in Chapter 4 (HeLa cell attenuated JE viruses were included in Chapter 6), 
suggest that they are useful for analyzing the structure of the E protein and the 
relation of its epitopes to biological activities, e.g. neutralization, HAI etc.. They may 
be also useful for identification of virulence markers as well as variants that are 
present in heterogeneous populations of wild-type or laboratory-passaged viruses and 
might be of value in vaccine screening (particular the wild-type specific MAbs) or 
vaccine production if the virulence markers can be consistently identified serologically 
They may be also useful in further defining the serological and antigenic relationships 
of JE virus to other fiaviviruses. Epidemiological studies suggest that different strains 
of JE virus vary in their virulence (Huang, 1982), but, to date, there have been no 
antigenic means to distinguish them. The results reported in this project suggest a
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potential tool for such an identification. Initially, comparative epitope mapping of the 
E protein of the wild-type and attenuated strains of JE virus physically (by 
competitive binding assay) and biologically (functions and activities of epitopes in N 
and HAI assays, etc.) may reveal important information about antigenicity, virulence 
and attenuation.
Both attenuated SA-14 series vaccines and Nakayama-0 HeLa p6 variants were 
found to have different binding activity to the MBTH (mouse brain tissue 
homogenate) and/or the membrane receptor preparation (MRP) made from it. 
Compared with the virulent wild-type parent strain SA-14 virus, the attenuated 
vaccine derivatives (SA-14-2-8, SA-14-5-3 and SA-14-14-2/PDK9) bound to the 
MBTH poorly. This correlates with the virulence characteristics of the viruses in that 
the vaccine viruses are avirulent, even following i.e. inoculation of 10^  pfu of the 
virus, while less than 100 pfu of the virulent parent virus are required to kill mice 
with 100% mortality. Although virulence is multifactorial, it seems likely that the 
attenuation of the strain SA-14 virus resulted in alteration of the interaction between 
the virus and its target host tissue at the level of viral attachment.
The binding activity of virulent wild-type and their attenuated derivative strains 
of JE virus were further examined and compared using the mouse brain cell MRP. 
No significant difference in the degree of the binding was observed between wild-type 
and attenuated strains of JE virus. However, it was found that attenuated JE virus 
variants (SA-14 series vaccine strains and Nakayama-0 HeLa p6) demonstrated 
different binding kinetics to that of their virulent wild-type parent strains. Both wild- 
type strains, SA-14 and Nakayama-0, showed a faster binding rate than their 
attenuated derivatives in that they reach the maximum (or nearly maximum) level of
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binding within one minute (see Fig. 7.2a and 7.3c in Chapter 7). Thus, the studies 
using either the MBTH or the MRP derived from it indicate that virulent wild-type 
strains of JE virus have different viral binding domain and/or different cell receptor 
to that of their attenuated derivatives. This speculation was supported by the 
observation showing that spiperone, an antagonist for dopamine Dg and 5-hydroxy- 
tryptamine (5-HT) 5-HT2 subtype receptors, specifically blocked the binding of wild- 
type strains of JE virus to the mouse brain cell MRP, but not the attenuated strains.
Based on the evidence obtained in this project, it is tempting to speculate that a 
dopamine and/or 5-HT subtype receptor may act as a binding site for wild-type JE 
virus but not attenuated strains. This shift of receptor site may account for the 
different binding activity between wild-type and their attenuated derivatives. The viral 
binding domains of fiaviviruses are believed to be on the E protein (Brinton, 1986). 
Thus, one or more of the amino acid substitutions (as discussed above) in the E 
protein is likely to contribute to this alteration in the cell receptor binding domain. 
It is noteworthy that attenuated SA-14 series vaccine strains also showed different 
binding kinetics to one another. However, whether or not attenuated strains of JE 
virus have different receptors is unknown.
None of the wild-type and vaccine specific MAbs examined (Chapter 7, Table 
7.13) were found to block wild-type or attenuated vaccine strains of JE virus to bind 
to the MRP. This observation suggests that these wild-type or vaccine specific 
epitopes are not associated with the viral binding domain. Based on the results 
available, it is unknown whether or not the amino acid substitutions in the E protein 
are physical components of the vaccine or wild-type epitopes, or the viral binding 
domain. It is possible that the emergence of vaccine specific epitope, loss of wild-type
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epitope , and the shift of cell receptor binding site are just the consequences of the 
rearrangement of the conformational structure of the E protein caused by the amino 
acid changes. Clearly, manipulation of JE virus infectious clone, as suggested above, 
would greatly aid in answering these possibilities.
A number of cell receptors for viruses have been identified in recent years (Lentz, 
1990). However, most of these refer to receptors on cells in culture. In this study, 
the receptor binding activity of JE virus was investigated using the materials directly 
derived from the virus target tissue (brain). Therefore, the results obtained from such 
a study are directly related to the natural interaction between the virus and its in vivo 
target cells (neurones in CNS systems). The specificity of spiperone blocking wild- 
type JE virus binding to the mouse brain cell MRP suggests that this binding may be 
important in vivo as the binding of attenuated derivatives was not blocked. It is 
interesting to speculate that wild-type JE virus acts as a ligand for dopamine and/or 
5-HT receptors and that this, in addition to cytopathology of the virus, contributes to 
the disease by affecting the second messenger activity of dopamine and/or 5-HT 
regulated system. The neurological sequelae after the acute JE disease includes 
clinical features which resemble Parkinsonism, symptoms caused by a deficiency in 
the dopamine biosynthetic pathway. Taken together, it is reasonable to speculate that 
the shift of virus receptor site on brain cells caused by the amino acid substitutions 
in the E protein is associated with attenuation and/or virulence of JE virus.
Although SA-14 series vaccine viruses are highly attenuated in adult mice with 
normal immune function, it was found that the SA-14-2-8 and SA-14-14-2/PHK and 
PDK9 derivatives were virulent in the immunocompromised mice treated with SATM. 
Therefore, the pathogenicity of these two vaccine virus strains was relatively
233
enhanced. However, no significant enhancement on the virulence of the wild-type 
parent strain SA-14 was observed in the SATM treated mice. This result suggests that 
the attenuation of these two vaccine strains are host immune-status dependent. Thus, 
the shift of cell receptor site caused by the amino acid substitutions in the E protein 
may not be the only determinant of attenuation and/or virulence of JE virus. It is 
likely that the sensitivity of JE virus replication in vivo to the effects conferred by 
host immune surveillance may be another determinant for attenuation and virulence. 
However, based on the evidence available, it is unclear which nucleotide changes that 
occurred during the attenuation process would be responsible.
In contrast to the vaccine strains SA-14-2-8 and SA-14-14-2/PHK and PDK9, 
another vaccine strain, SA-14-5-3, still remained markedly attenuated even in the 
immunocompromised mice treated with SATM. Thus, it indicates that the molecular 
basis for the attenuation and pathogenicity of the SA-14-5-3 virus may be different 
to that of the SA-14-2-8 and SA-14-14-2 derivatives. Nucleotide sequence comparison 
of SA-14-5-3 and SA-14-14-2/PHK and PDK9 virus genomes reveal that only two 
nucleotide substitutions are unique to the SA-14-5-3 strain. One nucleotide change 
occurred in the E gene (amino acid position 474), while another was in 5’-noncoding 
region (position 15, C^G, Trent, personal communication). Therefore, one or both 
of these nucleotide changes must be responsible for this unique attenuated phenotype 
of the SA-14-5-3 strain. Brinton and Dispoto (1988) showed that the 5’-noncoding 
region of some fiaviviruses contains a conserved sequence which forms a hairpin 
structure thought to be a signal for interaction between proteins and RNA. Hashimoto 
et al. (1989) proposed that the "frying-pan with clover-leaf handle" structure derived 
from folding of the 5’-noncoding region and the 3’-terminus of the Beijing-1 JE virus
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strain RNA is involved in translation of the virus polyprotein at the initial stage of 
virus infection. Also, changes in the sequence of the 5’-noncoding region of 
poliovirus RNA have been shown to alter the secondary structure of the RNA and 
consequently affect neurovirulence of the virus (Evans et al., 1985; Nomoto et al., 
1987). Therefore, it can be postulated that this nucleotide change in the 5’-noncoding 
region between JE vaccine strains SA-14-5-3 and SA-14-14-2/PHK and PDK9 may 
affect virus growth properties in vivo and consequently alter the virus neurovirulence. 
Alternatively, the amino acid substitution at position 474 (Ala->Val) may be 
important, since SA-14-5-3 virus had different binding kinetics to the MRP to that of 
the SA-14-2-8 and SA-14-14-2/PDK9 viruses. Thus, they may have different cell 
receptor sites.
In this project, wild-type strains of JE virus were attenuated for the first time 
using a continuous cell line, HeLa cells. The significance of this observation is two 
fold. Firstly, it expands the current information on attenuation of JE virus showing 
that very few passages of the wild-type JE virus strains in HeLa cells can result in 
the attenuation of the virus. In contrast to the HeLa cell studies, it is a rule that 
repeated prolonged passages are required to attenuate JE virus in primary cell cultures 
(see review in Chapter 1). Therefore, attenuation of JE virus following one or two 
passages in HeLa cells provides an excellent model system to analyze the molecular 
basis for attenuation and virulence of JE virus. Clearly, sequencing of the HeLa and 
non-HeLa passaged Nakayama-0 viruses will reveal important information on the 
molecular basis of attenuation of JE virus following passage in HeLa cells. Secondly, 
the HeLa cell attenuated Nakayama-0 virus (HeLa p6) can replicate to a high titre 
after being adapted to CEF cell cultures, which is an approved cell substrate by the
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World Health Organization (WHO) for human vaccine production,. Also, the CEF 
cell passaged Nakayama HeLa p6 virus was shown to have good immunogenic 
properties and may have application as a potential live attenuated JE vaccine, should 
the SA-14-14-2 vaccine prove to be poorly immunogenic following passage in PDK 
cells. Unpublished human trials in China indicated that passage of the SA-14-14-2 
PHK vaccine into PDK cells has resulted in the vaccine losing its immunogenicity in 
vaccinees (Barrett, personal communication). Should the HeLa passaged Nakayama 
virus be exploided for vaccine production, it will undoubtedly be met with 
apprehension as attenuation was achieved by passage through a human transformed 
cell line derived from a cervical carcinoma. How this is resolved remains to be seen 
in the future.
Overall, observations made in this thesis suggest that important determinants for 
JE virus attenuation and/or virulence are located in the E gene and, on the basis of 
extrapolation from the sequence data, the 5’-noncoding region. Clearly, more studies, 
especially the manipulation of JE virus infectious clone, are required to further 
elucidate the precise molecular basis for attenuation and/or virulence of JE virus.
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Appendix
1. Calculation of the average survival time (AST) and 
the standard error of the mean (SEM)
1) AST = X = —  
n
2) SEM =
fn
3) ^ ^
n - \
4) AST±SEM = x±—
fn
Where x  is the individual observation, x  is the mean (AST), n is the sample 
size and s is the standard deviation.
2. Student’s t tests
i. Comparison of a small sample mean with a standard 
(variance unknown) (n < 30)
s
fn
Where p is taken as Null Hypothesis, i.e. p = 0.
ii. comparison of means of two small samples (n<30)
t =
1 1
«1  «2
Where:
252
s =
N
'£^ (x- x^Ÿ+'E2(x-X2Ÿ
nj+«2-2
The designations of x, x, n and s are the same as above, except Xj is 
the mean of the first observation, is the mean of the second 
observation, Ej means summation over the first sample only, and 
summation over the second sample only.
3. Calculation of pfu/LD^g
The LD50 titre was calculated by the Reed-Muench method. The formula are 
as folhvings:
1) The proportionate distance of the 50% mortality endpoint = :
___________(% mortality at dilution next above 50%) - ('50%')_____ _________
(% mortality at dilution next above 50%) - (% mortality at dilution next below)
Where % mortality is calculated by the accumulated values: i.e. the 
number of dead at each dilution is taken as the accumulated value from 
the higher dilutions, whereas the number of survivals is taken as the 
accumulated value from the lower dilutions.
2) LD50 endpoint titre =:
Negative logarithm of the lower dilution (next 
above 50% mortality) plus (Proportionate 
Distance x dilution factor (LogjolO))
3) pfu/LDjo = :
volume of virus inoculum (ml) x virus infectivity titre 
(Logiopfu/ml) X 10^^
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